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Abstract of thesis 
 
Chapter 1  
 
Chapter 1 is a literature review investigating the incidence of cancer in children and 
young adults.  It describes the most important treatment options including 
chemotherapy, radiotherapy and surgery and the effect of treatment on future 
endocrine development and fertility. Different primary cancer sites are discussed in 
more detail. 
 
Chapter 2 
 
Chapter 2 is a literature review on the effects of cancer surgery in women and the 
options for fertility sparing.  Cervical cancer and pre-cancer are discussed in detail 
with options for more conservative surgery in selected patients.  A summary of the 
available published cases of trachelectomy with pregnancy outcomes is included.  
Other gynaecological cancers requiring surgery are also discussed with reference to 
conservative options. 
 
Chapter 3 
 
Chapter 3 is a literature review about the medical (pharmacological) options for 
protection of ovarian function in patients undergoing oncotherapy.  The role of 
gonadotrophin releasing hormone analogues and hormonal contraceptives in ovarian 
suppression is discussed in detail. 
 
Chapter 4 
 
This chapter examines germ cell physiology with reference to cryopreservation.  It 
includes two major parts.  Part 1 is the description of germ cell- and follicle 
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physiology, the principles of cryobiology followed by a review of oocyte 
cryopreservation and ovarian tissue preservation.  Both slow freezing and vitrification 
techniques are described.  The second part of chapter 4 is a report on a randomised 
controlled evaluation of two different slow freezing cryopreservation protocols.  This 
experimental study compared ultrastructural changes in fresh and previously 
cryopreserved ovarian cortical tissue after equilibration and thawing using two 
different cryoprotectants.  This is the first randomised investigation into DMSO and 
PROH as cryoprotectants. 
 
Chapter 5 
 
Chapter 5 is an investigation into cryopreservation of ovarian tissue as a strategy to 
protect hormonal function and fertility against gonadotoxic treatment.  This chapter 
consists of two parts.  The first part is a thorough literature review of all the published 
work about grafting of previously cryopreserved ovarian tissue.  The largest case 
series found from a single institution was five patients.  Another report of six patients 
included patients from various sites in Denmark.   
 
Part 2 is a description of a cohort of patients followed up after re-implantation of 
previously cryopreserved ovarian cortical tissue.  Follow-up hormone levels of 13 
individual cases are described in detail.  This is the largest case series ever 
reported. 
 
The experimental study described in Chapter 4 and the clinical study described in 
Chapter 5 was approved by the ethical research committee of the Faculty of Health 
Sciences, Stellenbosch University, project number N05/10/182. 
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Chapter 6 
 
Chapter 6 provides an integrated overview of the incidence and treatment of cancer 
in young women and how its negative effects may be prevented or mitigated. 
Aspects of chemotherapy, radiotherapy and surgery are evaluated where it may 
affect future reproductive health. The role of oocyte and ovarian tissue 
cryopreservation is discussed. Guidelines are provided for clinicians. 
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Opsomming van tesis 
 
Hoofstuk 1   
 
Hierdie is ‘n literatuuroorsig wat die insidensie van kanker in kinders en jong 
volwassenes ondersoek. Dit sluit die mees belangrike behandelingsopsies in, 
naamlik chemoterapie, radioterapie en chirurgie en die effek wat behandeling mag 
hê op toekomstige endokriene ontwikkeling en fertiliteit. ‘n Verskeidenheid kanker 
tipes word in meer detail beskryf.  
 
Hoofstuk 2 
 
Hoofstuk 2 is ‘n literatuuroorsig oor die effekte van kankerchirurgie in vroue en die 
geleenthede tot beskerming van fertiliteit. Servikale kanker en voorlopers van 
servikale kanker word bespreek en die opsies vir konserwatiewe chirurgie in 
uitgesoekte pasiënte word gegee. ‘n Opsomming van die inligting wat beskikbaar is 
oor tragelektomie en swangerskap uitkomste word ingesluit. Ander ginekologiese 
kankers wat chirurgie mag benodig, word ook bespreek met verwysing na 
konserwatiewe hantering.  
 
Hoofstuk 3 
 
‘n Literatuuroorsig oor die mediese (farmakologiese) opsies vir die beskerming van 
ovariële funksie in pasiënte wat behandeling ontvang vir kanker. Die rol van 
gonadotropien-vrystellingshormoon-analoë en hormonale kontrasepsie vir ovariële 
onderdrukking word in detail bespreek.  
 
Hoofstuk 4 
 
Hierdie hoofstuk ondersoek kiemselfisiologie met verwysing na vriesbewaring. Dit is 
verdeel in twee dele. Deel 1 is ‘n beskrywing van kiemsel- en follikelfisiologie en die 
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beginsels van vriesbiologie.  Dit word gevolg deur ‘n oorsig van oösiet vriesbewaring 
en ovariële weefselbewaring. Stadige bevriesing en vitrifikasie- metodes word 
bespreek. Die tweede deel van hoofstuk 4 is ‘n verslag oor ‘n gerandomiseerde, 
gekontroleerde evaluasie van twee stadige bevriesingsmetodes. Hierdie 
eksperimentele studie het die ultrastrukturele veranderinge vergelyk in vars en 
voorheen bevrore ovariële kortikale weefsel na ekwilibrasie en ontdooiing met twee 
verskillende vriesbeskermers. Dit is die eerste gerandomiseerde studie oor DMSO 
en PROH as vriesbeskermers. 
 
Hoofstuk 5 
 
Hierdie hoofstuk handel oor ‘n ondersoek na vriesbewaring van ovariële weefsel as 
‘n benadering tot beskerming van hormonale funksie en fertiliteit teen 
gonadotoksiese behandeling. Die hoofstuk bestaan uit twee dele. Die eerste deel is 
‘n deeglike oorsig van die literatuur oor al die beskikbare werk wat handel oor 
terugplasing van voorheen bevrore ovariële weefsel. Die grootste pasiëntreeks van 
‘n enkel instelling was slegs vyf pasiënte. ‘n Ander beskrywing van ses pasiënte het 
pasiënte van verskeie eenhede in Denemarke ingesluit.  
 
Deel 2 is ‘n beskrywing van ‘n groep pasiënte wat opgevolg is na oorplanting van 
voorheen bevrore ovariële kortikale weefsel. Opvolg hormoonvlakke van 13 gevalle 
word in detail bespreek. Hierdie is die grootste pasiëntreeks wat tot nog toe beskryf 
is. 
 
Die eksperimentele studie wat in hoofstuk 4 beskryf word en die kliniese studie wat 
in hoofstuk 5 beskryf word, is goedgekeur deur die etiese navorsingskomitee van die 
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Fakulteit Gesondheidswetenskappe van die Universiteit Stellenbosch met die 
projeknommer N05/10/182 
 
Hoofstuk 6 
 
Hierdie is ‘n geïntegreerde oorsig van die voorkoms en behandeling van kanker in 
jong vroue en hoe die negatiewe effekte daarvan voorkom of verminder kan word. 
Aspekte van chemoterapie, radioterapie en chirurgie word geëvalueer ten opsigte 
van die effek op toekomstige reproduktiewe gesondheid. Die rol van oösiet- en 
ovariële weefselvriesbewaring word bespreek. Riglyne vir klinici word gegee.  
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Chapter 1: Incidence and survival of childhood and 
adolescent cancer and the effects of treatment on future 
fertility and endocrine function. 
 
Abstract 
 
Cancer is not uncommon in children. The reproductive system is an important site for 
late effects of cancer treatment and normal pubertal development depends on an 
undamaged hypothalamic-pituitary-gonadal axis. Fertility compromise can occur due 
to chemotherapy and radiotherapy of the hypothalamic-pituitary-gonadal axis.  
 
This review describes the incidence of malignancies affecting children and young 
adults. Chemotherapy may cause premature ovarian failure through direct toxicity to 
germ cells and other mechanisms. Age at treatment and type and total dose of 
chemotherapy are predictors of risk. Ovarian tissue is very sensitive to radiotherapy 
induced damage.  
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Introduction 
 
Cancer is not an uncommon diagnosis in children.  The incidence of childhood 
cancer (generally calculated under and up to the age of 15) is 110 to 130 per million 
children per annum. [1]  It is estimated that the cumulative risk of a child being 
diagnosed with cancer is slightly higher in boys at 1:444 compared to girls which is 
one is 1:594. [2]  In South Africa accurate figures for childhood cancer are not 
available. The reported incidence is around 70-80 per million, however it is estimated 
that one in 600 children will suffer from cancer before they turn 16. Many of these 
cancers are diagnosed late or may not be diagnosed at all. [3] 
 
The prognosis for patients with cancer diagnosed before the age of 15 has improved 
dramatically over the last 30 years and there are now more than 80% of cases who 
survive longer than 5 years and more than 70% will be long-term survivors.  
Information from cancer statistics during the 1970 to 1980’s indicate that in the 
United States, the cure rate of all childhood cancers combined was between 70-
90%. [4]   The estimated 5 year survival of children of both sexes improved form 
50.4% in 1973 to 79.2% in 1990. [5]  
 
The age at diagnosis of cancer is important. Neuroblastomas and Wilms’ tumours 
are most common in infants less than five years old while Hodgkin’s lymphoma and 
bone tumours usually present in the teenage years and early adult life.  Leukaemia 
may occur at all ages.    
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 Incidence 100 000/y Cure rate (%) 
ALL* / non Hodgkin’s lymphoma 5.0-6.0 78-80 
Hodgkin’s lymphoma 0.4 >90 
Brain tumours 4.0 Depends on type 
Wilms’ tumour 0.9 80 
  
Table 1 Leukaemia and non-Hodgkin’s lymphoma represents the most 
common cancers in children. [6]   *Acute lymphoblastic leukaemia 
 
Older children and young adults have historically not been studied to the same 
extent as young children with regards to cancer incidence. The age range for 
adolescence for the purpose of this study has been set at 15-19 years. [7] More 
recently the concept of “Young Adult Oncology” refers to a larger group of young 
people aged 15-29. [8] This group of young people is at a very important 
developmental phase particularly for establishment of normal hormonal and sexual 
function.  The spectrum of cancers affecting this group will differ from younger 
children and from adults.  
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Age 15-19 20-24 25-29 
Lymphoma 26 22 16 
Leukaemia 12 7 4 
Central nervous system 10 7 5 
Endocrine system 9 12 11 
Skin 8 14 18 
Male genital 8 13 11 
Female genital 8 8 12 
Bone and joint 8 3 1 
Soft tissue 5 3 2 
Digestive system 2 3 5 
Oro-pharynx 2 3 2 
Respiratory system 2 2 2 
Urinary system 2 2 2 
Breast 0 2 8 
Other 2 2 1 
 
Table 2 The relative frequencies (%) of cancers in adolescents and young 
adults aged15-29. [9] Data from National Cancer Institute in the USA 
 
Tumours of the male and female genital tracts become more common in the young 
adult group.  Testicular cancer is the commonest form of solid malignancy amongst 
the young adult male group and the frequency increases with progressive age from 
15 to 29 years. [9] Cure rates for men with seminomas exceeds 90% but non-
18 
 
seminomatous tumours have poorer outcome. In young women from the developed 
world, 18% of the total malignancies are of gynaecological origin. [10] Carcinoma of 
the cervix becomes more frequent and germ cell tumours, particularly 
dysgerminoma, are also present.  
 
It is estimated that 1:570 adults are cancer survivors and that this will increase to 
1:250 by the year 2010. [5] The increased cure rate means that many more patients 
will reach adulthood with a history of cancer and a fertility wish. The reproductive 
system is an important site for late effects of cancer treatment and normal pubertal 
development depends on an undamaged hypothalamic-pituatary-gonadal axis. 
Practitioners should be aware of the potential harm to the endocrine and 
reproductive systems after life-saving but potentially toxic chemo- and/or 
radiotherapy. Fertility compromise can occur due to chemotherapy, due to 
radiotherapy of the hypothalamic-pituitary-gonadal axis or from surgery. 
Chemotherapy and radiotherapy may also be used in patients with non-malignant 
autoimmune diseases like systemic lupus erythematosis and rheumatoid arthritis as 
well as certain haematological diseases.  [11] 
  
The effects of chemotherapy on the ovary 
 
In females the production of sex-hormones requires the presence of germ cells.  
Young women will experience endocrine function loss after chemo-and radiotherapy 
in childhood and adolescence more often than boys.  Unlike men, women have a 
fixed number of germ cells that gradually diminish with age.  At puberty between 200 
000 and 400 000 follicles are present which may eventually mature and only 400 to 
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500 oocytes are produced in a normal reproductive life span. [12] At the age of 
menopause only a few hundred follicles are left. [13] Anti-cancer therapy may 
increase the rate of follicular loss and therefore also premature ovarian failure, with 
subsequent premature menopause which is one of the common toxic side effects of 
cancer treatment. [14] Chemotherapy may affect the ovary to cause amenorrhoea in 
between 40 to 68% of cases depending on various factors.  [15]  
 
Mechanisms of damage to ovarian function  
 
The pharmacological action of chemotherapy is mainly aimed at disrupting the 
process of DNA synthesis and cell replication.  In general the alkylating agents 
interact with DNA preventing replication and/or transcription.  Anti-tumour antibiotics 
like actinomycin D works on the same principle.  Other agents may damage the 
structure of DNA directly and adriamycin acts by damaging the plasma membrane.  
The plant-based chemotherapy agents like the taxanes disrupt the function of tubulin 
that is important in the normal functioning of the microtubules that is critical in the 
normal mitotic process. 
 
Specific chemotherapy agents, particularly the alkylating compounds e.g.  
cyclophosfamide and chlorambucil, may cause permanent DNA damage in ovarian 
follicles.  Other chemotherapy agents are less harmful and these include 5-
fluorouracil, methotrexate, etoposide and adriamycin. [16]  There are various 
mechanisms of damage to the ovaries.  The damage may be directly to the 
primordial follicles with demise of follicular cells.  Human and animal studies 
demonstrated that chemotherapy can damage ovarian pre-granulosa cells, [17] with 
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increased apoptosis during oocyte and follicle maturation. [18] Vascular 
complications associated with antineoplastic agents have been reported. One 
recognized mechanism for such toxicity includes drug-induced endovascular 
damage. [19]  
 
In a descriptive study Meirow and co-workers studied histology of ovarian tissue form 
17 women exposed to chemotherapy and compared it with 18 patients that were not 
exposed. [20]  The pathologists were blinded for patient characteristics. They found 
injury of blood vessels and focal fibrosis of the ovarian cortex to be present in 
ovaries of patients previously exposed to chemotherapy. Circulation for the cortex of 
the ovary is supplied by an end-artery system and the cortex is a fairly poorly 
oxygenated tissue.  After chemotherapy there is prominent thickening and narrowing 
of the vessels and neo-vascularisation with abnormal blood vessels to the ovarian 
cortex is seen on microscopy.  There is also cortical fibrosis. Direct damage to the 
follicles can also be seen after chemotherapy and there may be pre-granulosa cell 
swelling with increased apoptosis.  
 
More mature follicles are more vulnerable to chemotherapy damage. [21] Certain 
endocrine mechanisms may play a role in the damage to the ovarian function.  Anti-
Müllerian hormone (AMH) is mainly secreted by growing follicles and anti-Müllerian 
hormone levels drop significantly during therapy. [22] AMH may be used as a marker 
of ovarian reserve. Serum AMH levels can be measured to assess sub-clinical 
ovarian damage in patients treated with chemotherapy. [23] A drop in AMH may 
cause a raised recruitment and atresia.  A possible mechanism to protect ovarian 
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function may be to administer anti-Müllerian hormone during treatment with 
chemotherapy to reduce recruitment of follicles. 
 
Müllerian Inhibiting Substance (MIS), also known as anti-Müllerian hormone, has 
been successfully isolated and may in future be used clinically in the treatment of 
various cancers. [24] It is from the transforming growth factor beta (TGF-ß) 
superfamily and ovarian, prostate and breast cancer cell lines have shown 
regression after exposure to AMH.  A recombinant human MIS/AMH is available for 
research purposes. [25] 
 
Age at treatment 
 
One of the most important clinical factors that may influence the risk for permanent 
ovarian damage is the age at treatment. The risk for ovarian failure increases with 
age. [26] [27] [28] [29] This is due to the fact that the number of remaining primordial 
follicles is far more at a younger age.  
 
Amenorrhoea due to chemotherapy is more commonly found in treated women who 
were over the age of 30 years (50-89%) compared to younger women where normal 
menses was preserved in 48-100% of cases. [30] [31] [32] Chemotherapy related 
amenorrhoea may be transient. However, if the condition is present for more than 
one year after treatment, less than 11% of women over the age of 40 and 12-15% of 
women younger than 40 will experience a return to menses.  [33]  
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Age Premature ovarian failure 
<20 years 13% 
20–30 years 50% 
>30 years 100% 
 
Table 3  The incidence of ovarian failure after cyclophosfamide pulsed 
chemotherapy according to age [15] 
 
Treatment of young people with cancer  
 
There are many different malignancies affecting young people. The most common 
forms are summarised in Table 4. It is clear that multi agent chemotherapy regimens 
and radiation may contribute to reproductive failure. It is often difficult to determine 
the individual effect of specific therapies on fertility outcome. 
 
 Chemotherapy Cranial Ro Gonadal Ro 
Acute lymphoblastic leukaemia + ± ± 
Non-Hodgkin’s lymphoma + ± ± 
Hodgkin’s lymphoma + - ± 
Brain tumours ± ± ± 
Wilms’ tumour + - ± 
 
Table 4 Treatment modalities which are commonly used in the treatment of 
childhood cancers that may affect future fertility. [6] 
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Haematological malignancies 
 
There are a significant number of reports in the literature about the effects of 
chemotherapy on subsequent fertility and hormonal function following treatment for 
haematological malignancies in younger women.  Treatment for Hodgkin’s 
lymphoma with MVPP (mechlorethamine, vinblastine, procarbazine and 
prednisolone), MOPP (mechlorethamine, vincristine, procarbazine and prednisolone) 
or ChIVPP (chlorambucil, vinblastine, procarbazine and prednisolone) resulted in 
permanent ovarian failure in 19-63% of cases. [26] [31] [30] Treatment for Acute 
lymphoblastic leukaemia (ALL), however, had less long-term risk for permanent 
amenorrhoea. [34] [35] Conditioning with chemotherapy before bone marrow 
transplantation is usually associated with transient amenorrhoea.   Cyclophosfamide 
doses of 200mg/kg caused amenorrhoea in all women on treatment but all recovered 
to normal ovarian function after bone marrow transplantation. [36] Doses higher than 
200mg/kg may cause premature ovarian failure. [37] Multi-agent combination 
chemotherapy regimens will have synergistic toxicity and the specific contribution of 
each agent may be difficult to determine. 
 
Breast cancer 
 
In the United States breast cancer is the most common cancer in women of 
reproductive age (< 40 years of age) and approximately 13% of all breast cancer 
diagnoses are made in women younger than 45. [38] Alkylating agents (e.g.  
cyclophosfamide) are often included in the treatment regimes for breast cancer.  The 
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higher the cumulative dose of cyclophosfamide, the higher the risk for premature 
menopause.  In cases treated with CMF (cyclophosfamide, methotrexate and 5-
flurouracil) the incidence of amenorrhoea was 61% in patients younger than 40 years 
and 95% in patients older than 40 years. [29]  Slightly higher incidence of 
amenorrhoea was found with a regime containing FEC (5-flurouracil, epirubicine and 
cyclophosfamide) compared with CMF (51% vs 42.6%). [39] Anthracycline based 
regimes had a lower incidence of amenorrhoea. [16]  There is very little evidence 
with regard to taxanes and the risk for subsequent amenorrhoea.  There does not 
appear to be an increased overall risk when it is added to chemotherapy regimes. 
[40]   
Ovarian cancer 
 
Maltaris summarized the obstetric outcome in patients with previous epithelial 
ovarian carcinoma after receiving conservative treatment. [40] A total of eight studies 
were included in the review and out of the total of 282 patients, 113 pregnancies 
were described.  The number of term deliveries was 87. In this group the number of 
reported relapses of ovarian carcinoma was 33 and disease related deaths 16. Not 
all of these patients received chemotherapy. 
Choriocarcinoma 
 
At present the treatment for choriocarcinoma is surgical removal of the tumour 
together with multi agent chemotherapy; usually with methotrexate and/or 
actinomycin D combined with other agents.  In a study reported by Newlands, 
cyclophosfamide was associated with a reduction in the fertility rate when compared 
with treatment with methotrexate only. [39] 79% of the total number of patients 
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desiring pregnancy had at least one live birth after cyclophosfamide compared to 
86% in those receiving methotrexate only. 
 
Radiotherapy damage to hormone production and fertility in 
women 
 
Radiation therapy may affect many different sites of the hypothalamic-pituitary-
ovarian axis causing hormonal and reproductive failure. Effects on the uterus may 
also be directly responsible for poor pregnancy outcomes. 
 
Radiotherapy effects on the ovary 
 
The extent of radiotherapy damage to ovarian function and reproduction is 
determined by the total dose of radiation, the fractionation schedule and also the age 
of the patient at the time of treatment. [14] [41] The number of primordial follicles 
present at the start of treatment will depend on the age of the patient.  The number 
of primordial follicles will be higher the younger the child at the time of radiotherapy 
and the larger the remaining oocyte pool, the later the eventual age of menopause.  
The human oocyte is exquisitely sensitive to the damaging effects of radiation and 
the estimated median lethal dose (LD50) is less than 4 Gray. [14]  A descriptive study 
by Wallace found that 37 out of 38 females had ovarian failure after whole abdominal 
irradiation of 20 to 30 Gray in childhood.  71% had primary amenorrhoea i.e. they 
never had normal pubertal development and premature menopause occurred in the 
rest with a median age of 23.5 years. [41] Total body irradiation (TBI) is sometimes 
used alone or in combination with cyclophosfamide as conditioning for bone marrow 
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transplantation.  This treatment is often associated with infertility and only a small 
number of patients (9 out of 144) had normal ovarian function after TBI of a dose 9 - 
16 Gray combined with  cyclophosfamide 120mg/kg before bone marrow 
transplantation.  The effect of age at treatment was also demonstrated in this study 
with a greater probability of recovery of ovarian function observed in younger girls. 
[36]    
 
The largest cohort of cancer survivors studied for ovarian failure describe the long 
term follow up of 3390 cancer survivors. [42] The Childhood Cancer Survivor Study 
reported on loss of menstrual function within the first five years after diagnosis and 
excluded from analysis those with cranial radiation of more that 3000cGy, those with 
tumours of the hypothalamus or pituitary or who had bilateral oophorectomy.  215 Of 
the survivors developed ovarian failure. The cases of ovarian failure were older at 
treatment, had a higher incidence of pelvic and/or abdominal radiation or were 
treated with procarbazine. In multivariate analysis increasing doses of radiation was 
an independent risk factor. [42] 
 
It is clear from Table 5 that premature ovarian failure is higher if the patient receives 
treatment at an older age.  The number of viable follicles is reduced by the normal 
physiological processes and the surviving number is therefore less after an insult. 
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Dose Gy Effect on ovarian function 
0,6 No deleterious effect 
1,5 No effect in <40yr 
Some risk of POF in >40yr 
5 60% sterile <40yr 
100% sterile >40yr 
8 70% sterile <40yr 
100% sterile >40yr 
>8 100% sterile 
 
Table 5 The effect of radiation on ovarian function [43] 
 
Ovarian trans-position outside the field of radiotherapy may reduce the dose to the 
ovary. Howell described how lateral trans-position of the ovaries to the para-colic 
gutters may reduce the radiotherapy dose by up to 95%. [44]  This may protect the 
sensitive follicles to direct dose related damage. Other reports, however, were less 
optimistic and found that ovarian trans-position may compromise blood supply and 
there was mixed success with this technique due to scattered radiation and vascular 
compromise. [45] Ovarian transposition may have a place for fertility preservation in 
cases where the pelvic dose of radiotherapy is not high enough to be damaging to 
the other organs of the reproductive tract.  
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Radiotherapy effects on uterine function 
 
The uterus may be damaged by radiotherapy and reduced uterine volume and 
decreased elasticity of the myometrium can be found in girls who received pelvic-, 
abdominal- or total body irradiation before puberty. [46]  [47]  
 
Even though successful pregnancies following radiotherapy have been reported, 
there is an increased incidence of miscarriage, intrauterine growth restriction and 
premature delivery. [34] It is difficult to diagnose uterine damage after exposure of 
the uterus to radiotherapy but endometrial sampling may help in the assessment of 
endometrial function. Exact prediction of eventual reproductive outcome is however 
very difficult. 
 
Effects on the uterine volume  
 
When girls are irradiated before puberty and at very young age, final uterine volume 
is significantly lower compared to those irradiated at a later age. [48]  Damage to the 
uterus is usually greater in prepubertal than in pubertal girls. [49]  Uterine volume is 
directly affected by the dose of irradiation as described by Larsen in a large group of 
100 childhood cancer survivors. [50] Transvaginal ultrasound was used to evaluate 
the uterine volume.  The children were divided into four groups according to the 
amount of radiation exposure.  In control patients (n = 44) the median uterine volume 
was 47mls.  In those receiving radiation above the diaphragm (n=21) the median 
uterine volume was 40mls.  Young women treated with radiation below the 
diaphragm (n=19) had volumes of 34mls and in patients treated with direct uterine 
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radiation (n=16) the median uterine volume was only 13mls.  The treatment age was 
also significantly associated with smaller uterine volume (p=0.02).  There was a 
significant increase in the mid-trimester miscarriage rate in those having exposure to 
therapy.  
 
Holm followed 12 female patients who had total body irradiation at a median age of 
12.7 years for childhood leukaemia.  They found a significantly decreased uterine 
volume - 2.6 standard deviations below that of controls. [51]  
 
Not only is radiotherapy associated with reduced uterine volume but also with 
impaired blood flow.  In a study of 12 leukaemia survivors who received total body 
irradiation, uterine blood flow was reduced. [51]  The reduced blood flow may be due 
to direct vascular damage or hormonal factors and fibrosis. [48] [46]  There is some 
evidence that uterine blood flow is better in women who have premature ovarian 
failure due to causes other than radiotherapy which would support a direct radiation 
linked damage to the vasculature of the uterus. [52]  
 
Delanian described histological changes of the irradiated uterus. [53] Two major 
features are identified namely  
1. Necrosis and atrophy of the endometrium, inflammation and later fibrosis with 
telangiectasis of the inner layer.   
2. Arteriolar sclerosis, fibrosis and muscular atrophy of the myometrium. 
 
Evidence of endometrial necrosis and atrophy is described in MRI follow up studies 
of patients receiving uterine radiotherapy. [54]   
30 
 
 
The observed effects on uterine volume, decreased blood flow and endometrial 
atrophy appears to increase the risk for pregnancy related complications.  Case 
reports of placenta accreta and even uterine rupture in patients with previous total 
body irradiation and pelvic radiation have been described. [55] [56]  Low birth weight 
infants and placental abnormalities have also been described. [57] Abnormal 
placentation was described after midtrimester miscarriage in a 23-year old woman 
who had 70 Gray to the pelvis for treatment of a sarcoma. She had intraperitoneal 
bleeding and a subsequent hysterectomy. Histology on the removed uterus showed 
fibrosis and an area where the chorionic villi were implanted directly into the 
myometrium. [56] Another case report describes uterine rupture occurring at 17 
weeks of gestation in a patient with placenta accreta secondary to previous radiation 
for chronic myeloid leukaemia. [55]  
 
There may be an increased risk for congenital abnormalities in the offspring of 
childhood cancer survivors.  In the Wilms’ tumour study group, 10% of offspring of 
the irradiated group was born with congenital abnormalities compared to 3.2% in the 
non-irradiated group. [58]  The same study also described an increase in premature 
labour, relative risk (RR) 2.36 [0.93 - 6.02] and also a higher incidence of low birth 
weight ( <2500 grams at birth) RR 1.85 [1.07 to 3.18]  Radiation was an independent 
risk factor after controlling for factors like age, parity, smoking, alcohol intake and 
education. 
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Strategies to improve uterine function after previous radiation 
 
A combination of direct radiation toxicity to the myometrial and endometrial tissues 
combined with poor circulating hormone levels will cause low uterine volume and a 
thin endometrium.  Hormone replacement therapy will improve uterine blood flow 
and endometrial development as well as overall uterine size. [52]  Girls exposed to 
radiation before puberty showed a smaller improvement in uterine volume than girls 
treated after the menarche. [50]  However, those receiving in excess of 30 Gray had 
no improvement in uterine volume after hormonal treatment. [50]  
 
Pentoxifylline (PTX) and vitamin E in combination have demonstrated the ability to 
reverse certain effects of chronic radiation damage. [59] This led to a small 
therapeutic trial of 800mg of PTX combined with vitamin E 1000 IU daily 
administered for one year to women who previously received high dose ( >45 Gray) 
radiotherapy in childhood. [60] These patients also received hormone therapy for 
premature ovarian failure.  After adding the additional PTX and vitamin E treatment,  
vascularity improved significantly.  There was also an increase in the endometrial 
thickness and uterine size.  The effect on subsequent pregnancy is still largely 
unknown but spontaneous pregnancies leading to the birth of healthy children have 
been described after combination therapy with PTX and vitamin E. [61]  
 
Effects of cranial radiation 
 
Cranial irradiation may cause hypo-pituitarism in doses over 30 Gray. [62] [63]  Up  
to 60% of patients experienced a gonadotrophin deficiency four years after treatment 
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with cranial irradiation. [63] Effects on other pituitary hormones like growth hormones 
have also been reported. [64]  In a report by Nygaard, a cranial radiation dose of 
between 18 and 24 Gray has been identified as a possible risk factor for a 
significantly lower first birth rate compared to those without any radiation. [65]  The 
presence of a regular menstrual cycle may not be an adequate indication of 
hypothalamic-pituitary function and women who received cranial radiation with 
infertility need careful hormonal assessment. 
 
Prophylactic cranial radiation (PCI) was often used as treatment for children with 
leukaemia.  The effect of PCI on future reproduction mainly revolves around two 
issues namely an increased risk for precocious puberty and the possibility of 
gonadotrophin impairment.  A population based cohort study from Scandinavia found 
that women, who were treated as children for acute lymphoblastic leukaemia with 
PCI doses of 18 to 24 Gray, had a significantly decreased birth rate when compared 
to those who never received radiation. [65] In another review of long-term survivors 
of acute lymphoblastic leukaemia after PCI, 12 women who received radiation were 
compared to healthy controls. [66] Despite the fact that the entire group of young 
women achieved adult sexual development and menstrual cycles, they had 
decreased levels of LH secretion and shorter luteal phases when compared to 
controls.  Because of the luteal phase deficiency, prepubertal girls who received low 
dose PCI may have a higher risk for ovarian failure and a higher miscarriage rate. 
[67]    
 
There is a link between cranial irradiation and precocious puberty.  In a report of 46 
children receiving an average of 30 Gray for brain tumours, puberty was earlier for 
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both boys and girls (girls 8.5 versus 11.2 years and boys 9.2 versus 11.6 years). [68]  
In another cohort of 36 children treated with high dose cranial irradiation (the 
hypothalamic pituitary dose was between 30-72 Gray) all the young people were 
treated before the age of 9 years. [69] In girls the median age of puberty was 9.3 
years versus 10.9 in controls and for boys 11 years versus 11.5 years in controls.  
There was a significant positive correlation between the age at diagnosis and the 
eventual age of puberty in both sexes.  
 
The effects of cranial irradiation on postpubertal children confirm the negative effect 
on hormonal function.  In a group of 16 women and 16 men treated at an average 
age of 19 with cranial doses of 40-70 Gray, 70% of females developed 
oligomenorrhoea and 50% showed low oestrogen concentrations after a mean 
follow-up of 7 years. [70] There was also an incidence of 50% for 
hyperprolactinemia.  Damage to the hypothalamus and pituitary gland was also 
confirmed in an observational study of 107 adults who received radiotherapy to the 
base of the skull.  [71]  Seventy-two percent of cases developed hyperprolactinemia 
and 29% developed hypogonadism within 5 years.  This increased to 84% for 
hyperprolactinemia and 36% for hypogonadism after 10 years.  It is important to note 
that there may be a significant period of latency between treatment and subsequent 
hormonal dysfunction.  It is therefore necessary to follow these patients for a long 
time. 
Chemotherapy and testicular function 
 
In men endocrine and exocrine functions of the gonads are separate. The average 
age of the spermarche is at 13.4 years.  The alkylating agents are gonadotoxic with 
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procarbazine particularly harmful.  This is a very useful drug used in the treatment of 
Hodgkin’s lymphoma where repeated courses of alkylating agents are often needed.  
The Sertoli and germ cells are more sensitive than the Leydig cells; therefore a 
patient with normal testosterone production may have azoospermia. [72] 
Azoospermia is likely if the volumes of the post pubertal testes are less than 10ml as 
measured by the Prader orchidometer.   
 
A combination of chemotherapy for Hodgkin’s disease may include the following 
regimes: MOPP (mechlorethamine, vincristine, procarbazine and prednisolone) or 
ChIVPP (chlorambucil, vinblastine, procarbazine and prednisolone) or COPP 
(cyclophosfamide, vincristine, procarbazine and prednisolone).  It is clear that in 
these multi-agent regimes there may be synergistic toxicity of individual agents and it 
is often very difficult to determine the specific contribution of each agent.  Certain 
agents have been identified as been more gonadotoxic to the testes including the 
alkylating agents procarbazine, cisplatinum and vinblastine.  [73] [74] [75] [76] [77] 
[78] [79] [80]  Newer regimes like the ABVD combination (adriamycin, bleomycin, 
vinblastine and decarbazine) have been shown to be less gonadotoxic with full 
recovery after 18 months of treatment in nearly all patients. [79]  Cyclophosfamide 
may cause azoospermia in up to 13% and oligozoospermia in 30% of patients 
treated with a total dose of 560-840mg/kg. [77]  The estimated threshold for impaired 
spermatogenesis was a total dose of 10g.  Ifosfamide is sometimes used for the 
treatment of sarcomas and a dose of between 84-126mg/m2 was associated with 
impaired spermatogenesis.  [81] The testicular seminiferous epithelium that is 
responsible for spermatogenesis is very sensitive to the effects of chemotherapy, 
however, the Leydig cells are more resistant to damage and in certain cases, 
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although secondary sexual characteristics may develop normally, there may be 
severe impairment of sperm production.  [82] [72]  In higher cumulative doses Leydig 
cells may also be damaged [83] however this rarely occurs in clinical practice.  
 
Radiotherapy and testicular function 
 
Radiotherapy may damage the hypothalamic pituitary axis if the dose is more than 
30 Gray to the cranial region.  Radiotherapy can also damage the testes directly and 
the damage may be reversible if the dose is between 20-200 cGray but irreversible 
azoospermia will develop over 400 cGray.  A low production of testosterone will only 
occur when the dose goes above 1500 cGray. 
 
It is important to consider collecting a semen sample before the initiation of 
chemotherapy. [81] Cryopreservation of sperm is a well known technique and has 
excellent outcomes. If pre-pubertal boys cannot produce a sample through 
masturbation, testicular biopsies are a viable alternative. [84]  
 
Pubertal development is usually normal after treatment with TBI in preparation for 
bone marrow transplantation. [85] It was found that these boys had slightly higher 
levels of FSH and that mean testicular volume was lower than normal at an average 
of 10.5ml.  LH was elevated which may indicate subtle hormonal dysfunction of the 
Leydig cells. [85]  Other reported studies found no change in LH levels after 
preparation for bone marrow transplantation. [86] [87] 
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Figure 1 Schematic view of fertility preservation options in males. Adapted from [84] 
 
 
In cases of acquired hypogonadotrophic hypogonadism, gonadotrophin therapy is an 
option for treating pituitary hormone deficiencies (LH and FSH). [84] Damage to the 
GnRh production from the hypothalamus will also lead to hypogonadotrophic 
hypogonadism. GnRh administration in a pulsitile or intermittent regime may induce 
spontaneous spermatogenesis in selected patients. [88] [89]  
 
Where testicular damage is a high likelihood because of planned treatment, pre-
treatment semen samples should be collected for cryopreservation.  In young boys 
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who are unable to produce semen samples testicular tissue can be collected for 
storage.  Studies in animal models have demonstrated the possibility of in vitro 
maturation of sperm from spermatogonal stem cells. [90] [91] “Testicular sperm 
extraction and testicular tissue freezing in the prepubertal child is experimental”.  [84] 
[92] 
 
Conclusion 
 
Cancer survivors often are left with long term sequelae after treatment. They are at 
risk of losing endocrine and exocrine functions of reproduction.  The team of 
clinicians involved in the care of young people with cancer should be aware of the 
potential harm done by treatment. The clinician can plan strategies to minimize risk 
and still have a safe oncological outcome.  Cryotherapy techniques offer real hope to 
boys and girls who need gonadotoxic therapy and ovarian tissue, testicular tissue, 
sperm and ova may be retrieved before treatment is started.  
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Chapter 2: Gynaecological cancer surgery and the options 
for fertility sparing.  
 
Abstract 
 
There are various strategies to protect fertility potential against the possibly harmful 
effects of cancer therapy. Options range from newly emerging pharmacological 
treatment (e.g. ovarian suppression, apoptotic inhibitors) to cryopreservation 
techniques (e.g. embryo, oocyte, ovarian tissue).   
 
Surgical interventions for cancer treatment may directly or indirectly harm future 
fertility potential.  New developments in the surgery for tumours are affording 
different approaches to fertility-sparing options and these surgical approaches can 
be employed successfully in a large number of situations. This review investigates 
surgical treatments and its effect on future fertility in women with pre-malignant and 
invasive cancer of the cervix, uterus and ovary.  
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Introduction 
 
A significant number of young women are diagnosed with a malignancy during their 
childbearing years.  At present there are various strategies to protect fertility potential 
against the possibly harmful effects of cancer therapy. The understanding of tumour 
biology, prognostic factors, epidemiology and behaviour at a microscopic and 
biochemical level improved over the years. Because of the better understanding of 
cancer, there are more effective therapies to cure the disease but also to minimise 
problems associated with treatment. Developments in the surgery for tumours make 
fertility-sparing options possible in a large number of situations. 
 
Surgical intervention for cancer may directly or indirectly harm future fertility 
potential.  The aim of this chapter is to investigate surgical treatment for pre-
malignant disease and cancer of the cervix, uterus and ovary and its effect on future 
fertility.   
 
Cervical disease 
 
According to the International Agency for Research on Cancer (IARC), cervical 
cancer accounts for 23% of all new cancers diagnosed in South Africa annually. [1] 
The age standardized incidence rate for cervical carcinoma in Southern Africa is 
approximately 35 per 100 000 women years. That is one of the highest incidence 
rates in the world.  An estimated 3 700 deaths in South Africa during 2002 were 
because of cervical cancer. 
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Cervical pre-cancer 
 
Screening for cervical carcinoma in well-organized programmes has been shown to 
be effective in reducing the incidence and death rates due to the disease. [2]  The 
aim of a cervical cytology screening programme is to detect pre-malignant lesions of 
the transformation zone of the cervix. Those patients with abnormal cytological 
results are then referred for further management.  In South Africa the cytological 
screening programme is not always well organized. [3] Despite this many screening 
smears are performed.  Patients with abnormal cytological results are referred for 
further management, usually to dedicated colposcopy clinics. The current referral 
criteria is a single smear with a HSIL (High grade Squamous Intra-epithelial Lesion) 
or two LSIL (Low grade Squamous Intra-epithelial Lesion) smears. The aim of 
colposcopy is to detect the most abnormal area on the cervix and to direct the 
clinician to the area of biopsy.   
 
In many clinics a “see-and-treat” approach is used and a patient with an abnormal 
smear often gets treatment at her first visit to the colposcopy clinic. [4] If the referral 
cytology indicates a high grade abnormality and the colposcopic assessment 
supports the cytological diagnosis, a confirmatory biopsy of the cervix is not needed 
before excisional treatment is offered. The rationale may be that, in the public sector 
at least, follow-up rates are poor and that transport to and from clinics is difficult.  
One has to caution against blanket treatment of all patients purely on cytological 
results. Certain authors have shown that between five and 40% of all patients with 
abnormal cytology might not have histological abnormality on LLETZ cone biopsy. [5] 
It is therefore necessary to do a thorough colposcopic evaluation and to treat only 
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those patients with a recognizable abnormality.  If there is doubt about the severity of 
the abnormality, a biopsy should confirm a CIN II lesion or higher to justify treatment 
by destruction or resection of the transformation zone.  Over-treatment may 
jeopardize a patient’s future reproductive performance. 
 
Anatomical considerations 
 
The anatomy of the cervix is an important consideration when discussing potential 
longer-term side effects of cervical conisation.  The cervix has a specialised 
epithelial layer which is very important to both the cyto-pathologist and the 
gynaecologist.  All the investigations and treatments are aimed at the transformation 
zone which is the area between the original squamo-columnar junction and the 
current squamo-columnar junction.  This area is very susceptible to the oncogenic 
effects of the human papilloma virus.  On histology the transformation zone consists 
of ectocervical squamous epithelium covering the underlying stroma with glandular 
components. The endocervical glands may be involved with intra-epithelial neoplasia 
and may lie as deep as 7 mm from the surface epithelium. Treatment for intra-
epithelial neoplasia should be at least 1 cm deep to include these crypts. 
 
Treatment for cervical pre-cancer 
 
When treatment is planned for intra-epithelial neoplasia, the treatment should include 
the whole lesion as visible on colposcopy.  It should also include the upper border of 
the metaplastic epithelium. That might be slightly higher up in the endocervical canal, 
particularly in peri-menopausal patients.  The squamo-columnar junction might not 
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be visible during colposcopy (incomplete colposcopy). In order to achieve complete 
excision of the transformation zone in those cases, it is necessary to aim treatment 
even higher up in the endocervical canal.  A LLETZ cone biopsy should be of 
adequate size to achieve disease free margins and include the whole transformation 
zone.  It has been shown that incomplete excision margins may lead to a higher rate 
of treatment failure. 
 
Since 1965 it has been shown that locally destructive techniques might be as 
effective as hysterectomy in preventing the subsequent development of a CIN lesion 
into cancer.  These techniques include cryotherapy, coagulation, conisation and 
laser treatment.  Prendeville, during the late 1980’s, popularised the concept of large 
loop excision of the transformation zone although it was first described by another 
author a few years previously. [6] The principle of a LLETZ is that a high current is 
created in a very thin wire loop, which then produces a steam envelope in tissue that 
has a high water content.  This steam envelope cuts the tissue with minimal thermal 
damage to the surrounding tissue.  It is important that the sample produced after a 
LLETZ cone biopsy has as little thermal damage as possible. Thermal damage 
adversely affects the histological examination of the specimen.  Prendeville, in his 
original work, suggested that the depth of the cervical cone be between 0.7 and 
1.5cm.  
 
A cold knife cone biopsy has the potential advantage that there is a very clear 
surgical margin. That would make histological examination much more accurate.  A 
cold knife cone biopsy allows  tissue to be obtained higher up in the canal without 
damaging the histological sample. It is therefore preferred in some situations. If the 
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cytological evaluation suggests an endocervical lesion or if microscopic invasive 
cancer is suspected, the clinician may choose a cold knife procedure above a Lletz 
procedure.  Because of the more invasive nature of a cold knife cone biopsy, it might 
cause more long-term morbidity.  Whenever the underlying stroma of the cervix is 
included in the biopsy, the remaining cervix is shortened and the supportive tissue is 
potentially less capable of supporting an intra-uterine pregnancy. 
 
Reproductive outcome 
 
Cervical intra-epithelial neoplasia is most often diagnosed in women of reproductive 
years. [7]  When treatment for a CIN lesion is considered, it would be prudent to take 
note of a patient’s future reproductive wishes and to be aware of any adverse effects 
that cervical conisation might have on her future fertility and obstetrical outcome. 
Cervical conisation could theoretically have an adverse effect on a patient’s fertility 
and lead to an increase in the incidence of miscarriage, premature rupture of 
membranes, premature labour, cervical and precipitate labour.  
 
Infertility 
 
There is limited information in the literature about the effect of cervical conisation on 
fertility. Buller found no evidence of secondary infertility in a group treated by cold 
knife conisation. [8]  Keijser, Turlington, Bigrigg and Cruikshank did retrospective 
cohort studies on the effect of LLETZ conisation on subsequent pregnancy outcome. 
[9] [10] [11] [12] They could show no decrease in pregnancy rate in the treatment 
groups compared to the cohorts. Similarly Ferenczy, in a prospective cohort study of 
patients treated by LLETZ, could demonstrate no deleterious effect on fertility. [13]  
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Kyrgiou in an excellent meta-analysis concluded: “...despite these difficulties, the 
available evidence suggests that fertility is not impaired after treatment for cervical 
intraepithelial neoplasia.” [14] 
 
These studies provide some reassurance that cervical conisation is not a major 
cause of infertility. They unfortunately do not have sufficient power to exclude a 
subtle influence. 
 
Cervical conisation might lead to infertility by causing cervical stenosis or a decrease 
in the production of cervical mucus. Very rarely an ascending infection, caused by 
the conisation, might lead to tubal damage. There have been case reports of women 
presenting with secondary infertility due to cervical stenosis and amucorrhea post 
LLETZ.  [15]   Cervical stenosis seems to occur more often after cold knife cone 
biopsy than laser conisation or LLETZ. With all modalities, a higher cone is 
associated with a greater occurrence of cervical stenosis. [16] [17]  
 
It is important to remember that the patient who presents with a CIN lesion (caused 
by sexually transmitted HPV infection) is also at risk for tubal damage due to other 
sexually transmitted diseases. [8] This will need to be taken into account when any 
conclusions regarding the effect of cervical conisation on fertility are made. 
 
Miscarriage 
 
Cervical conisation has not been shown to have any effect on the occurrence of first 
trimester miscarriages. Midtrimester miscarriages do seem to be significantly more 
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common after cold knife conisation. Moinian compared the pregnancies in a group of 
414 patients before and after cold knife conisation.  He found late spontaneous 
miscarriages to be seven times more frequent after cold knife conisation than before. 
This complication increases proportionately to the size of the cone biopsy. [18] [19]  
 
Laser conisation and LLETZ do not seem to cause an increase in the incidence of 
midtrimester miscarriages. This is possibly due to the smaller amount of cervical 
tissue removed by these methods when compared to cold knife conisation. In a 
prospective study of 50 pregnancies in 86 patients treated by cold knife conisation, 
LLETZ or laser conisation, Mathevet observed no late miscarriages. [16] In a group 
of 54 women treated by laser conisation, Sagot noted no late spontaneous abortions 
in 71 pregnancies following conisation. [20] Similarly, Althuisius found no second 
trimester abortions in 56 women delivering after LLETZ. [21] These studies were 
unfortunately not large enough to detect less overt effects of conisation on the 
incidence of miscarriage. Nevertheless, it would seem prudent to rather do a LLETZ 
or laser conisation and only perform a cold knife conisation if it is specifically 
indicated. 
 
PPROM and premature labour 
 
In any study of the effect of cone biopsy on preterm premature rupture of 
membranes (PPROM) and preterm labour, it is important to bear in mind that CIN 
lesions have risk factors such as smoking, multiple sex partners and sexually 
transmitted diseases in common with both PPROM and premature labour.  [22] 
There are a number of mechanisms whereby a prior cone biopsy could lead to 
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PPROM and preterm labour. The structural change in the cervix after a cone biopsy 
is important. The cervix might be shortened and the collagen formed in the scar 
tissue could be more fragile and react in a different manner from normal tissue to the 
hormonal changes of pregnancy. Especially with the larger cones that remove 
endocervical glands, the formation of cervical mucus may be impaired. The 
protective mucus plug and local immunological mechanisms are compromised. This 
might lead to ascending infections, the release of prostaglandins and PPROM or 
premature labour. [22]  
 
Kristensen examined a cohort of 14 233 women of whom 170 had a cervical 
conisation. [22] Women who had cone biopsies for CIN lesions had a significantly 
increased risk of premature labour before 37 weeks when compared to the general 
population. This risk is increased before conisation, but even more so after 
conisation. The author postulates that the same risk factors that predispose patients 
to develop CIN lesions are also associated with premature labour, but that cervical 
conisation has an additive effect. 
 
Other earlier studies found cold knife and laser cervical conisation to be associated 
with delivery before 37 weeks gestation. [23] [24] [25] There are, however, also a 
number of studies that found cold knife or laser conisation and LLETZ not to be 
associated with preterm delivery or PPROM. [8] [12] [16] [20] [26] These conflicting 
results can be explained by the generally small size of the study groups and the 
resultant lack of power to detect significant differences in the incidence of preterm 
birth. 
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Crane did a systematic review on the effect of LLETZ on subsequent pregnancy 
outcomes [27] and found LLETZ to be significantly associated with preterm birth 
before 37 weeks gestation. In a retrospective cohort study of 571 women who 
delivered after a LLETZ, Samson found LLETZ to be associated with low birth 
weight, PPROM and preterm delivery before 37 weeks. [28]  The increase in delivery 
before 34 weeks was not significant. Sadler found both laser conisation and LLETZ 
to be associated with a significantly increased risk of PPROM and subsequent 
preterm delivery. This effect was more marked with increasing cone height. [29]   
 
In a large meta-analysis, there was a statistically significant association between 
cold knife conisation and preterm delivery RR 2·59 (1·80–3·72) and low birth weight 
RR 2·53 (1·19–5·36). [14] LLETZ was also significantly associated with preterm 
delivery RR1·70 (1·24–2·35) and low birth weight RR 1·82 (1·09–3·06). Laser 
procedures, both ablation and conisation, were not associated with preterm delivery 
or low birth weight infants. 
 
While it seems clear that cervical conisation results in a greater risk of PPROM and 
preterm delivery and that this effect increases with increasing size of the cone, most 
women will have uncomplicated pregnancies following cervical conisation. It remains 
to identify those at increased risk of having a complicated pregnancy after cervical 
conisation. Berghella found a cervical length on ultrasound of less than 25 mm to be 
predictive of preterm birth in patients with prior cone biopsy. [30]  It is unfortunately 
not yet clear how to best manage these patients. Prophylactic cerclage does not 
appear to prevent preterm labour in patients with prior cervical conisation. [31]   
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Despite excitement in the literature about the potential role of progesterone therapy 
in patients with premature labour, [32] a recent Cochrane review on the topic 
concluded with “there is insufficient evidence to advocate progestational agents as a 
tocolytic agent for women presenting with preterm labour”. [33]  Even though cervical 
length shortening was measured as an important outcome measure in the Cochrane 
review, no mention is made of any factors like previous cervical surgery or LLETZ 
procedures.  It is therefore very difficult to speculate on the effect of progesterone on 
the pregnancy outcome after LLETZ procedures. 
 
Precipitate labour and cervical dystocia 
 
Cervical conisation disturbs the structural integrity of the cervix. The resultant scar 
tissue might not respond appropriately to the hormonal changes of parturition and 
result in an abnormal pattern of labour. It has been shown that neither precipitate nor 
prolonged labour is more common after cervical conisation. [23] [27]  There is, 
however, a small increase in the number of caesarean sections done for cervical 
dystocia. [18] [19] [20]    
 
Conclusion 
 
Cervical conisation is an indispensable tool in the management of cervical intra-
epithelial neoplasia but is not without risks.  The risk of intra-operative complications 
is low and significant postoperative bleeding is rare. It may, however, also have long 
term adverse effects on a patient’s future fertility and obstetric outcome.  Cervical 
conisation is associated with a small but significant increase in the incidence of 
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PPROM and premature labour. The greater the amount of tissue removed by the 
cone, the greater is this effect. In isolated cases cervical conisation might cause 
cervical stenosis and amucorrhea which could lead to infertility.  
 
It is important to be aware of these possible complications and to appropriately 
counsel the patient before she undergoes treatment. The indications for conisation 
should be sound and should be based on a careful colposcopic examination of the 
cervix.  This would make unnecessary surgical intervention a rare event. It would 
seem prudent to remove as little cervical tissue as will treat the CIN lesion. During 
pregnancy the patient should be carefully monitored. Measurement of cervical length 
during the second trimester would identify those at higher risk of premature labour, 
but it is not yet clear how to best manage those patients. The role of prophylactic 
cerclage in the patient with a shortened cervix following conisation needs to be 
elucidated. 
 
Invasive cervical cancer 
 
 
Invasive cervical cancer remains one of the most common cancers affecting women.  
In certain parts of the world and in particular southern and eastern Africa, the 
incidence for cervical cancer is in the region of 30-50 cases per 100 000 women per 
year. [1] Cervical cancer is the most common cancer of women in South Africa. [34] 
The chances for developing cervical cancer increases with age, although about a 
third of cancers occur in patients during their fertile years. Figures from the National 
cancer registry of South Africa clearly show that the most common cancer of 
reproductive women in South Africa is cervical cancer.  
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Figure 2 Percentage distribution of 10 most common cancers by sex, 1998 and 1999, 
15-29 years [34] 
 
 
Figure 3 Percentage distribution of 10 most common cancers by sex, 1998 and 1999, 
30-54 years [34] 
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A significant number of women may be diagnosed with invasive cervical cancer 
before they have completed their families. Screening for cancer of the cervix results 
in a younger age at diagnosis but also often an earlier stage at diagnosis.  Many 
women and their partners prefer to delay childbearing to first establish their careers 
and this may increase the risk for developing cancer when fertility is still very 
important.  In Africa the HIV epidemic causes rapid progression from cervical cancer 
precursors to invasive carcinoma and the average age of diagnosis is 15 years 
younger in HIV positive individuals. [35] The average age of infiltrating cancer in a 
South African study was 39.8 years in HIV positive individuals versus 55.2 years in 
HIV negative individuals. Another study from Johannesburg confirmed the earlier 
age at which HIV infected women develop invasive cervical cancer. In that cohort the 
average age at presentation of HIV infected women with cervical cancer were 44 
years compared to 53 years in non-infected women. [36] An earlier study by 
Ellerbrock also showed that 20% of HIV positive women would develop biopsy 
proven CIN within three years. [37] This highlights the effect of HIV infection on the 
rapid progression from HPV infection to proven CIN lesions.  Evidence for the 
association between cytological abnormalities and HIV is seen in a study performed 
in Cape Town where an HIV positive population on anti-retroviral therapy was 
compared to historical control groups.  The incidence of HSIL in the HIV group was 
29.5% and the incidence of invasive carcinoma a staggering 3.1%.  When compared 
to historical controls (0.84 and 1.8% respectively for HSIL and 0.2% and 0.47% for 
invasive carcinoma) the effect is very clear. [38]  
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Factors affecting prognosis 
1) Tumour Volume 
 
Tumour volume is one of the most important predictors of outcome in cervical 
cancer.  Both adeno- and squamous carcinomas are staged according to the FIGO 
classification and microscopic disease is staged according to tumour volume. [39] 
Stage Ia1 indicates stromal invasion of less than 3mm in depth and less than 7mm of 
horizontal spread on the cervix.  Stage Ia2 refers to depth of stromal invasion 
between the 3mm and 5mm with horizontal spread of less than 7mm.  Any 
measurement above 5mm in depth and more than 7mm on the surface is regarded 
as a stage Ib tumour.  Any tumour visible to the naked eye is also regarded as stage 
Ib.  
 
Stage Pelvic Para-aortic 
Ia1 0.5 0 
Ia2 4.8 <1 
Ib 15.9 2.2 
IIa 24.5 11 
IIb 31.4 19 
III 44.8 30 
IVa 55 40 
 
Table 6 Importance of tumour volume (as defined by FIGO stage) as a 
predictor for lymph node involvement. [40] (Outcomes shown as %) 
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Careful pathological examination of early invasive cervical cancer is of utmost 
importance. During the pathology examination stromal invasion should be measured 
from the basement membrane of the nearest endocervical gland.  Adequate number 
of sections should be performed in cervical biopsies (LLETZ or cold knife cone) and 
an adequate number of sections, preferably less than 100 microns apart, should be 
examined by a dedicated gynaecological pathologist.  Lymphovascular space 
invasion and excision margins should be reported in addition to tumour size. 
 
Depth of stromal invasion in the 1994 FIGO staging divides stage Ia into Ia1 for 
tumours less than 3mm in depth and Ia2 for tumours invading more than 3mm but 
less than 5 mm. The horizontal spread must be less than 7mm. The FIGO staging 
before 1994 did not clearly state depth of “early stromal invasion” and most authors 
used 1mm as the upper limit. Some earlier studies using the 1985 FIGO staging may 
therefore have underestimated the risk for lymph node metastases in stage 1a2 
cancers. [41] A few published series reported on depth of invasion of 3-5mm but 
horizontal spread was not limited to less than 7mm. In these reports a total of 262 
patients had 7.3% risk for lymph node metastases but it varied from 0.0% to 13.8% 
in different reports.  A good review article by Sevin concluded that patients, with a 
stromal invasion of 3.1-5.0 mm, have a significantly higher risk of up to 7.4% for 
lymph node involvement and 5.4% for invasive cancer recurrence. [42]  
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Author n Nodal 
metastases 
Invasive 
recurrences 
Dead of  
disease 
Van Nagell 1983 [43] 32 3 (9.4%) 3 2 
Hasumi 1980 [44] 29 4 (13.8%) NS NS 
Simon 1986 [45] 26 1 (3.8%) 0 0 
Maiman 1988 [46] 30 4 (13.3%) 0 0 
Buckley 1996 [47] 94 7 (7,4%) 5 4 
Creasman 1998 [48] 51 0 (0.0%) 0 0 
Total 262 19 (7.3%) 8 (3.1%) 6 (2.3%) 
 
Table 7 Incidence of lymph node metastases with stromal invasion of 3-5 mm – 
horizontal dimension not stated.  [49]  
 
Width (or horizontal spread) of the tumour is also measure of tumour volume. FIGO 
staging incorporate surface spread in the diagnosis of stage Ia tumours by defing the 
maximum spread as 7mm.  See Table 8. 
Horizontal width 
(stromal invasion <5 
mm) 
Positive pelvic 
nodes (%) 
Recurrence (%) 
>7 mm 7.4 4.2 
<7mm 2 0.3 
 
Table 8 Importance of width of lesion (as defined by FIGO stage) as a predictor 
for lymph node involvement. [50] 
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2) Lymphovascular space involvement 
 
It is clear that lymph node involvement in cervical cancer conveys a poor prognosis 
for ultimate disease free survival. The numbers of cases with confirmed lymph node 
metastases decrease with decreasing stage. It would be ideal to identify those early 
cases with an increased risk for nodal involvement and a high risk for recurrence.  
Lymphatic- and/or vascular invasion by tumour indicate a higher risk for a poor 
prognosis. [51] Lymph node micro-metastases are associated with lymphovascular 
space involvement. [52]  The volume of lymphovascular space involvement, as 
defined by the percentage of all sections with lymphovascular space involvement 
and total number of foci with lymphovascular space involvement, is an independent 
prognostic factor for time to recurrence in women with early-stage squamous 
carcinoma of the cervix. [53]  
 
Stage LVI Lymph nodes % Recurrence % 
1a1 Pos 
Neg 
4.7 
0.5 
4.6 
0.6 
1a2 Pos 
Neg 
11.1 
3.4 
17.4 
0.9 
 
Table 9 Importance of lymphovascular space involvement as a predictor for 
lymph node involvement and recurrence of disease [54]  
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Lymphovascular space involvement as an independent indicator of risk may 
influence the decision to treat early invasive cervical cancer with uterus sparing 
surgery or not and may necessitate the addition of adjuvant chemo/radiation. 
 
3) Para-cervical or parametrial invasion 
 
Not all tumours are surgically treatable and full surgical staging is not possible in 
more advanced case of cervical cancer. However in early operable disease 
parametrial invasion in surgical specimens is a significant poor prognostic factor for 
disease free survival and overall survival. [55] [56] [57] Pre-operative clinical 
evaluation of parametrial invasion is subjective and there may be a high degree of 
inter-observer variability.  Magnetic resonance (MR) imaging may be the best 
imaging modality to detect parametrial invasion with the least inter-observer 
variability. [58] [59] Other authors question whether MRI is cost effective for the 
evaluation of parametrial invasion because preoperative MRI showed low PPV for 
detecting LN involvement and parametrial invasion in cervical cancer. [60] 
 
4) Lymph node metastases 
 
Lymph node involvement in cervical cancer increases with increasing stage.  Within 
stages, those with involved lymph nodes have a poorer prognosis and shorter 
disease free survival. [61] [62] Factors that influence lymph node involvement 
include tumour volume, lymphovascular space involvement, stage and parametrial 
involvement. [62] 
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Stage n % Pelvic nodes % Para-aortic 
nodes 
Ia1 179 0.5 0 
Ia2 84 4.8 <1 
Ib 1926 15.9 2.2 
IIa 110 24.5 11 
IIb 324 31.4 19 
III 125 44.8 30 
IVa 23 55 40 
 
Table 10 Lymph node metastases by stage. From [63] 
 
5) Resection margin status 
 
Cervical cancer surgery as a single modality for the treatment to safeguard fertility 
will only be successful if clear surgical margins can be guaranteed. [64] The 
accepted pathological tumour free margin is 3-5mm. [65] [66] In cases where 
conservative surgery for fertility preservation is attempted, intra-operative frozen 
section to evaluate surgical margins is essential. [67] If, during uterus sparing 
surgery, the specimen is not clear at the resection margin at as determined by frozen 
section, a further (deeper) resection should be done or a completion operation 
performed. 
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Stage 0  Carcinoma in situ, cervical intra-epithelial neoplasia grade 3 
Stage I  The carcinoma is strictly confined to the cervix (extension to the corpus would be disregarded 
 IA Invasive carcinoma which can be diagnosed only by microscopy.All macroscopically visible lesions—even with superficial invasion—are allotted to 
stage IB carcinomas. Invasion is limited to a measured stromal invasion with a maximal depth of 5.0 mm and a horizontal extension of not >7.0 
mm. Depth of invasion should not be>5.0 mm taken from the base of the epithelium of the original tissue—superficial or glandular. The 
involvement of vascular spaces—venous or lymphatic—should not change the stage allotment 
 IA1 Measured stromal invasion of not >3.0 mm in depth and extension of not >7.0 mm 
 IA2 Measured stromal invasion of >3.0 mm and not >5.0 mm with an extension of not >7.0 mm 
 IB Clinically visible lesions limited to the cervix uteri or preclinical cancers greater than stage IA 
 IB1 Clinically visible lesions not <4.0 cm 
 IB2 Clinically visible lesions >4.0 cm 
Stage II  Cervical carcinoma invades beyond the uterus but not to the pelvic wall or to the lower third of the vagina 
 IIA No obvious parametrial involvement 
 IIB Obvious parametrial involvement 
Stage III  The carcinoma has extended to the pelvic wall. On rectal examination, there is no cancer-free space between the tumour and the pelvic wall. The 
tumour involves the lower third of the vagina. All cases with hydronephrosis or nonfunctioning kidney are included unless they are known to be 
due to other causes  
 IIIA Tumour involves lower third of vagina with no extension to the pelvic wall  
 IIIB Extension to the pelvic wall and/or hydronephrosis or non-functioning kidney  
Stage IV  The carcinoma has extended beyond the true pelvis, or has involved (biopsy proven) the mucosa of the bladder or rectum. A bullous oedema, as 
such, does not permit a case to be allotted to stage IV  
 IVA Spread of the growth to adjacent organs 
 IVB Spread to distant organs 
 
Table 11 Carcinoma of the cervix uteri: FIGO nomenclature (Montreal 1994) 
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Treatment for stage Ia1 cervix cancer 
 
A small volume tumour, FIGO stage Ia1, with depth of invasion of less than 3mm and 
less than 7mm on the surface, is adequately treated with a cold knife cone biopsy. 
[68] [69] [70] Laser conisation has also been reported as a safe option. [71] Care 
should be taken where lymphatic- and or vascular invasion is present on initial 
biopsy and pelvic lymphadenectomy should be part of surgical management.  It is 
important to consider excision margin status and the cone edges should be negative 
not only for invasive carcinoma but also for intra-epithelial disease.  Ideally pathology 
should be reviewed at a multi-disciplinary team meeting and after treatment the 
patient should have careful cytology follow-up on a regular basis.  Evaluation of the 
vulva and vagina is important when micro invasive cervical cancer is diagnosed 
because of the high incidence of multi-focal human papilloma virus disease. 
 
Even if stage 1a adenocarcinoma of the cervix is diagnosed during pregnancy, a 
conservative approach may be reasonable. A cone biopsy (also sometimes called a 
coin biopsy because of flatter shape to avoid membrane rupture) during pregnancy 
with careful follow-up is acceptable as reported from Japan. [72] 
 
Cold knife conisation may shorten the cervix and may impair the ability of the uterus 
to sustain a pregnancy. The increased incidence of premature labour and premature 
rupture of membranes has been discussed earlier.  
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Treatment for stage Ia2 to Ib1 cervix cancer 
 
The standard approach for treatment for slightly larger volume disease historically 
has been radical hysterectomy with pelvic lymph node dissection. [69] However, with 
radical hysterectomy or pelvic radiotherapy the patient was not only rendered infertile 
but in addition both neurological and rectal dysfunction was unfortunate 
complications. [73] Some authors now argue that a simple hysterectomy, or even 
cone biopsy, with pelvic lymphadenectomy is adequate treatment. [70] [68] This 
approach afforded at least a 90% cure rate if lymph nodes were found to be negative 
during surgery.   
 
The rationale for less aggressive surgery 
 
Less than 31% of all stage Ib1 cases will have parametrial involvement. [57] Another 
retrospective report found that “positive parametrial involvement in stage Ia and Ib1 
cervical cancer is infrequent.” [74] In an attempt to predict which individuals are likely 
to have parametrial involvement, Bennedetti-Panici further found that parametrial 
involvement was found in less than 2% of cases if pelvic lymph nodes were negative. 
[75]   Some authors have questioned the need of a complete parametrial excision in 
early cervical cancer. [76] A suitable approach intra-operatively may therefore be to 
do a frozen section of the pelvic lymph nodes before continuing with the radical 
hysterectomy and this approach can predict parametrial invasion with 90% sensitivity 
and 100% specificity.  Those cases that were not accurately predicted had 
metastases less than 4mm in diameter. [75]  
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The history of surgical treatment for cervix cancer 
 
Hippocrates, in approximately 400 BC, carried out the first known cervixectomy or 
trachelectomy (from the Greek word t??????? for neck) in order to remove bleeding 
tumours.  This approach was clearly unsatisfactory and had little chance of cure. [77] 
Radical operations in surgical oncology became popular in the beginning of the 20th 
century after the hypothesis of Halstead and Meyer became dogma.  The initial work 
was described for the management of breast cancer and the hypothesis was that 
cancer spread from the primary site through the lymph nodes to distant sites.  
Removal of the entire breast together with the tumour and also adding healthy 
adjacent tissue with removal of nearby lymph nodes was the best way to prevent 
future persistence of disease.  In the next 20 years following the initial reports, 
Halstead and his followers expanded on the hypothesis of “contagious spread” of 
breast carcinoma to other forms of cancer. A colleague of Halstead called JD Clarke; 
also working at John’s Hopkins in Baltimore, applied the same principles to cervix 
cancer and did the first radical hysterectomy for cervix cancer in 1895. This was 
followed in 1896 by Wertheim.  Wertheim described a procedure for removing the 
uterus with the cervical tumour and a wide tumour free margin. The removed tissue 
included the upper part of the vagina, the para-cervical and parametrial tissue and 
sampling of the pelvic lymph nodes. Wertheim reported the outcomes of his first 270 
patients in 1905. The peri-operative mortality rate was 18% and the major morbidity 
rate was 31%. [78] Other authors (notably Schauta who was Wertheim’s 
predecessor) described similar procedures that were performed vaginally and 
achieved lower operative mortality rates than the abdominal approach.  Meigs 
revived interest in the radical surgical approach from 1944 when he developed a 
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modified Wertheim operation with removal of all pelvic nodes. Meigs reported a 
much improved survival rate of 75% for patients with stage I disease and 
demonstrated an operative mortality rate of only 1% when these procedures were 
performed by a specially trained gynaecologist.  
 
From the late 1940’s the concept of pre-malignant disease of the cervix became 
better known and in 1948 Franz Novak performed surgical removal of the cervix for 
an intra-epithelial neoplasia.  This procedure was the predecessor of modern cone 
biopsies that led eventually to work of Burghardt and Holzer on micro-invasive 
carcinoma of the cervix where they stated that it was not always imperative to 
remove the whole uterus for small early cervical cancers. [79]  
 
Dargent and co-workers described “la trachelectomie elargie” (TE). [80]  (reference 
taken from [77] ) This was a new concept of radical surgery for an early cervical 
tumour with conservation of the uterine corpus.  The technique has subsequently 
been modified slightly by Shepherd and co-workers. [81] Roy and Plante followed 
soon after with a report of a successful pregnancy after such treatment.  [82] Radical 
removal of the cervix with conservation of uterine function has become an 
established treatment option, where expertise is available, for the treatment of early 
stage cervical cancer in patients with a fertility wish. 
 
Dargent’s operation (radical vaginal trachelectomy) 
 
Dargent and other authors developed a radical operation for the treatment of early 
cervical tumours. [83] [84] This operation follows Halstead’s principals but aims to 
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preserve uterine function and makes conception, normal menstruation and even 
pregnancy possible.  The removal of the cancer should include an adequate surgical 
margin and the resection includes parametrial tissue and pelvic lymph nodes.  The 
aim of the operation is to include the whole of the cervix with a clear 1cm margin 
beyond the tumour and a vaginal cuff and para-cervical tissues of approximately 
2cm. 
 
The first step in Dargent’s operation is a pelvic lymph node dissection with a 
laparoscopic approach.  Intra-operative frozen sections are done of the lymph nodes 
and if these are negative the cervix is removed together with the parametria through 
the vaginal route.  The endocervical margin is also checked for possible malignancy 
and if the excision margin is positive a further portion of the cervix should be 
removed.  The last aspect of this operation is to include a “cervical” cerclage. With 
adenocarcinomas, removal of the entire endocervical canal is essential; skip lesions 
and field change effects may affect the canal higher (and separate from) the initial 
tumour. [85] Since the first description of vaginal trachelectomy, a few modifications 
have been published of which an open abdominal procedure was described by Abu-
Rustum in 2006.  [86] Another approach was to do extra-peritoneal abdominal lymph 
node dissection, a technique that is described for radical vaginal hysterectomy [87] , 
and in this way prevent adhesion formation due to manipulation of the Fallopian 
tubes and the ovaries.  [88] 
 
Laparoscopic lymphadenectomy requires advanced laparoscopic pelvic sidewall 
dissection and training and expertise is not always available. Additional to this, 
advanced laparoscopy is time consuming and expensive and requires a highly 
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equipped theatre. In South Africa and other developing countries where the 
incidence of cervical cancer is high, a more pragmatic approach would be to do an 
extra-peritoneal lymphadenectomy through an abdominal incision. This will also have 
the added benefit of protecting the intra-peritoneal environment against infection and 
adhesion formation.  
 
Selection criteria for radical trachelectomy 
 
Radical trachelectomy, whether it is done abdominally or trans-vaginally, should still 
be considered as a highly specialised procedure that should be performed in centres 
with the necessary surgical skill. When the decision is taken to be conservative in a 
patient with invasive cancer, oncological outcome should not be compromised in 
order to safeguard fertility. Only if the following criteria are met should a 
trachelectomy be offered: [89] 
 
· Carcinoma of the cervix 
· Younger than 40 years of age with fertility desire 
· No unfavourable histology (eg neuro-endocrine tumours) 
· Stage Ia1 with lymphovascular space invasion 
· Stage Ia2 or Ib1 with tumours less than 2cm 
· If the endocervix is involved with tumour, colposcopy (with the aid of Kogan’s 
endocervical speculum) or MRI is important to see the upper limit of the 
tumour 
· No radiological evidence of lymph node- or systemic metastases 
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Oncological features 
  
The oncological outcome of trachelectomy procedures, as measured by tumour 
recurrences, compares very favourably with standard radical hysterectomy and is in 
the region of approximately 4%. [90] [77]  Recurrences occurred up to eight years 
after the surgery, and although the recurrence rates are less than expected for a 
similar group of patients with stage Ib1 disease, it may be because of the good 
prognostic small tumours that have been selected for this specific procedure.  
Despite the fact that the recurrence rates are very low, it is still very important that 
patients should have careful cytological, colposcopic and clinical follow-up on a 
regular basis.  The oncological features of a total of 520 cases from different centres 
are summarised in Table 12. 
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Authors Dargent 
n=95 [91] 
[92] 
Plante, Roy 
n=72 [93] 
Covens 
n=93 
[94] [89] 
Burnett 
n=21 
 [95] 
Schlearth 
n=10 
[96] 
Hertel 
n=108 
[97] 
Shepherd 
n=123 
[98] 
Total 
n=520 
Age 32 31 30 30 31 32 31 31 
Follow-up (mths) 76 (4-176) 60 (6-156) 30 (1-103) 31 (23-41) 47 (28-84) - 45 (1-120) 48 (1-176) 
Squamous cell 76 (80%) 42 (58%) 42 (48%) 10 (53%) 4 (40%) 75 (69%) 83 (67.5%) 332 (60%) 
Adenocarcinoma 19 (20%) 30 (42%) 44 (52%) 9 (47%) 6 (60%) 33 (31%) 33 (27%) 174 (40%) 
LVSI 23 (24%) 14 (20%) 31 (36%) 2 (11%) 1 (10%) 38 (35%) 39 (32%) 148 (24%) 
Size <2cm 74 (78%) 64 (89%) 85 (91%) 19 (100%) 8 (80%) * N.R. 250 (88%) 
Size >2cm 21 (22%) 8 (11%) 8 (9%) 0 (0%) 2 (20%) * N.R. 39 (12%) 
Op. time (min) 163 250 180 220 N.R. 253 N.R. 213 
Recurrence rates 4.2% 2.8% 7.3% 0 0 4% 2.7% 4.2% 
Death rates 3.1% 1.4% 4.2% 0 0 2% 3.3% 2.8% 
 
Table 12 Oncological features of trachelectomy series from different units 
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Pregnancy outcomes for trachelectomy 
 
 
In the general population, the average accepted fertility rate is in the region of about 
85%. [99] Bernardini is of the opinion that the incidence of infertility, in a patient 
population suitable for conservative cervical cancer surgery, may be higher. [100] 
There is support for this opinion from Dargent [101] and Shepherd. [85]  In an earlier 
report from Roy and Plante, none of the six patients trying to fall pregnant, could 
achieve a pregnancy. [82] Possible reasons for a decreased fertility rate in this 
population may include the fact that human papilloma virus infection is a marker of 
sexually transmitted diseases.  This could also indicate a population that is at higher 
risk for tubal damage due to previous upper genital tract infections.  The 
trachelectomy procedure in itself may also compromise tubal function.  If an open 
laparotomy is performed for the pelvic lymphadenectomy, manipulation of the uterus 
and other pelvic organs during surgery may cause adhesions. 
 
Over the last decade, a few larger series have been published about pregnancy 
outcome in this patient population.  The biggest risks for pregnancies after 
trachelectomy procedures are miscarriage, premature preterm rupture of 
membranes, early delivery and subsequent premature infants.  This pregnancy loss 
occurs despite prophylactic cervical cerclage.  In a review published during 2005 by 
Shepherd of a total of 406 cases, he described 171 pregnancies which occurred in 
118 women, resulting in 109 live births.  Seventeen of the live born infants delivered 
before 32 weeks gestation.  [77] Pregnancy loss before viability also is a serious 
concern.  The number of first and second trimester losses from six different authors 
are summarised in Table 13.  It is clear that less than 60% of all deliveries occurred 
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at term.  Approximately 32% of pregnancies ended in loss and before viability. The 
first trimester losses may be similar to that of the general population, but the second 
trimester loss rate is much higher than expected.  
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Table 13 Pregnancy loss rates after trachelectomy from different units 
  
Author Schlaerth 
[96] 
Burnett [95] Shepherd 
[85] 
Dargent/ 
Mathevet 
[16] 
Bernardini 
[100] 
Roy/Plante 
[82] 
Total 
1st trimester loss % 0 0 29 16 14 16 13 
2nd trimester loss % 50 33 7 14 5 4 19 
Delivery> 37 Weeks % 50 50 22 85 67 78 59 
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Bernardini speculates that the amount of cervical tissue remaining after 
trachelectomy may influence the incidence PPROM. [100]  The material used for the 
cervical cerclage may also make a clinical difference.  A procedure called “Early 
Total Cervical Occlusion” (ETCO), has been suggested as a possible solution for 
PPROM. [102] [100] The specific factors causing premature rupture of membranes 
have been well studied, but there are no definitive conclusions. Both mechanical and 
infectious pathways may be involved in post-trachelectomy patients.  The mucus 
plug, which may protect against infection, is usually absent if the patient has a short 
cervix.  The absence of the mucus plug may lead to ascending infection.  [85] The 
use of prophylactic antibiotics between 14 and 16 weeks, with regular bimonthly 
vaginal swabs for bacterial infections has also been suggested as a possible 
management strategy. [100] Because of the higher rate of premature delivery, a 
single dose of corticosteroids, given routinely during the second trimester, may be a 
useful intervention.  [103] In general obstetric literature regular sonographic 
evaluation for cervical incompetence have also been suggested as a possible early 
warning sign of premature birth. [104] [105]  
 
Shepherd describes a single case where, as a result of a lower segment transverse 
caesarean section, extensive bleeding occurred when the incision extended into a 
uterine vessel. [77] Because of this risk of uterine tears and bleeding, the suggestion 
is made that these patients should always have an elective caesarean section by a 
lower vertical midline incision (classical caesarean section), as the lower segment is 
usually not well developed.  Shepherd also describes an abdominal cerclage in a 
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case where the insertion of the initial cerclage was impossible due to the very limited 
cervical tissue. 
 
Neo-adjuvant chemotherapy followed by uterus conserving surgery 
 
Plante described in 2006 three cases with locally advanced cervical cancer treated 
with neo-adjuvant chemotherapy (NACT) and radical vaginal trachelectomy. [106] All 
these patients were young, pre-menopausal patients who required future fertility.  
They were treated with: 
o Paclitaxol 175mg/m2 on day 1 
o Cisplatinum 75mg/m2 on day 2 
o Ifosfamide 5g/m2 over 24h and 
o Mesna 5g/m2 on day 2 and 3 
These cycles are to be repeated every three weeks. 
 
The chemotherapy was followed by laparoscopic pelvic lymph node dissection and 
radical vaginal trachelectomy.  All cases had initial tumour sizes of less than 4x4cm 
on MRI imaging.  All patients had excellent pathological response on chemotherapy 
with negative nodes and surgical margins during surgery.  However, the 
chemotherapy caused significant bone marrow suppression and there is also a 
concern about the use of ifosphamide and cisplatinum for ovarian follicle reserve.  A 
successful pregnancy after treatment for invasive cervical cancer treated by NACT 
followed by conisation has also been described. [107] Although NACT could make 
more patients suitable for uterus conserving surgery, it may reduce follicular reserve 
and cause premature ovarian failure. 
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Conservative surgery in endometrial cancer 
 
Endometrial carcinoma is usually a disease of peri- or post-menopausal women.  
There are, however, a number of younger women who develop endometrial cancer, 
who usually present with excess oestrogen associated with obesity, infertility and 
nulliparity.  Overall, 2-14% of endometrial cancers occur in women younger than 40 
of age. [108] [109]  There are many case reports in the literature of early stage, low-
grade endometrial cancers that have been treated using uterus conserving 
therapies. [110] [111] [112] [113] Hormonal treatment with progesterone, with or 
without additional gonadotrophin- releasing- hormone analogue (GnRHa), often have 
the result that these early-stage tumours respond adequately to allow time for 
pregnancy.  Surgery as part of conservative management of endometrial carcinoma 
or atypical endometrial hyperplasia has been described by Jadoul. [109] A small 
number of early-stage endometrial cancers were treated with partial hysteroscopic 
resection followed by GnRHa for three months. [109] Regular endometrial curettage, 
combined with medroxyprogesterone acetate, has also been used for the treatment 
of early-stage tumours. [114]   
 
Despite the many case reports of successful conservative management, there 
remain some doubt about the safety of this approach. There have been isolated 
reports of metastatic disease in the myometrium or ovaries after conservative 
treatment.  [115] [116]    
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Fertility sparing surgery in ovarian cancer 
 
Ovarian cancer is the sixth most common form of cancer in women but is the fourth 
leading cause of cancer death in the more developed regions of the world. [1] The 
symptoms are usually mild and the cancer is usually only diagnosed in advanced 
stages of the diseases.  It occurs mainly in older women, but below the age of 40 
years, the incidence can be as high as 3/ 100 000 women per year. [117]  In these 
young women the question arises whether fertility sparing surgery is possible without 
compromising survival.  Selected patients with Borderline Ovarian Tumours (BOTs) 
or early stage invasive epithelial cancer (FIGO stage Ia) with well differentiated 
tumours may be managed with fertility sparing surgery. [117] [118] [119] [120] [121] 
[122]  
 
Successful pregnancies after conservative surgery for BOTs have been reported by 
various authors. [120] [119] [117] Selection criteria for conservative fertility-sparing 
management of BOTs depend on the risk for recurrence with invasive disease. The 
following factors may influence the risk for invasive disease: 
 
· DNA ploidy status (Aneuploid tumours had 19x higher risk of dying of 
disease) 
· Stage at presentation 
· Histological type (serous types have better outcome) 
· Age at diagnosis [123] 
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The presence of micro-invasion together with BOT has been seen as a possible poor 
prognostic indicator but a large meta analysis showed no increased risk for poor 
prognosis. [124]  The World Health Organization (WHO) classification system states 
that, in borderline tumours, it is acceptable for stromal micro-invasion up to 5mm of 
measurement in any single focus or peritoneal implant. [125] Surgery for borderline 
tumours may include unilateral oophorectomy in patients with unilateral disease or 
an ovarian cystectomy with resection of all peritoneal and omental deposits in 
patients with bilateral disease.  Careful surgical staging is important.  After 
completion of the family, completion surgery with a total hysterectomy and removal 
of any ovarian tissue is debatable.  However, some authors suggest that late 
recurrences are reported in retrospective reports and therefore completion surgery is 
indicated. [117] 
 
Early stage, well-differentiated invasive epithelial ovarian carcinoma can also be 
treated successfully with fertility sparing surgery.  In these patients accurate surgical 
staging is of the utmost importance.  A surgical staging procedure should include 
peritoneal washings, removal of the primary tumour, multiple random peritoneal 
biopsies and infracolic omentectomy. A lymph node dissection may be considered in 
poorly differentiated tumours.  Only if, after careful surgical staging, the patient 
remains a FIGO stage Ia can conservative management and omission of adjuvant 
therapy be safely advised. 
 
Epithelial ovarian cancer infrequently occurs at a young age. The place for 
conservative management in invasive epithelial cancer is limited.  Colombo and co-
workers reported data on 99 patients younger than 40 who had treatment for stage I 
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ovarian carcinoma. [126] Fifty-six percent of these patients had fertility sparing 
conservative surgery over a period of 10 years between 1982 and 1992.  Of the total 
of the 99 patients, only 16 received adjuvant chemotherapy consisting of cisplatinum 
alone before 1988 and carboplatinum after 1989.  The recurrence rate among the 
patients who had conservative surgery and those who had radical surgery is shown 
in Table 14.  The patients were followed up for a median of 75 months.   
 
 Surgery 
 Fertility sparing Complete staging (radical) 
Stage 1a   
Grade 1 1/24 0/15 
Grade 2 1/8 1/5 
Grade 3 1/4 1/3 
Stage Ib 0/1 1/4 
Stage Ic 0/19 2/16 
Total 3/56 5/42 
 
Table 14 Relapses in patients <40 years according to type of surgery. Data 
represented as relapses per group. Adapted from [126] 
 
Colombo et al state that “our experience suggests the possibility of some extension 
of the traditional conservative approach to patients with unfavourable prognostic 
factors. When a stage I ovarian carcinoma is found at the time of first laparotomy we 
believe that conservative surgery can be performed regardless of the histo-type and 
histological grade”. [126]  Many of the patients included in this long-term follow-up 
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study attempted pregnancy. Of the 17 patients attempting pregnancy all women 
conceived. A total of 16 healthy babies were born. Two patients had ectopic 
pregnancies, 4 miscarried and 4 had elective terminations. 
 
In a review on the role of surgery in ovarian carcinoma, the authors state that “in 
selected patients desiring fertility who have stage Ia G1 or 2 ovarian tumours, 
unilateral salpingo-oophorectomy with inspection of the contra-lateral ovary and 
comprehensive staging is an option with a low risk of recurrence”. [127]  This 
approach is supported by the work published by Maltaris where 113 pregnancies 
resulted after conservative treatment in 282 patients with early invasive ovarian 
carcinoma. [90]  Sixteen of the 282 patients died due to ovarian cancer disease and 
a total of 33 developed recurrences. 
 
A summary of the literature is presented in Table 15. 
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Author Patients (n) Pregnancies (n) Term deliveries (n) Relapses (n) Death disease (n) 
Colombo [126] 56 25 16 3 2 
Zanetta [128] 84 33 22 5 3 
Duska [129] 6 2 2 1 1 
Morice [130] 34 10 7 10 4 
Schilder [131] 52 17 26 5 2 
Raspagliesi [132] 10 3 3 0 0 
Colombo [133] 24 7 6 7 2 
Park [134] 62 15 22 11 6 
Kajiyama [135] 60 13 9 8 7 
Satoh [136] 211 56 56 18 5 
 
Table 15 Reproductive and oncological outcome in patients with epithelial ovarian cancer after conservative treatment 
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Surgery for non-epithelial ovarian cancer should be individualized but fertility sparing 
surgery is a real option.  Many of the germ cell and sex cord stromal tumours 
respond well to surgery alone or a combination of surgery and chemotherapy. [90] 
[137] Individualization of care after final histological diagnosis will depend on the 
particular histological type. 
 
Surgical ovarian trans-position 
 
The human oocyte is exquisitely sensitive to the damaging effects of radiation and 
the estimated LD50 is less than 4 Gray. [138]  A descriptive study by Wallace found 
that 37 out of 38 females had ovarian failure after whole abdominal irradiation of 20 
to 30 Gray in childhood.  Seventy-one percent had primary amenorrhoea i.e. they 
never had normal pubertal development and premature menopause occurred in the 
rest with a median age of 23.5 years. [139] Ovarian trans-position outside the field of 
radiotherapy may reduce the dose to the ovary. Howell described how lateral trans-
position of the ovaries to the para-colic gutters may reduce the radiotherapy dose by 
up to 95%.[140] This may protect the sensitive follicles to direct dose related 
damage. Other reports, however, were less optimistic and found that ovarian trans-
position may compromise blood supply and there was mixed success with this 
technique due to scatter radiation and vascular compromise. [141] Ovarian 
transposition may have a place in cases where the pelvic dose of radiotherapy is not 
high enough to be damaging to the other organs of the reproductive tract.  
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Conclusion 
 
Surgery remains an effective treatment option for many gynaecological cancers. The 
surgeon should be aware of the potential effects of treatment on future reproductive 
outcome. Procedures for the treatment of pre-malignant cervical disease may cause 
premature rupture of membranes in subsequent pregnancies. Premature labour and 
midtrimester miscarriages are also more frequent in women who had cervical 
surgery. 
 
Small early stage cervical cancers may be suitable for uterus-sparing surgery.  
Premature rupture of the membranes and premature labour are risks after radical 
trachelectomy procedures.  Ovarian function may be preserved in advanced cases 
by ovarian cryopreservation. 
 
In selected cases of early, low risk ovarian and endometrial cancers, fertility sparing 
conservative surgery can be a safe and reasonable option.   Quality of life in young 
cancer survivors may be as important as oncological outcome. 
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Chapter 3: Pharmacological options for the protection of 
ovarian function in patients undergoing chemotherapy  
 
 
Abstract 
 
Chemotherapy, particularly alkylating agents, can be toxic to germ cells and may 
lead to chemotherapy induced amenorrhoea in young women.  The age at which 
chemotherapy is administered is a strong predictor of subsequent premature ovarian 
failure with older patients at the highest risk.   
 
Smaller primordial follicles may survive the insult of chemotherapy better and 
suppression of follicle development may protect the germ cell pool. Suppression of 
follicle development by gonadotrophin-releasing hormone agonists (or antagonists) 
(GnRHa) or combined oral contraceptives have been reported in the literature. The 
results are promising but conflicting reports of the protection makes further studies 
essential. 
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Introduction 
 
Over the last few decades major improvements have been made in the treatment of 
childhood and adolescent malignancies.  However, treatment modalities may have 
serious harmful effects on ovarian function and the incidence of premature ovarian 
failure in patients who received chemotherapy and/or radiotherapy is increased from 
the general population. [1] [2]  The late effects of cancer treatment have been a 
popular topic for discussion in the medical literature and various attempts have been 
made to protect young women against the potential harm of chemo- and 
radiotherapy.  Chemotherapy and radiotherapy may permanently harm reproductive 
ability and a high rate of premature ovarian failure due to damage to germ cells and 
follicles is widely reported. [1] [3] [4]  Age at treatment with chemotherapy remains 
one of the most important determinants of the incidence of ovarian failure.  The risk 
increases with age of exposure. [5] [6] [7] Increasing age is as an important 
predictive factor for chemotherapy-induced amenorrhoea. [8] Differing response to 
chemotherapy was demonstrated between pre-pubertal girls and adult women during 
treatment for lymphoma.[9]  
 
Many theories have been put forward to explain the age phenomenon.  A popular 
theory is that the number of primordial follicles decreases with age as demonstrated 
by the Faddy-Gosden differential equation. [10] [11] [12] It is argued that a constant 
fraction of the primordial follicles will be damaged during a particular cycle of 
chemotherapy (or radiotherapy).  Therefore the remaining number is directly 
proportional to the initial population. This initial population decreases at a logarithmic 
rate and hence the older the patient the lower the initial population of primordial 
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follicles will be.  The total number of oocytes in the ovary is a combination of 
primordial, small primary and intermediary follicles. [13]  
 
GnRH agonists 
 
Almost 30 years ago Glode tested the possibility of testicular protection against 
cyclophosfamide induced damage in male mice and found a protective effect of 
GnRH- agonists. [14] 
 
Ataya demonstrated that GnRHa may protect against chemotherapy induced ovarian 
compromise in a murine model as early as 1985 and other reports from studies in 
female rats, seemed to confirm this work. [15] [16] [17] [18] The data from Letterie, 
however, did not show improvement in outcome in the same animal model.  [19] In 
another study, mice were treated with cyclophosfamide and combined 
oestrogen/progesterone or leuprolide acetate. The author concluded that neither 
method of ovulation suppression protected the mice against gonadal toxicity. Despite 
the promising work in rats where GnRH-agonists inhibited chemotherapy induced 
ovarian damage, many authors remain sceptical about its application in humans. [20]  
[21]  A possible reason for the difference between rats and humans may be the 
lower incidence of GnRHa receptors in human ovarian tissue. [22] [23]   
 
Ataya later showed in three adult menstruating female rhesus monkeys (Macaca 
Mulatta) treated with GnRHa during chemotherapy that they had more primordial 
follicles after treatment than those not receiving GnRHa. [24]  The possible 
protective mechanisms postulated were: 
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· Suppression of the levels of gonadotrophins in the ovary 
· A direct influence of GnRHa mediated through receptors in the ovary 
· A reduction in the metabolism of the ovary resulting in a decrease in the blood 
flow to the ovary 
 
Oral contraceptives also may reduce the gonadotrophin levels in the follicular 
environment and therefore may also create a similar environment for protection. [25] 
 
For ovulation to occur during a particular menstrual cycle a single oocyte within a 
dominant follicle must develop.  This whole process starts when a group of 
primordial follicles starts to develop. From this group a single follicle is selected to 
eventually effect ovulation.  Growing follicles makes up less than 10% of the total 
number of follicles but after initiation of the growth process either ovulation or atresia 
is inevitable. [26] The initial growth is independent of gonadotrophins. [13]  It does 
not make a plausible argument that GnRHa works as a protective mechanism during 
chemotherapy by keeping follicles outside of this growth phase because the initial 
process is gonadotrophin independent.  Some interesting work found that in human 
ovarian cells GnRHa receptors are absent before reaching the stage of pre-ovulatory 
follicle and the corpus luteum; therefore no GnRHa stimulation is possible in the 
primordial and early follicular stages of development. [27] [28]   
 
Imai, in 2007, demonstrated that  Buserelin acetate was protective against damage 
by doxyrubicine on human granulosa cells. [29] It was an in vitro study of cultured 
cells exposed to chemotherapy and provided additional support for a protective 
action of GnRHa on stromal cell damage. The authors found that doxorubicin 
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damage caused irreversible decreases in oestrogen production and that by adding 
GnRHa before or during exposure protected granulosa cells.  Granulosa cells only 
showed receptors for GnRHa in mature follicles; therefore the presence or absence 
of GnRHa receptors as the mechanism through which GnRHa analogues protects 
against chemotherapy damage also does not make biological sense. It is important 
to remember that, although this study had as its primary measure to determine 
GnRHa analogues protection against granulosa cell damage, it was performed in 
vitro; therefore a direct influence on the cell environment may play a role and not the 
hypo-gonadotrophic environment that would be created in the usual clinical situation. 
 
The cortex of the ovary is a relatively avascular area.  GnRHa down regulation of 
pituitary stimulation may further reduce the blood flow in the ovary. Ultrasound 
studies have shown reduced perfusion during reduced pituitary stimulation. [30] [31]  
By reducing blood flow, the exposure of follicles to harmful chemotherapy may be 
decreased.  Although this is plausible, there is conflicting evidence that the blood 
flow may not significantly change after treatment with GnRHa when measured by 
Doppler flow studies. A three dimensional doppler flow study of 85 women who were 
treated with short term Buserelin did not show significant changes in antral follicle 
count, stromal blood flow or ovarian volume.  [32]  
 
GnRH-agonists may up-regulate the production of anti-apoptotic molecules such as 
sphingosin-1-phosphate. [33]  It may also affect molecules like transforming growth 
factor-b. [34] Other growth factors in the transforming growth factor super-family may 
also be influenced by GnRH-analogues.  However, the complex interaction of all 
these growth factors is very difficult to show and control in an experimental model.  
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Some work suggests that the transition between primordial to primary follicle may be 
influenced by ligands produced by growing follicles (these growing follicles will be 
under the influence of gonadotrophins). [35]  Through this secondary pathway down-
regulation of growing follicles by an absence of FSH stimulation may lead to a lesser 
number of follicles being recruited. 
 
Whatever the mechanism that may be involved in protection, it has been shown 
convincingly that the prepubescent girls are less likely to develop premature ovarian 
failure after chemotherapy than older patients.  This led to the assumption that an 
artificial pre-pubertal environment might lead to ovarian protection.  This argument 
may be inaccurate and has not been conclusively shown in experimental models.  
The reason why young girls may have less obvious functional damage is likely due 
to the fact that the total number of follicles available is much higher at younger age.  
This argument is supported by long-term follow-up of young girls who have received 
chemotherapy and who eventually did have premature menopause. [36] In a large 
post treatment follow-up study relative risk of menopause in the third decade was 9.2 
after treatment with alkylating agents alone [37]  
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Literature review on ovarian suppression for protection against 
chemotherapy induced ovarian damage 
 
Author and year GnRHa % Control % Follow up  
years 
Waxman 1987 [38] 50.0 67 2.3 
Blumenfeld 2000 [39] 0 66 - 
Pereyra Pacheco 2001[40] 0 100 <5 
Blumenfeld & Eckman 2005 [3] 7 54  
Franke 2005 [41] 20 - <1 
Dann 2005 [42] 0 17 5.3 
Somers 2005 [43] 5 30 - 
Elis 2006 [44] 0 8.7 - 
Del Mastro 2006 [45] 3 - 1 
Recchia 2006 [46] 33  6.3 
Giuseppe 2007 [4] 0 47 2.4 
Castelo-Branco 2007 [47] 7 77 - 
Blumenfeld 2008 [25] 3 37 8 
Huser 2008  [48] 21 71 1 
 
Table 16 Incidence of ovarian failure in different studies with and without GnRHa 
administration. 
 
Two recent review articles on the topic of ovulation suppression to protect against 
chemotherapy induced ovarian toxicity and amenorrhoea was published in the same 
issue of the Human Reproduction Update.  [34] [49]  Beck-Fruchter et al was of the 
opinion that the currently available information in the literature is not enough to reach 
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a definite conclusion that GnRH-agonists are beneficial in protecting against 
chemotherapy induced damage.  They argue that on the basis of the current 
evidence it is possible to draw the wrong conclusions from the published data.  
There are many drawbacks to the published studies and in their meta-analysis of the 
literature where a large number of studies were combined, most of the patients 
included were from non-randomised studies. [34] Very often the studies were not 
controlled at all or had historical controls.  This would suggest that the control groups 
were more likely to have reached the point where the premature ovarian failure has 
occurred at the time of the evaluation for the study.  There were many treatment 
protocols, many different indications for chemotherapy and the definition of ovarian 
function was not always the same.  Various parameters were included like the 
presence or absence of menstruation, hormone levels, ultrasound appearance of the 
ovaries and even cycle regularity.  In most of the published data indications of what 
is meant by preserved ovarian function and ovarian failure is not clearly outlined.  
They mention that the two largest studies (those by Castelo-Branco and Huser) [47] 
[48] had unexpectedly high incidences of premature ovarian failure (POF) in the 
control groups.  This high POF rate was higher than expected when compared to 
other studies of Hodgkin’s lymphoma survivors, which is usually in the region of 32-
37%. [50]  [51]   This high POF rate in the control group of the larger studies will 
influence any meta-analysis currently performed.   
 
Blumenfeld published a review in the same journal and came to a slightly more 
positive conclusion. [49] However, they also concluded their review by stating that 
there is not enough convincing statistical evidence concerning the reduction of POF 
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to treat young women with GnRH agonists.  More large prospective randomised 
studies are needed. 
 
Embryo cryopreservation is illegal in Italy. That makes other strategies for fertility 
preservation perhaps even more important. A group from Bari evaluated ovarian 
reserve in 29 patients treated for Hodgkin’s disease. [4] They used serum levels of 
follicle stimulating hormone, luteinizing hormone, Inhibin B, anti-Mullerian hormone 
(AMH) and the ultrasound antral follicular count as markers of ovarian reserve after 
chemotherapy. The patients randomly had GnRHa or not at the time of 
chemotherapy. It is not clear from the article which specific analogue was used. Of 
the 14 women who received GnRHa, not one developed amenorrhoea.  Seven out of 
15 (46%) not receiving GnRHa showed clinical symptoms of ovarian failure 
“suggesting a possible protective action of GnRH-a”. However, when the results of 
the ovarian reserve parameters were compared, those treated with GnRHa had 
similar results suggesting that chemotherapy results in depletion of the follicular pool. 
 
A different Italian group from Pescara treated 61 women with triptorelin a 
gonadotrophin-releasing hormone analogue (GnRHa) given monthly during 
chemotherapy treatment for patients with Hodgkin’s lymphoma. [52] At completion of 
the study, the majority (81%) recovered normal menses while 6% had irregular 
cycles and the remaining 12% developed premature ovarian failure. They felt 
confident enough about the results to recommend that all young women should 
receive GnRHa co-treatment from the onset of chemotherapy. 
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A recent report from Korea investigated the incidence of chemotherapy-related 
amenorrhoea in pre-menopausal women with breast cancer. [53]  In this study 238 
women received adjuvant endocrine therapy for oestrogen/progesterone receptor 
positivity.  The adjuvant endocrine therapy included selective oestrogen-receptor 
modulators (toremifene citrate and tamoxifen), aromatase inhibitors (letrozole and 
anastrozle) or luteinizing hormone-releasing hormone. The two important predictors 
for amenorrhoea were older age at treatment and the use of endocrine treatment. 
Interestingly “the use of adjuvant endocrine therapy was more likely to result in 
permanent chemotherapy-related amenorrhoea compared with no use (P = 0.006)”. 
 
Potential problems with GnRHa treatment 
 
The GnRH-agonists are not without problems.  The side effects include 
postmenopausal symptoms like hot flushes and a decreased bone mineral density.  
It is also of importance to note that GnRHa receptors have been found in certain 
tumour cell lines and the effect that GnRHa may have on tumour progression has not 
been studied carefully. [20] [54]  Some reassuring data can be found in a study on 
10 women who were treated by Leuprolide acetate before bone marrow 
transplantation. [55] The authors found no adverse effects of the GnRHa treatment.  
 
With GnRHa 7 to 10 days may be needed for complete ovarian suppression. 
However, with a GnRH antagonist used alone or together with GnRHa the “induction 
time” will be reduced. GnRH antagonists block GnRH receptors immediately. The 
waiting time before chemotherapy could be reduced to less than 4 days.  [56] 
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Potential (non-fertility) benefits of GnRH treatment 
 
GnRHa may be beneficial in patients with early breast carcinoma where suppression 
of oestrogen production will lead to a better outcome.  A recent Cochrane review on 
GnRHa in adjuvant therapy setting for early breast cancer in pre-menopausal women 
found that the therapy may be of clinical benefit.  The authors concluded that the 
current data strongly supports the continuation of further trials on LhRH agonists in 
early breast cancer treatment.  [57] Similar results were reported from a study on 
100 women treated for breast cancer and who received GnRHa. [46] Not only was 
the treatment tolerated well and there was some long term protection of ovarian 
function but the authors also stated that the GnRHa “appeared to improve the 
expected clinical outcome.” 
 
Other potential benefits of GnRHa not related to ovarian function include reduction of 
menorrhagia during chemotherapy especially at the time when myelosuppression 
may be an important complication of chemotherapy. A recent systematic review has 
found that GnRH agonist therapy is highly effective for prevention of excessive 
uterine bleeding in women being treated for haematological malignancies. [58]   
 
Contraceptives as a strategy to reduce ovarian damage  
 
Combined oral contraceptives 
 
Suppression of follicle development during the administration of chemotherapy may 
reduce the risk of follicular damage.  A group of 31 young women who received neo-
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adjuvant chemotherapy for the treatment of osteosarcoma were observed for 
chemotherapy-induced menopause. [59] All these patients received high dose 
ifosfamide, methrotrexate, adriamycin and cisplatinum.  They were treated with oral 
contraceptives for the duration of chemotherapy. 
 
Three out of nineteen patients developed early menopause in the treatment group.  
They were compared with an historical control group in which three out of 71 patients 
developed chemotherapy-induced menopause.  The authors concluded that oral 
contraceptives during chemotherapy do not protect ovarian function in patients 
receiving high-dose alkylating chemotherapy and that age at treatment and the total 
dose of alkylating agents are the most important predictors for ovarian failure. [59]  
 
An earlier retrospective report on the reproductive outcome of women treated for 
Hodgkin’s disease included a total of 44 females followed up after chemotherapy 
(MVPP). [5] Nine of these patients took combined oral contraceptives throughout the 
administration of chemotherapy of which four subsequently developed amenorrhoea 
and a further three developed oligomenorrhoea.  It seems as if oral contraceptives 
did not protect these patients against chemotherapy induced ovarian damage.  
 
A report on a small number of women from 1981 evaluated the use of oral 
contraceptives in six young women treated with MVPP for Hodgkin’s disease. [60] 
They were followed up for between four and twelve months and had post-therapy 
ovarian biopsies and menstrual history to determine fertility potential.  Five out of six 
patients had normal menstruation after discontinuation of the chemotherapy.  The 
three cases that had ovarian biopsies were 18, 19 and 28 years respectively. The 
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19-year old had more than 1000 follicles per section after chemotherapy.  It is 
difficult to know whether histological evaluation of follicle numbers will predict 
eventual menstrual function but despite the small numbers in this study the authors 
concluded “that suppression of ovarian function by combination oral contraceptives 
protects the ova against an otherwise certain injury by the chemotherapeutic drugs”. 
[60] 
 
In a report on the post-treatment fertility status in women who had received 
aggressive treatment for non-Hodgkin’s lymphoma, a group from Israel found that 
age was the most important risk factor and that older women were at the highest risk 
for chemotherapy related amenorrhoea. [44] In their cohort of patients, fertility 
preserving measures in the form of GnRHa were used in three patients and nine 
received combined oral contraceptives.  When these latter patients were compared 
to the rest of the group there was no significant difference in the rate of ovarian 
failure.  
 
The best evidence so far for the potential benefit of oral contraceptives during 
chemotherapy is from a large retrospective report from Germany. [61] A total of 405 
women answered a questionnaire about menstrual status after therapy for Hodgkin’s 
lymphoma.  These patients were all younger than 40 years of age at treatment.  The 
rate of amenorrhoea was significantly higher in women not taking oral contraceptives 
when compared to women on oral contraceptives during chemotherapy (44.1% 
versus 10.1%) (p < .0001).  Looking at all the different factors evaluated in the 
retrospective evaluation, a multivariate analysis was performed looking at age, 
chemotherapy regime, stage of disease, the use of oral contraceptives during 
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chemotherapy and the effect on amenorrhoea.  Two-hundred-and-fourteen of the 
total 405 women had enough information to be included into the multivariate analysis 
and the following were found to be significant predictors of amenorrhoea: 
· Receiving eight cycles of dose escalated BEACOPP when compared to other 
less toxic regimes 
· Amenorrhoea was statistically significantly higher in women with advanced 
stage (p < .0001) 
· Age over 30 years at treatment (p = .0065) 
· Not taking oral contraceptives during chemotherapy (p = .0002) 
 
This study provides the strongest evidence so far for the potential effect of oral 
contraceptives in the protection of ovarian function during chemotherapy.   
 
However, oral contraceptives have never been adequately tested in a randomised 
controlled trial. [62] A randomised phase II trial performed by the German Hodgkin’s 
lymphoma study group, the protection of ovarian fertility study (PROFE), evaluating 
the use of GnRHa and oral contraceptives for patients receiving treatment for 
Hodgkin’s lymphoma, was stopped early after only 23 patients enrolled. The reason 
for the early termination of the study was mainly that most women already received 
GnRH-analogues as recommended by their gynaecologists.  Twelve patients 
received oral contraceptives and 11 GnRH-analogues. The respective infertility rates 
were 90% for contraceptives and 100% with GnRHa. The conclusion of the authors 
was that treatment with GnRHa or oral contraceptives conferred no meaningful 
ovarian protection.  
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Medroxyprogesterone acetate 
 
The only report on the effect of medroxyprogesterone acetate on ovarian protection 
during chemotherapy is a small descriptive study from Italy. [63] Twelve women had 
ovarian biopsies of which four received no chemotherapy or MPA, four received no 
chemotherapy and 250mg MPA and the last four received chemotherapy and 250mg 
MPA per month.  Ovarian biopsies were taken and electron microscopy studies were 
done.  Despite the very small number of cases this did not prevent the authors from 
stating that “the results presented here demonstrated that the administration of MPA 
to patients with Hodgkin’s disease protects the ovary against an acute effect of 
chemotherapy”.  It is not clear from the discussion how the authors concluded that 
there was a protective effect because the studied follicles of patients receiving 
chemotherapy and MPA had substantial morphological damage.  At present there is 
no strong argument in the literature to suggest the protective effect of the MPA 
against chemotherapy induced amenorrhoea. 
 
Conclusion 
 
It is very difficult to reach a conclusion about the use of ovarian suppression during 
chemotherapy in an attempt to prevent subsequent chemotherapy induced ovarian 
failure.  Most of the evidence in the literature is from non-randomised case reports; 
often with historical or no controls. Various chemotherapy regimes were used, doses 
of GnRHa and COC’s were not similar and the number of patients was in general 
very low.  There is no randomised controlled trial to evaluate either COC’s or GnRHa 
in this clinical scenario. 
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The only way to reach consensus would be to test COC’s and GnRHa in a properly 
designed prospective randomised trial.  Numbers of young patients with cancer are 
usually small in individual institutions and it is extremely important to combine data 
from multiple sites to reach useful results. 
 
At present the indication for oral contraceptives or GnRHa may be for other non-
fertility benefits.  GnRHa and oral contraceptives may be used to reduce menstrual 
blood loss which is often increased during treatment because of abnormal clotting 
and platelet function.  Where hormones may be contra-indicated due to hormone 
sensitive tumours, GnRHa can be very useful.  There is some evidence that GnRHa 
administration may improve the outcome in oestrogen receptor positive breast 
carcinoma. 
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Chapter 4: Germ cell physiology with reference to 
cryopreservation 
 
Abstract 
The cryopreservation and transplantation of ovarian tissue have been shown to 
restore ovarian function temporarily and may also preserve the fertility of young 
female cancer patients until after their sterilizing cancer treatment.  Since tissue 
samples are large and morphologically complex, the cryopreservation methodology 
is difficult to optimise and standardise.  Ovarian tissue cryopreservation is still in its 
experimental stages and is not a routine option offered to cancer patients. 
 
This review describes oocyte maturation with reference to follicular development and 
the possible effects of cryopreservation on normal function. Oocyte cryopreservation, 
including slow freezing and vitrification are becoming more successful and 
reproductive outcomes are summarised. 
 
A randomised controlled investigation of 1,2-Propanediol (PROH) and Dimethyl 
Sulphoxide (DMSO) cryopreserved tissue was performed. The tissue was evaluated 
with transmission electron microscopy for morphological features of damage. No 
significant difference was found between the two groups. Slow freezing using DMSO 
and PROH were associated with ultrastructural changes, but had no significant 
difference with fresh tissue. Slow freezing and rapid thawing of ovarian cortical tissue 
is a promising option for protection of fertility. 
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Introduction 
Ovarian germ cell reserve  
 
The number of oocytes in humans peaks at around six to seven million by 20 weeks 
of gestation. [1] There is a sharp decline in the number of oocytes from around 20 
weeks after gestation to birth when only about one to two million oocytes remain in 
the ovary. See Figure 4.  Further atresia of the oogonia occurs and at the start of the 
first menstruation. About three hundred to four hundred thousand of the original 
seven million oocytes remain available for ovulation.  Four hundred to five hundred 
of these will ultimately ovulate and the process of ovulation is carefully controlled by 
endocrine, autocrine and paracrine factors.  No new oogonia are formed after birth 
and all the available oocytes at birth are in the diplotene (dyctyate) phase of meiosis 
and will only continue further in the process of meiosis at the time of antral 
development.  At the diplotene stage, the resting phase of the meiotic division, the 
oogonia becomes surrounded by granulosa cells in a single layer.  The oogonia that 
failed to become surrounded by granulosa cells will undergo atresia.   
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Figure 4 Follicular reserve (germ cells) at different ages. From [2] 
 
Cell division 
 
Meiosis is usually divided into four stages; prophase, metaphase, anaphase and 
telophase.  The prophase of meiosis is further divided into five stages namely 
leptotene, zygotene, pachytene, diplotene and diakinesis.  As soon as the oogonia 
begin developing into the meiotic prophase they are known as primary oocytes. [3] 
This process begins around 8 weeks of gestation and if meiosis does not occur the 
oogonia will undergo atresia and apoptosis.  The oocytes arrested in prophase (that 
is the late diplotene or dictyate stage) will remain so until the time of ovulation when, 
during oocyte development, further meiotic processes will occur usually at the time of 
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the LH surge.  This resting phase of the development is believed to be, at least 
partly, controlled by oocyte maturation inhibitor (OMI) produced by granulosa cells. 
[4]  
 
Germ cell physiology 
 
The relative fecundity of a particular individual varies widely between different 
species.  It depends on the specific reproductive strategy where a different kind of 
investment is made in the production of oocytes.  An example of very efficient 
oogenesis is broadcast spawners like fish while on the other side of the spectrum 
primates, including humans, have a highly selective process where oocytes are 
selected through a process of attrition to allow only a small number of individual 
oocytes to progress to ovulation throughout the reproductive lifespan.  Where 
damage to the relatively small surviving pool of oocytes occur in relatively low 
producers of oocytes it is essential to understand the specific mechanisms of follicle 
development in order to minimise damage by these clinical interventions.   
 
The understanding of germ cell physiology has improved tremendously over the last 
few decades. Since the advent of assisted reproductive technologies in the early 
1970’s it is estimated that more than 3 million children have been born using 
assisted reproductive techniques.  [5]  
 
Oogenesis is regulated at many levels.  The exact process by which the activation of 
primordial follicles is achieved is not clearly described.  The process through which 
the granulosa cells proliferate and change their shape from squamous to cuboidal 
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ends with the establishment of a primary follicle. [6] [7]  This transition is under 
control of many different factors.  There are physical and hormonal contacts between 
the oocyte and granulosa cells and various autocrine and paracrine factors have 
been described.  
 
Physical communication between oocytes and granulosa cells are extremely 
important.  The structures that provide connections are called trans-zonal projections 
and maintain the physical contact between the different cell types. [8]   At the end of 
these trans-zonal projections, gap junctions allow physical connection through 
groups of proteins called connexins.  Connexins are the functional units of the gap 
junctions and are intercellular membrane channels that allow the sharing of small 
molecules between neighbouring cells. [9]  Specific proteins like connexin 37 is 
unique to the oocyte-granulosa cell interaction and the absence of these connecting 
proteins may lead to a failure of ovum maturation. [10]  Physical properties of trans-
zonal projections include microtubules and actin filaments. [11] [12]  These structural 
elements may be damaged by cryotherapy.  These physical connections, providing a 
communication network between the oocyte and the surrounding ovarian stroma, 
should remain intact in order for complete meiotic division to take place and eventual 
follicle development. [11]  [13]  
 
Many inter-cellular autocrine factors have a role in the development of successful 
follicles.  Anti-Müllerian Hormone (AMH) has been implicated in maintaining 
primordial follicles in the resting phase. [14] AMH is also a regulator of FSH and may 
inhibit primordial follicle activation. [15]  The Forkhead Transcription factor 03 (FOX 
03) is another potential inhibitor of primordial follicle activation. [16] Stimulatory 
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effects on the activation of the transition from primordial to primary follicle were also 
demonstrated for compounds like basic fibroblast growth factor (bFGF). [17], Bmp4  
[18] Keratinocyte Growth Factor (KGF)(also known as FGF7) [19] and platelet 
derived growth factor (PdGF) [20]  
 
 
Figure 5 Schematic representation summarizing the inhibitory and stimulatory factors 
involved in primordial to primary follicle transition [5] 
 
Follicle development 
 
Primary to multi-layered follicles 
 
 
The growth of the oocyte in the primary follicle is quite slow and is accompanied by a 
slow rate of granulosa cell proliferation.  The granulosa cell layers increase from one 
to six or seven in the pre-antral stage.  [21] The growth of the follicle and oocyte may 
be influenced by factors like GDF9 [22] and other oocyte specific factors like BMP15 
[23] and GDF9b [24]  Activin and Inhibin are both members of the transforming 
growth factor beta (TGF beta) family and these compounds were both identified in 
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follicular fluid during development of the antral follicle.  Both these compounds have 
effects of FSH production.  [25] [26]  Other compounds also affecting FSH 
production include Follistatin which is a single chain glycoprotein with certain 
similarities to the alpha and beta subunits of the Inhibin-Activin family. [27] In 
patients with tissue re-implanted after cryopreservation levels of Inhibin may be 
similar to pre-menopausal women due to low follicle number.  Insulin-like growth 
factor 1 (IGF1) plays a role in FSH sensitivity in granulosa cells. [28]   AMH is also a 
regulator of FSH and may inhibit primordial follicle activation. [15] 
 
Antral follicle to ovulation 
 
The second phase of follicogenesis starts when granulosa cells become responsive 
to FSH.  For this FSH receptors need to be present which is under the control of 
IGF1. [28]  Oestrogen acts in a stimulatory fashion by enhancing FSH action on 
granulosa cells. [29] LH responsiveness in the granulosa cells only develop with the 
presence of LH receptors. [30] [31] The LH surge begins a process where 
luteinisation signals the terminal differentiation of the granulosa cells and they stop 
proliferating.  At the same time the oocyte resumes meiosis and ovulation occurs. 
[32] [31]  
 
Anatomical considerations 
 
When the anatomy of the ovary is considered, it is important to note that oocytes and 
therefore also follicles are present just below the peritoneal epithelium.  If ovarian 
tissue is cryopreserved only the cortex needs to be dissected and frozen.  
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Figure 6 H&E stain of the cortex containing early follicles (black arrows) and the 
stroma of the ovary, containing blood vessels (white arrows). 
(http://www.siumed.edu/~dking2/erg/images/RE002b.jpg) 
 
The blood supply to the developing follicle is not with direct vessel support but 
through an end artery system. [33] That means the ovarian cortex is a relatively 
hypoxic tissue and probably protects oocytes during the process of removal, freezing 
and thawing before re-implantation. 
 
During follicogenesis the oocyte is dependent on the surrounding tissue for hormonal 
support. If successful follicle development is required, consideration of the effect of 
the intervention on granulosa cells, extra-cellular matrix and stromal cells is 
important. 
 
Relative size of the follicle directly affects the physics of freezing. There is a linear 
relationship between the volume and complexity of the tissue and the eventual 
cellular damage. Cryoprotectants fail to penetrate larger tissue samples effectively 
and heat transfer is impaired. The larger the amount of tissue, the more pronounced 
the damage. Table 17 shows a summary of the histological characteristics of 
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different stages of follicle development and Figure 7 demonstrates the increasing 
volume and complexity of the developing follicle. 
 
Stage Description Size 
Primordial Resting, small, one layer 
of flat granulosa cells 
0.03-0.05 mm 
Primary (germinal 
vesicle stage) 
Mitotic cells, cuboidal 
granulosa cells 
< 0.1 mm  
Secondary Presence of theca cells, 
multiple layers of 
granulosa cells 
0.2 mm  
Early tertiary 
(Antral) 
Formation of an antrum Early tertiary follicle: 
Class 1~ 0.2 mm * 
Class 2 ~ 0.4 mm 
Class 3 ~ 0.9 mm 
Class 4 ~ 2 mm 
Class 5 ~ 5 mm. 
Late tertiary Fully formed antrum, no 
further  cell differentiation 
Class 6 ~10 mm  
Class 7 ~ 16 mm 
Class 8 ~ 20 mm.  
Non-dominant follicles 
may grow beyond class 5, 
but rarely more than one 
class 8 follicle. 
Pre-ovulatory Increase oestrogen in 
dominant follicle and all 
other follicles atretic  
 
 
Table 17 Summary of characteristics of follicle development stages. Adapted 
from [34]  *Class refers to Pedersen and Peters classification. [35] 
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Figure 7 Diagram of follicular development showing relative sizes of developing 
follicles. From [1] 
 
Antral follicles have higher water content and will undergo more pronounced 
contraction and expansion during freezing.  Contraction and distortion of cells may 
cause breaks in intercellular connections including the gap junctions. Smaller follicles 
survive the insults of cryopreservation better. [36] 
132 
 
Cryobiology 
Introduction 
 
Preservation of tissue without damage to individual cells is possible only under well 
controlled conditions.  There are three stages of lowering temperature that may 
affect cell physiology.  The first is temperatures below body temperature down to 0º 
Celsius which may be damaging if the exposure is prolonged. [37] Many cells and 
tissues can survive low temperatures down to 0º for a limited period of time.   
 
A second stage of cooling is reached between 0 and -40º Celsius where ice crystal 
formation in water may damage tissues significantly.  Most sub-cellular damage will 
happen at these temperatures. Water freezes with nucleation and crystallization and 
very few cells will survive exposure to these temperatures for a long period of time.   
 
A third stage of cooling with temperatures between -40° C to the temperature of 
liquid nitrogen of -196º C is very useful for preservation of tissues and cells and will 
limit damage to sub-cellular structures since physiological processes and 
biochemical mechanisms cease at these temperatures.  It is often the process of 
cooling down to these very low temperatures and the warming or thawing that are 
the damaging stages and not the storage at very low temperature. [38]  
 
Intra-cellular ice formation is very damaging to cells.  Fine ultra-structural properties 
may be directly damaged due to mechanical stress of ice crystals or may be 
displaced within the cell due to dehydration.  Ice crystal formation also causes 
expansion of volume which may cause permanent and fatal damage to cell 
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membranes and certain structures within the cytoplasm. [38]  Dehydration can be 
fatal to a cell.  Ice crystals contain only water molecules and as the water freezes 
solids are concentrated in the remaining cytoplasm.  The high solid concentration 
may reach toxic levels and lead to unfolding and denaturing of enzymes. [38]   
 
 To try and minimise the effect of intra-cellular ice formation the following strategies 
may be used: 
· Super cooling and freezing point depression 
· Dehydration 
· Vitrification  
 
Super-cooling and freezing point depression 
 
Super cooling is a freezing avoidance mechanism where solutions are cooled to 
below the freezing point while remaining in a liquid state.  This allows slower than 
normal metabolism.  In practice only small volumes (micro litres of pure liquids) can 
be super cooled to a few °C below the equilibrium freezing point.  Biological tissues 
are inherently unstable with so many ice nucleators and if only one ice crystal is 
formed the solution will freeze immediately. 
 
In nature many plants and animals can increase the amount of suspended solutes 
intra and intercellular in a response to cold conditions.  This will decrease the 
temperature at which the tissue freezes. The process is well described for certain 
arctic fish species. [39] Water freezes at 0°C but if the temperature of freezing can 
be artificially lowered in tissue it may allow the scientist to control the process better. 
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The main aim of freezing point depression is the avoidance of ice crystal formation at 
relatively warm sub-zero temperatures which is characterised by disorganised and 
unpredictable crystallization.  
 
Crystal formation of freezing starts with a process called nucleation of water 
molecules.  Just before freezing water molecules with lower kinetic energy will start 
to arrange into a lattice formation.  When this crystal lattice reaches a critical point 
freezing will start quickly and in a disorganised way.  Freezing point depression is a 
technique that allows a scientist to do manual seeding which introduces 
crystallisation in an organised predictable way. 
 
By adding cryoprotectants lower freezing points can be achieved.  By increasing 
concentrations of cryoprotectants like dimethyl sulfoxide (DMSO) and 1,2 propylene 
glycol (PROH) freezing point temperatures can be lowered. [40] Sugars can also be 
added to reduce freezing temperatures and high concentrations can be tolerated by 
biological tissues without severe damage. [38]  
 
Dehydration 
 
Extra-cellular freezing usually occurs first because the volume is larger. If extra-
cellular water freezes it draws liquid water out of the cell causing a rapid change of 
shape. By increasing extra-cellular osmotic pressure before freezing, water moves 
out of the cytoplasm resulting in cellular dehydration.  This will reduce the amount of 
water left in the cell to freeze.  Many seeds and spores use dehydration to survive 
extreme low temperatures. 
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Dehydration with cryoprotectants should not be too severe.  The osmotic pressure 
has to be carefully controlled. Moderate dehydration and cell contraction can be 
achieved by a cryoprotectant like hydroxyl ethyl starch (HES) or dextrone. [38]  
Vitrification 
 
Cryopreservation through vitrification attempts to achieve ultra low temperatures 
without intra-cellular ice crystal formation and membrane damage.  If a liquid can be 
cooled sufficiently fast the viscosity increases rapidly to form a glasslike vitreous 
solid state.  The viscosity of the liquid becomes so high that nucleation (and 
therefore crystallisation) becomes impossible. A glass is amorphous with no long 
term crystalline structure but at the same time has the mechanical properties of a 
solid.   
Rapid Thawing 
 
 
Thawing represents another critical period for the tissue. The most harmful period for 
complex sub-cellular structures is the subzero temperatures near the equilibrium 
freezing point. At this point crystallization is unpredictable and ice may form 
randomly in a disorganized way. If extra-cellular tissue thaws there is a sudden 
decrease in the osmotic pressure which may cause rapid movement of fluids across 
the cell membrane. Rapid thawing avoids many of the dangers. [38]  
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Oocyte cryopreservation 
Slow freezing of oocytes 
 
The survival and ultimate normal functioning of an oocyte after the process of 
cryopreservation has been more difficult to achieve when compared to sperms and 
embryos. Success is compromised by the complexity of the intra- and sub-cellular 
organelles which are far more complex than in smaller cells like sperm and pre-
implantation embryos.  Early work done on frozen murine oocytes showed spindle 
abnormalities and other damage due to cryopreservation and exposure to 
cryoprotectants.  [41] [42] Metaphase II oocytes are structurally quite complex with 
the fragile meiotic spindle one of the most vulnerable structures.   
 
Immature oocytes have been successfully cryopreserved and matured in vitro, 
however, the clinical application of this technique is at present not clear.  Some 
authors postulate that cryopreservation with an earlier oocyte (e.g. human oocytes at 
the germinal vesicle phase) may have better survival. [43]  A study done on the 
microscopy of metaphase II oocytes compared to germinal vesicle oocytes showed a 
significant difference regarding spindle and chromosome abnormalities. [43]  The 
oocytes that were cryopreserved at the germinal vesicle stage and then matured in 
vitro showed less spindle damage.  With improved in-vitro maturation techniques this 
may become a clinical option.  The process of in vitro maturation of germinal vesicle 
oocytes involves the removal of the cumulus cells in order to get a fertilizable egg. 
 
It is postulated that the high lipid content of cell membranes play a role and that 
improved results may be achieved by manipulating the lipid phase transition where 
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lipids change from liquids to solid state during the freezing process. [44] Some 
Antarctic fish contain a natural anti-freeze protein that can shift the lipid phase 
transition. Adding agents like phosphotadylglycerol may alter these lipid phase 
transitions. Cryoprotectants in themselves may however also act as toxins to the 
oocyte and cause irreparable damage even before the start of the freezing protocol. 
[45]   
 
Intracellular micro-injection of certain cryoprotectants like trehalose at a 
concentration of 0.15M (molar) showed promising protection against freeze 
associated stresses.  An interesting in-vitro study describes the survival of three 
different groups of human oocytes of which one was a control group, one group had 
extra-cellular trehalose and the third had intra-cellular injection of trehalose. The 57 
oocytes with injected trehalose had statistically significantly better survival even at 
very low temperatures. [46]  Trehalose is an interesting compound and is a naturally 
occurring disaccharide found in nature.  It can be produced by fungi, plants and even 
certain insects.  The sugar allows plants and animals to withstand long periods of 
desiccation and allows cells to significantly dehydrate without serious damage.  It is 
commercially used in various food applications and is also extensively used in the 
pharmaceutical industry. 
 
Cryoprotectants 
 
 
PROH and DMSO have been described as choices for oocyte protection and the first 
live birth from a DMSO cryopreserved thawed oocyte was reported by Chen in 1986. 
[47]  Two pregnancies from PROH protected oocytes were reported in 1985 but they 
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did not end in live births. [48]  In a report from the late 1980’s a comparison between 
PROH and DMSO found PROH to be superior in terms of oocyte survival. [49]   The 
mechanism by which the cryoprotectants are directly toxic can be due to volume and 
concentration changes in the intra-cellular milieu as described by Fahy. [45] 
Exposure to cryoprotectant agents has been implicated in changing in the 
characteristics of the zona pellucida making it more impenetrable to sperms. All the 
mechanisms through which failure to fertilize after cryopreservation are not clearly 
understood but zona pellucida effects may play an important role as demonstrated 
by Matson in mice.  [50]    After an experimental study in mice, the investigators 
concluded that intracytoplasmic sperm injection (ICSI) may be beneficial after 
cryopreservation of oocytes in humans.   
 
Two years before the animal work by Matson was published, a study from the United 
Kingdom showed that fertilization and cleavage rates of human oocytes were 
significantly improved when oocytes were fertilized by ICSI compared to 
conventional IVF i.e. 13.5% of oocytes fertilized by IVF only compared to 45.9% 
fertilization in the group with ICSI.  [51]  This makes ICSI the preferred option for 
patients wanting to fall pregnant from cryopreserved oocytes. [52] There are 
indications that with improving technical ability freezing of oocytes is becoming more 
efficient with increases in survival rates of individual oocytes, better fertilization rates 
and ultimately an improvement in pregnancy rates.  [53]   
 
A meta-analysis published on the efficiency of oocyte cryopreservation found that 
success rates with slow frozen oocytes were statistically significantly poorer when 
compared with fertilization of non frozen oocytes.  However, the authors 
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acknowledge possible improvement in outcome after 2005 which may suggest that 
with improvement in technique slow freezing may have even better fertilization rates 
in future.  [54]  
 
Possible improvements in the slow freezing of oocytes may be achieved by changing 
cryoprotectant concentration.  One example may be to alter the concentration of 
sucrose as a cryoprotectant as reported by Bianchi. [55] The temperature at which 
cryoprotectants are introduced may play a role in the eventual survival.  If 
cryoprotectants exposure happens at body temperature it may decrease the injury to 
the cytoskeleton of the human oocyte.  [56]  
 
Pregnancy results from oocytes preserved by slow freezing 
 
 
One of the largest series reported on pregnancies from cryopreserved oocytes 
demonstrated 11 live births from cryopreservation of 1796 oocytes.  Despite 
promising results in small numbers of patients the overall live birth rate from 
previously frozen oocytes is only about 2% which is lower than that with IVF using 
fresh oocytes. [57]  
 
A large meta-analysis confirmed this figure of around 2% of live birth rate after using 
frozen oocytes. [54] It is important to note that in a report from Porcu [58]  their 
stimulation protocol was used on 18 young women with a mean age of 19 years and 
a range between 14 and 26 years.  The number of days used for stimulation was a 
mean of 11, ranging from 8 to 14.  They could retrieve an average of 15 oocytes per 
cycle.  The stimulation period remains the most problematic aspect of oocyte 
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cryopreservation because of the delay in the start of treatment for patients with 
underlying malignancy. In order to reduce the time necessary for stimulation before 
oocyte retrieval ovarian stimulation may be started in the luteal phase. [59]  A very 
similar time from start to retrieval was achieved in patients starting stimulation in the 
follicular phase and the luteal phase of the menstrual cycle. 
 
A concern about possible increased incidence of chromosomal abnormalities in 
cryopreserved oocytes seems to be ungrounded.  There is no evidence that 
chromosomal abnormalities are more frequent when fertilization does occur, even if 
it is at a lower rate than with fresh oocytes,  [60]  [61]  
 
Oocyte Vitrification 
 
Technique 
 
Recently vitrification (ultra rapid cooling technique) of human oocytes has been 
described and the success rate after vitrification seems to be improving.  High 
concentrations of cryoprotectant and very quick cooling, in order to prevent 
crystallization or ice formation, cause the intra-cellular water to form a glassy solid 
state directly from liquid phase.  [62] Usually a very small volume of high 
concentration cryoprotectant is used and the cooling rate is extremely fast.   
 
A theoretical concern is direct toxicity of liquid nitrogen to the cell. Vitrification of 
oocytes has recently become safer with the introduction of properly sealed 
containers like the Cryotop system. [63]  This sealed system reduces many of the 
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concerns about potential contamination of oocytes in an open bath of liquid nitrogen.  
A concern with vitrification remains the high levels of exposure to cryoprotectants. 
 
A recent review by Nagy gives a good overview of the history of human oocyte 
vitrification. [64] The authors have a very positive experience of recent improvements 
in vitrification techniques and describe the following phases in the development of 
vitrification: 
 
1. Identification of the best solutions for the different stages of vitrification 
namely equilibration, cooling, warming and rehydration. 
2. The establishment of techniques to achieve extremely high cooling and 
warming rates to minimize oocyte damage. 
3. To work out the detail of concentrations and times exposed to 
cryoprotectants. 
4. To eliminate the risk of disease transmission during all phases of cooling and 
thawing. 
 
From this review it is interesting to note that many developing countries from South 
America have high success rates with live births after oocytes vitrification.  See 
Table 18 for approximate numbers of births as reported by Nagy. 
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Country Approximate number of Births 
United States 35-40 
Canada 35-40 
Italy 10-20 
Japan 40-60 
Spain 40-50 
Mexico 100 
Colombia 200 
 
Table 18 Number of babies born from vitrified oocytes. From [64] 
 
The author gives a comprehensive list of indications for human oocyte 
cryopreservation which include the obvious indication of fertility preservation in 
cancer survivors but also include non-medical indications. These include a wish to 
delay motherhood for various reasons like career development, storage of excess 
donor oocytes, oocyte donation from mother to daughter e.g. in a case with Turner 
syndrome, severe endometriosis and also poor responders to ovarian stimulation.  
Some of these indications indeed raise moral questions but the most obvious 
indication still remains fertility preservation for cancer patients. 
 
The potential safety problems associated with vitrification is discussed in detail.  
Despite the fact that liquid nitrogen at a temperature of minus 196 degrees Celsius 
slows down most biological processes to virtual zero, many micro-organisms will 
survive this environment.  There is the possibility of transfer of pathogens and a 
description of hepatitis B virus contamination among bone marrow transplant 
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specimens was described in 1995. [65] Direct viral transmission between embryos 
has also been described by Bielanski. [66] In the review by Nagy and co-workers the 
suggestion is made that the separate phases of vitrification namely cooling, storage 
and warming should be separated. [64] They give a detailed description of 
methodology which may reduce the risk for transmission and included in this 
description is the filtration of liquid nitrogen and the sterilization of containers with 
bleach. 
 
Despite the concern this review shows vitrification of oocytes in a very positive light 
with excellent outcome figures.  There is concern, however, that this optimism may 
not be reflected in everyday practice due to varying standards of quality control. 
 
Pregnancy outcome with oocytes preserved with vitrification 
 
 A pregnancy using previously vitrified oocytes has been described by a group 
already in 1999. [67] The attraction of using vitrification instead of the traditional slow 
freezing methods is that expensive slow cooling technology is not necessary and 
that it is much quicker than the long cryopreservation protocols. 
 
It is difficult to compare cryopreservation of oocytes by slow freezing and vitrification 
because of many variables involved in each process.  However, a group from China 
reports on their experience with a total of 605 oocytes preserved either with slow 
freezing or vitrification.  The survival rate of the vitrification group was 91.8% 
compared to 61% in the slow freezing group.  However, the fertilization rate was 
approximately the same for both groups.  Of the fertilized oocytes the vitrification 
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group had higher rates of blastocyst formation and had less damage when examined 
with microscopy. [68]  
Cryopreservation of ovarian tissue  
Introduction 
 
The exact methodology of cryopreservation of human ovarian tissue is not yet 
standardized and the technique is not routinely offered to patients. [69] [70]  Ovarian 
tissue is morphologically complex due to multiple cell types with different 
characteristics. Intercellular connections and intracellular micro architecture may be 
damaged with ice crystal formation and contraction or expansion of volume. Follicles, 
even at quiescent primordial stage, may sustain injury from cryopreservation. [71]   
 
Ovarian tissue cryopreservation protocols are complex. Ovarian tissue consist of 
multiple cell types with varying volumes and water permeability which may alter the 
way cryoprotectants protects against cell damage. Even minor changes may greatly 
affect the success of the protocol.  Cryopreservation of ovarian tissue is similar to 
whole organ cryopreservation when compared to the preservation of single cells like 
gametes. [71] [72]   
 
Cryopreservation of ovarian tissue is mainly aimed at optimising the primordial 
follicle survival rate. [71]  [72]  [73] [74]   Larger, more complex follicles may have too 
many sites where freezing can harm the ultrastructure and intercellular connections 
between cells. 
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Early functional studies of ovarian transplantation 
 
Early primate transplant data was published in 2002 by a group from Norfolk. [75]  A 
total of 16 Cynomolgus monkeys were used in an experimental design to show that 
transplanted ovarian tissue will function to produce hormones and normal menstrual 
cycles.  The monkeys were divided into three groups.  The first group had no ovarian 
tissue replaced (so-called sham group), group two where ovarian tissue was 
transferred and a third group where the transplanted ovarian tissue was supported 
by administration of 1 µg of VEGF (vascular endothelial growth factor).  The authors 
did not state the anatomical site where the transplantation was performed but gave a 
very good description of the hormonal and physiological function in these animals 
after transplantation.  In the group of monkeys that received transplantation without 
VEGF support, five out of six had functioning transplants and two out of five of the 
animals with VEGF had functioning ovarian transplants.  At a later stage in this study 
previously cryopreserved ovarian tissue was transplanted into the so-called sham 
group and 50% (2 out of 4) of the animals developed hormonal function.  Despite the 
low numbers this work supported the potential of this technique to safeguard at least 
hormonal function of ovarian grafts.  The authors concluded that “the administration 
of VEGF at the dose tested did not appear to improve transplant outcome”. [75] 
 
Cryoprotectants  
 
It is clear that two protectant media, Dimethyl sulfoxide (DMSO) and 1,2-Propanediol 
(PROH) showed better results when used in combination with controlled slow-
freezing and rapid thawing when compared to other cryoprotective media. More 
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normal oocytes with intact cytoplasmic organelles survived when compared to fresh 
control groups.  [70] [71] [73] [74]  [76]  
 
Two animal studies compared DMSO and PROH as cryoprotectants in slow-freezing 
cryopreservation. Similar results with high percentages of morphologically normal 
follicles were found. [77]  [78]  
 
Another animal study on goats using controlled slow-freezing of ovarian tissue found 
that 1.5M DMSO, when compared to 3M DMSO and corresponding PROH 
concentrations, resulted in a significantly higher percentage morphological normal 
primordial follicles. [79]  
 
A summary of clinically relevant ovarian tissue cryoprotectant protocols are included 
in Table 19. 
 
Vitrification of ovarian tissue 
 
Vitrification and other methods of rapid cooling of ovarian tissue have been 
investigated but only a few studies have been published on rapid cooling methods. 
[71] [80] [81] Where the volume of the cells are smaller and the structure of the 
tissue is less complex, vitrification may be more useful. 
 
A recent publication from Germany describes the histological evaluation of xeno-
transplanted human ovarian tissue studied for signs of neovascularisation 
development. [82] The aim of this experimental study was to describe the amount of 
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revascularisation in three different groups of human ovarian tissue.  It was previously 
suggested that transplantation rather than cryopreservation caused the majority of 
primordial follicle loss in animal models. [83] To try and demonstrate the validity of 
this, the authors studied fragments of ovarian tissue from three different treatment 
groups.  Group A was fresh non-treated tissue, group B was tissue previously frozen 
with a slow freezing protocol and group C was tissue that was previously vitrified.  A 
standard thawing methodology was used for all specimens and the tissue was then 
transplanted to SCID mice.  The tissue was then examined for neovascularisation by 
staining with anti-mouse platelet epithelial cell adhesion molecule (PECAM-1) at 
progressively longer intervals.  The amount of fluorescence was used as a quantitive 
indication of neovascularisation.  The main findings were that there was no 
difference in the amount of revascularisation between the types of tissue treatment 
i.e. the revascularisation was independent of treatment method that is 
cryopreservation through slow freezing, vitrification or no treatment at all.  There was 
an observed loss of follicles that was more pronounced within the first week after re-
implantation (13%) when compared to follicle loss later after transplantation (5%) in 
the following three weeks.  This would support the findings by Oktay [84] that 
suggests the most important period for follicle loss is in the initial re-vascularisation 
period where most ischemic damage occurs.  
 
  
148 
 
Reference Study 
Sample 
Approach CPA 
& Base 
solution 
Non- 
Permeable 
CPA 
Tissue size Equilibration 
Time & 
Temperature 
Cooling rate 
(ºC/min) 
Seeding 
Method  
Thawing 
& Wash out 
Result 
Gosden 
1994 [85] 
 
Sheep Slow rate, 
controlled 
1.5M DMSO 
in Leibowitz-
15 
0.1M 
sucrose 
10% calf 
serum 
Tissue: 
5-15x5mm 
Vials: 2ml  
15min, 
on ice 
2 to -7, 
0.3 to -40, 
10 to 140, 
plunged 
Manual, 
-7ºC, hold 
10min after 
In air, 
water 
bath,10min in 
Leibowitz-15 
Live births 
Oktay 2000 
[86] 
 
Case study: 
POF patient 
Slow rate, 
controlled 
1.5M DMSO 
in D-PBS 
0.1M sucrose 
20% serum 
Tissue: 
1-3x3-10mm 
30min 
4ºC 
2 to -7, 
0.3 to -40,  
10 to -140, 
plunged 
Manual, 
-7ºC, hold 
10min 
before 
In air 30s, 
37ºC water, 
âCPA 
4x5min 
Ovarian 
function, 
ovulation 
Radford 
2001 [87] 
 
Case study: 
POF cancer 
patient 
Slow rate, 
controlled 
1.5M DMSO 
in Leibowitz-
15 
2.5% HSA Tissue: 
1x5x10mm 
Vials: 1ml  
30min, 
4ºC 
2 to -9, 
0.3 to -40, 
10 to -140, 
plunged 
Manual, 
-9ºC 
In air 30s, 
1min 37ºC 
water,3x5m  
Leibowitz-15 
Ovarian 
function  
for 
2 months 
Oktay 2004 
[88] 
 
Case study: 
POF cancer 
patient 
Slow rate, 
controlled 
1.5M DMSO 
in D-PBS 
0.1M sucrose 
20% serum 
Tissue: 
1-3x3-10mm 
30min 
4ºC 
2 to -7, 
0.3 to -40,  
10 to -140, 
plunged 
Manual, 
-7ºC, hold 
10min 
before 
Air 30s, 37ºC 
water bath, 
âCPA 4x 
5min 
Ovarian 
function, 
ICSI-ET, 
No 
pregnancy 
Donnez 
2004 [89] 
 
Case study: 
POF cancer 
patient 
Slow rate, 
controlled 
1.5M DMSO 
in Leibowitz-
15 
4mg/ml HSA Tissue: 
2x2mm 
Vials: 2ml  
_ 2 to -8, 
0.3 to -40, 
30 to -150, 
plunged 
Manual, -8ºC In air 2min, 
2min 37ºC 
water,3x in 
Leibowitz-15 
Ovarian 
function, 
Spontaneous 
Live birth 
Meirow 2005 
[90] 
 
Case study: 
POF cancer 
patient 
Slow rate, 
controlled 
1.5M DMSO 
in D-PBS 
15% 
synthetic 
serum 
Tissue: 
1-2x5x5mm, 
Vials: 2ml  
30min 1 to -9, 
0.3 to -36, 
5 to -140, 
plunged 
Manual, 
 -9ºC 
In air 30s, 
2min 37ºC 
water, âCPA  
4x 5min 
Ovarian 
function, 
IVF-ET, 
Live birth 
Demeestere 
2006 [91] 
 
Case study: 
POF cancer 
patient 
Slow rate, 
controlled 
1.5M DMSO 
in D-PBS 
0.1M 
sucrose 
10% patient’s 
serum 
Tissue: 
2x5x5mm, 
Vials: 2ml  
30min, 
4ºC 
 
2 to -7, 
0.3 to -40 
-10 to 140, 
plunged 
Manual, 
-7ºC, hold 
10min 
before 
In air 2min, 
2min 25ºC 
water, âCPA 
4x 5m 
Ovarian 
function, 
Spontaneous 
pregnancy 
 
Table 19 Summary of cryopreservation methods achieving successful results after cryopreservation of ovarian tissue. 
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Whole Ovary cryopreservation  
 
Whole ovary cryopreservation may become an option if certain technical difficulties 
can be overcome. In slow freezing, the precise controlled rate of cooling is important 
for individual cell survival. Due to the complex structural and physical properties of 
larger volume tissue, survival and normal function of whole organs after freezing and 
transplantation is often difficult to achieve. There are signs however that the 
progress in cryobiology in the late 1990’s may overcome some of these difficulties. 
 
An early report of whole ovary cryopreservation and re-transplantation performed on 
rats was reported in 2002 by Wang. [92] Since then many other primate models, 
including humans, have followed.  
 
Whole ovary cryopreservation studies in animals  
 
Work on mammalian ovaries includes a description of cryopreservation of pig ovaries 
with slow freezing and storage for 3 weeks. [76] The ovaries were then thawed and 
examined by light and electron microscopy for morphological appearance. Follicles 
containing intact oocytes were considered viable. The investigators found a survival 
rate of more than 80% for primordial follicles but conceded that “morphologic 
methods cannot provide final proof of viability, which clearly requires assessment of 
the in vivo function of cryopreserved whole ovaries.”  
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A summary of the most important animal work is summarised in Table 20. It is clear 
that techniques are not standardised and the results are variable. 
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Author Year Model Cryo - method Transplant Important outcome measures 
Bedaiwy 
[93] 
2003 
 
11 sheep Slow cooling Vascular 
anastomosis 
· Short term vascular patency 100% 
· Long term vascular patency 27% 
· Postoperative FSH similar than pre-operative if vessels patent 
Revel [94] 2004  8 sheep Slow cooling Vascular 
anastomosis 
· Menstrual cycles after transplant 37.5% 
· Successful establishment of bloodflow in ovary 62.5% 
Imhof [76] 2004 10 pigs Slow freezing 
&  vitrification 
Not 
transplanted 
· Morphology – 84.4% viable (slow freezing) 
· Morphology – 21.1% viable (cryopreservation) 
Arav [95] 2005 8 sheep Slow cooling Vascular 
anastomosis 
· 3 of 8 sheep  had hormone activity 24 to 36 months post-
transplantation 
· In 2 of 8 sheep oocyte retrieval was successful 
Imhof [96] 2006 9 sheep Slow cooling Vascular 
anastomosis 
· 4 of 9 sheep had hormonal function 
· One of 9 sheep conceived after spontaneous intercourse and 
delivered a healthy lamb 545 days after transplantation 
· Follicular survival rate was 1.7%–7.6% 
Baudot  [97] 2007 sheep  Vitrification Not 
transplanted 
· 61% small follicles viable on dye test after thaw 
· 48% primordial follicles normal after thaw 
Grazul-
Bilska [98] 
2008 
 
4 sheep Slow cooling Vascular 
anastomosis 
· 2 of 8 ovaries with showed developing follicles  
· Morphology similar to control group 
Qi [99] 2008 10 rats  Slow cooling Vascular 
anastomosis 
· 100% survival on histological evaluation 
· 80% hormone production recovery 
Courbiere 
[100]  
2008 
2009 
5 sheep Vitrification Vascular 
anastomosis 
· 1 of 5 sheep recovered endocrine function after 6 months 
· 100% follicle loss in all sheep on histological evaluation  
Arav [101] 2010 3 sheep Slow cooling  · 2 of 3 sheep had follicles 6 years after transplantation 
· 3 of 3 sheep had intact vascular supply 
Onions 
[102] 
2009 8 sheep Slow freezing Vascular 
anastomosis 
· 7 of 8 sheep had vascular patency after implantation 
· 3 of 8 sheep resumed hormone production 
 
Table 20 Summary of animal data on whole ovary cryopreservation. 
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In a review by Bromer, a strong argument is made about ischemia that may occur at 
the time of re-implantation of previously cryopreserved ovarian cortical strips. [103] 
The authors argue that small tissue fragments need to establish neovascularisation 
after grafting and that this process may require at least seven days during which time 
many cell populations undergo hypoxic damage with a significant loss in primordial 
follicle numbers.  In work previously published by the group of Gosden, [104] the loss 
of primordial follicles after transplantation of previously cryopreserved sheep ovarian 
cortical tissue was calculated to be due to ischemia in 60-70% of follicles after the 
transplantation but only 7% due to the cryopreservation procedure.  Bromer and 
Patrizio support the argument of follicular loss after transplantation with the fact that 
the resumption of endocrine function only appears after a few months and that the 
life span of the transplanted tissue in terms of hormone production is limited to two to 
three years. [103] Cryopreservation of the whole ovary on a vascular pedicle may 
limit some of the ischemic time after transplantation and limit the primordial follicle 
loss.  Perfusion of the whole ovary will be almost immediate after transplantation. 
[105] [106]  
 
Studies on human ovary freezing and transplantation are promising. In all the 
published work, slow cooling was used. [105] [106] [107] [108] DMSO was used in 
most of the freezing protocols and follicle viability was assessed by evaluation of 
apoptosis and microscopy. In an experimental study published by Martinez Madrid in 
2004, whole human ovaries were perfused with Heparin and cryoprotectants before 
slow cooling to -80° C. [105] After thawing, 75% of follicles were considered to be 
viable on microscopy.  There are no reports yet of transplantation of previously 
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cryopreserved whole intact ovaries in a human model. Live follicle rates after thawing 
ranged from 75.1% [105] to 78%. [107] 
 
Bromer and Patrizio concluded with the statement that “cryopreservation of the 
whole ovary could potentially provide an alternative to patients requiring this method 
of fertility preservation”.  The fact that numerous animal studies have had positive 
results makes it likely that this option for fertility preservation will be investigated as 
another option in humans. 
 
Whole ovary transplantation with vascular anastomosis 
 
There are very few reports in the literature about successful whole ovary 
transplantation.  Fresh whole ovary transplantation was described from the United 
States in a patient with premature ovarian failure. [109] The donor was a 
monozygotic twin sister.  During the removal of the donor ovary the ovarian veins 
could easily be identified but the ovarian artery was not visible with the naked eye.  
With an operating microscope vascular anastomosis was created between the 
recipient vessels using 10.0 Nylon sutures.  A figure from Silver is shown (Figure 8).  
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Figure 8 Diagrams from [109] demonstrating transplantation of whole human ovary. 
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 After transplantation the patient resumed normal menstrual cycles but it is not stated 
in the report how long after transplantation the endocrine function returned.  The 
authors stated that “we suspect follicle ischemia was minimal”.  Unfortunately this 
description was not detailed enough about preoperative assessment of premature 
ovarian failure and the condition of the contra-lateral ovary.  The patient previously 
had two normal pregnancies and in a table from the same report it is apparent that 
she was on oral contraceptives.  Whether the menstrual cycles were indeed due to 
the transplanted ovary is difficult to confirm or evaluate from this.  Mhatre & Mhatre 
claim to have performed a surgical fresh whole human ovary transplantation on a 
vascular pedicle in an orthotopic position on 29 March 2002. [110]  An end-to-end 
anastomosis of the ovarian artery to the recipient inferior epigastric artery is 
described with venous drainage directly into the external iliac vein.  It is difficult to 
understand exactly where the donor ovary was positioned because the authors state 
that “having achieved the vascular anastomosis extra-peritoneally the ovary is 
placed orthotopically in close proximity to the uterus and Fallopian tube.   
 
Another description of the same case clearly states that “the donor ovary was placed 
orthotopically and supported with multiple 3/0 Vicryl sutures in the round ligament 
and the peritoneum”. [111]   The patient then had immune suppression with a 
combination of cyclosporine and prednisolone which were weaned over time.  It is 
interesting to note that the recipient was discharged only on day 15 postoperatively.  
The patient had almost immediate recovery of hormonal function and still had 
spontaneous menstruation, ovulation and development of secondary sexual 
characteristics.  The patient was a 17-year old with Turner’s syndrome and the donor 
was a “biologically related sister” aged 26 with two living children. 
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The obvious advantage of rapid re-perfusion after transplantation implies that the 
time between ligation of the ovarian pedicle and the cryopreservation procedure 
should be as short as possible.  This concept is supported by interesting basic 
scientific work by Coskun and co-workers where they aimed to determine the 
ischemic time necessary for tissue damage to the ovary. [112]  This group studied 36 
rats divided into four experimental groups.  Each group had an explorative 
laparotomy and were randomised to one of four intra-operative procedures.  Group 1 
had no ovarian manipulation, group 2 was subjected to ischemia of the ovary by 
twisting the pedicle for one hour and then re-perfusion of one hour, group 3 had 
induced ischemia for two hours and re-perfusion for one hour and group 4 had 
ischemia for three hours and then re-perfusion for one hour.  After the laparotomy 
and ischemic event (or no ischemic event in the case of group 1) the ovaries were 
removed and sent for histopathological evaluation.  The authors concluded that the 
critical ischemic time for rat ovaries was two hours when early signs of haemorrhage 
indicated early necrosis. [112]  This important basic scientific work gives some 
reassurance that there is at least a small window of opportunity for cryopreservation 
before ischemic damage occurs. This window may be as long as two hours, at least 
in the rat model. 
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Randomised controlled evaluation comparing ultrastructural 
damage of ovarian tissue after two slow freezing ovarian tissue 
protocols  
Aim 
 
The ultrastructural effects after cryopreservation with two well-known 
cryoprotectants, dimethyl sulfoxide (DMSO) and 1,2-propylene glycol (PROH), on 
early human follicles were investigated and compared to fresh tissue.  
Ethics approval 
 
This study was approved by the local institutional review board of the Faculty of 
Health Sciences, Stellenbosch University. Project number: N05/10/182 
 
Materials and methods  
 
Eleven women with advanced cervical cancer had oophorectomy before the initiation 
of cancer treatment. Ovarian tissue was obtained by laparoscopic oophorectomy.  
After dissection of the ovarian cortex, fresh stromal tissue was sent for metastatic 
analysis (by histological evaluation). Fresh cortical tissue samples were also taken 
as control.  Remaining dissected ovarian cortical tissue sections of each patient were 
equally divided into the two cryoprotectant groups.  Samples were taken from each 
cryoprotectant group, after equilibration before and after freezing.  Five resulting 
groups could be compared:  
i. Fresh tissue (control group) 
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ii. Tissue equilibrated in DMSO 
iii. Tissue equilibrated in PROH 
iv. Tissue equilibrated and cryopreserved in DMSO 
v. Tissue equilibrated and cryopreserved in PROH.   
 
Five tissue samples per patient were fixed for standard histological haematoxylin and 
eosin (HE) staining and transmission electron microscopy (TEM).  Tissue samples 
showing early follicles on HE slides were evaluated by TEM.   
 
 
Figure 9 Two primordial follicles under light microscopy on H&E stained slide. x20. 
 
Ultrastructural studies on micrographs of primordial and primary follicles were 
assessed according to a scoring system which gave an indication of follicular health.  
Appropriate statistical tests were applied to analyse the mean scores and P=0.05 
was considered as significant. 
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Protocol for ovarian tissue freezing in current study 
 
After laparoscopic oophorectomy the ovaries were transported either in a 
laparoscopic endobag or were transported in a standard sterile 90ml specimen 
container with 40ml Quinn’s advantage medium with HEPES.  The ovary was 
dissected in a laminar flow cabinet under sterile conditions by first bisecting the 
ovary and removing the ovarian stroma.  The dissection was performed in Quinn’s 
advantage medium with HEPES at room temperature.  The cortex of the ovary was 
dissected into small strips with as little manipulation of the tissue as possible.  After 
dissection the tissue was handed over to the scientist.   
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Ovarian Tissue Retrieval 
Collection 
 
1 or 2 ovaries 
 
 
Dissection 
 
 
 60-130 ovary strips 
 
Cryopreservation 
 
      EM 
 
DMSO Equilibration PROH 
  
 
   EM           EM 
DMSO PROH 
 
Controlled slow-freezing 
 
 Storage 
DMSO  PROH 
 
    Rapid thawing 
 
 
       EM  EM 
 
 
Histological processing  
& Ultrastructural evaluation 
Transplantation 
Figure 10 Flow diagram of cryopreservation protocol. (EM indicates where tissue was 
taken and prepared for ultrastructural study) 
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Protocol for DMSO and PROH  
(Details of chemical compounds, mediums and consumables used attached as 
addendum B) 
 
The ovarian tissue strips were washed in 10ml of Quinn’s advantage medium with 
HEPES and then counted and divided into two groups.  Half of the tissue was in the 
DMSO group and the other half in the PROH group.  The final equilibration and 
cryopreservation in the PROH group resulted in 0.2 micro millilitre medium 
containing 1.5M 1.2 propanediol plus 0.1M sucrose plus 10mg per millilitre Quinn’s 
advantage human serum albumin in DPBS. [113]  The equilibration cryopreservation 
of each vial in the DMSO group contained 0.2 micro-millilitres sterile filtered DMSO 
medium containing 1.5M, DMSO 0.1M sucrose and DPPS pre-cooled to 4 °C.  The 
PROH group was equilibrated for 90 minutes at room temperature and the DMSO 
group for 30 minutes.  See Figure 11. 
 
 
Figure 11 Accurate timing of equilibration time of tissue in cryoprotectants 
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Slow freezing of ovarian tissue 
 
Slow freezing of the tissue was achieved by using a specialised electronic 
cryochamber.  The Cryologic freeze control system (see Figures 12 and 13) run by 
cryo-genesis version V software allowed customisation of the slow freezing protocol 
accurately. See Figure 8   
 
 
Figure 12 The CryoLogic Freeze Control® System 
 
An example of the screen print from the cryo-genesis software is included below.  
This figure shows how the drop in temperature was carefully controlled from room 
temperature to 4 °C at a constant cooling rate of 2°C per minute. (See Figure 13)  At 
4 °C the DMSO vials were added and then from 4 °C to -7 °C again cooled at a 
constant rate of 2 °C per minute.  
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Figure 13 A cryopreservation protocol is programmed and saved in the CryoGenesis™ 
software.   
 
At minus 7 °C freezing was started in a controlled way through a process called 
manual seeding where the side of the vial was touched by an ultra cooled cotton 
swab that was recently dipped in liquid nitrogen.  It was previously demonstrated in 
an experimental study that “there was a significant difference in primordial and 
primary follicle density” between tissue samples that were allowed to crystallize 
spontaneously and those that were started through a process of seeding.  [114] The 
ice crystal formation started in an organised fashion to try and prevent unnecessary 
ice crystal formation.  From minus 7°C the temperature was reduced at a slower rate 
of 0.3 °C per minute to minus 40°C.  The temperature was then allowed to free fall 
until minus 60 °C at which point the samples were plunged into the liquid nitrogen.  
164 
 
The tissue samples were stored in liquid nitrogen until they were required for use.  
See Figure 14. 
 
 
Figure 14 Cryovials packed in cryochamber for controlled slow freezing 
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Rapid thawing 
Tissue for evaluation was thawed through a rapid process to minimise reheating 
injury. The vial was unclipped and kept at room temperature for a few seconds to 
remove excess liquid nitrogen. [113] Vials were transferred into sterile water bath at 
±37°C. The vials were gently swirled while completely immersed for ±5 minutes until 
the medium and the tissue sample were completely thawed.  See Figure 15. 
 
 
Figure 15 Cryovial thawed in water bath 
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Tissue sample were thereafter decanted into a small sterile culture dish and strips 
were transferred to wash-out media with sterile forceps. The samples were washed 
step-wise in lower concentrations of cryoprotectant media at room temperature to 
remove all cryoprotectant.   
 
The PROH group was washed for 5 minutes in 10ml sterile-filtered medium 
containing 0.75M PROH + 0.2M + 10mg/ml Quinn’s Advantage™ HSA in D-PBS and 
then in 10ml 0.2M sucrose + 10mg/ml Quinn’s Advantage™ HSA in D-PBS for 10 
minutes  
 
The DMSO group was washed for 5 minutes in 10ml sterile-filtered medium 
containing 0.75M DMSO + 0.25M sucrose in D-PBS and then in 10ml 0.25M sucrose 
in D-PBS for 10 minutes  
 
 
Figure 16 Storage of tissue in liquid nitrogen. 
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The ultra structural evaluations were performed after micrographs were printed and 
delivered to Prof M Sousa in Spain.  The follicles were examined for various 
characteristics and evaluation was done using a novel scoring system.  
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Ultrastructural evaluation  
Ultrastructural evaluation was done on original printed micrographs.  Micrographs 
were individually evaluated and the evaluator was blinded for the group.  The 
following ultrastructures of each primordial or primary follicle were evaluated on the 
micrographs: 
· Stroma: 
- Stromal cells: membrane, nucleus, cytosol, organelles. 
- Extra-cellular matrix. 
- Basal lamina. 
· Granulosa cell layer: 
- Nucleus: nuclear envelope, nuclear pore complexes, nuclear lamina, 
heterochromatin, euchromatin, nucleolus. 
- Cytoplasm: membrane, interdigitations /microvilli, pinocytosis, receptor 
mediated endocytosis, exocytosis, desmosomes, gap junctions, 
mitochondria, peroxisomes, primary lysosomes, refractile bodies, Golgi 
complexes, secretory vesicles, smooth endoplasmic reticulum, rough 
endoplasmic reticulum, lipid droplets, centrosome, microfilaments, 
intermediary filaments, microtubules, cytosol. 
· Oocyte: 
- Nucleus: nuclear envelope, nuclear pore complexes, nuclear lamina, 
heterochromatin, euchromatin, nucleolus. 
- Cytoplasm: membrane, interdigitations / microvilli, pinocytosis, receptor 
mediated endocytosis, exocytosis, desmosomes, gap junctions, 
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mitochondria, peroxisomes, primary lysosomes, refractile bodies, Golgi 
complexes, cortical vesicles, smooth endoplasmic reticulum, rough 
endoplasmic reticulum, annulate lamellae, nuage, lipid droplets, 
centrosome, microfilaments, intermediary filaments, microtubules, 
cytosol. 
- Perivitelline space. 
- Zona Pellucida. 
 
Evaluation was done using the following scoring system: 
1 = Poor, degenerative; 
2 = Fair, severe damage; 
3 = Average, recoverable damage; 
4 = Good, little damage; 
5 = Excellent, normal, no damage. 
 
No scores were awarded in cases where a structure or organelle was absent or 
could not be seen clearly enough for evaluation on the micrograph. Examples of 
electron micrographs are attached as Addendums A 1-4. 
 
 After cryopreservation many of the examined cells showed ultra structural damage 
including lytic damage to cell membranes, organelles and general degeneration. Due 
to relatively low number of specimens and low number of evaluated follicle structures 
that could be compared, no statistically significant changes were seen between the 
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different groups.  This may suggest that both cryopreservation protocols were 
equally effective. However, in a post-hoc analysis of the results where p-values were 
below the 10% threshold, a possible superior result for DMSO is described. [115]  
The results are summarised in Table 21. 
 
Evaluated Follicle Structure P Result 
Ovarian Stroma   
Stroma (overall) 0.85 NS 
Stromal cells 0.57 NS 
Extracellular matrix 0.15 Trend 
Basal lamina 0.74 NS 
Granulosa cells   
Granulosa cells (overall) 0.34 Trend 
Cytoplasm  0.35 Trend 
Mitochondria  0.60 NS 
Smooth and rough endoplasmic reticulum  0.13 Trend 
Nuclei of granulosa cells 0.09 Trend 
Oocytes   
Oocyte (overall) 0.62 NS 
Perivitelline space 0.32 Trend 
Cytoplasm of oocytes 0.54 NS 
Mitochondria of oocytes 0.91 NS 
Smooth and Rough endoplasmic reticulum of 
oocytes 
0.69 NS 
Nuclei of oocytes 0.14 Trend 
 
Table 21 Summary of the treatment effect (equilibration and cryopreservation) 
test results on follicle structures compared to the control sample. 
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Compared Follicle Structures r  
(correlation 
coefficient) 
P Relationship 
Stroma Granulosa cells 0.60 <0.01 Positive linear 
Stroma Oocyte 0.68 <0.01 Positive linear 
Granulosa cells Oocyte 0.77 <0.01 Positive linear 
Nuclei of 
granulosa cells 
Nuclei of oocytes 0.86 <0.01 Positive linear 
Cytoplasm of 
granulosa cells 
Cytoplasm of 
oocytes 
0.68 <0.01 Positive linear 
Mitochondria of 
granulosa cells 
Mitochondria of 
oocytes 
0.62 <0.01 Positive linear 
ER of granulosa 
cells 
ER of oocytes 0.65 <0.01 Positive linear 
Stroma Extracellular 
matrix 
-0.18 0.44 NS 
 
Table 22 Summary of the Spearman rank correlation test results on follicle 
structures. 
 
The follicle scoring data was examined to determine whether certain cell types were 
affected to a greater or lesser extent by the cryopreservation procedure.  
Spearman’s rank correlation coefficient is a statistical description of correlation 
between two non-parametric variables.  When the variables are not arranged in a 
direct linear distribution but rather in a monotonic relationship, the Spearman 
correlation should be used instead of the Pearson correlation coefficient. If the two 
variables (the dependant and independent) behave similarly e.g. structure Y will 
change in the same way as structure X under the same circumstances, the 
correlation will be positive.  The strong correlation in the scores when different 
cellular structures were compared indicates that different tissue elements responded 
in similar ways to the environment.  
172 
 
Conclusion 
 
Oocyte numbers are limited and decrease rapidly with age.  Women near the age of 
menopause have depleted ovarian follicle reserve and they are at the highest risk for 
developing premature ovarian failure due to cancer treatment.  Oocytes are complex 
cells with complex intra-cellular substructures that may be damaged by freezing.  It is 
however not only intra-cellular damage but also damage to inter-cellular and extra-
cellular structures that may influence the eventual survival of germ cells after 
cryopreservation.  The intimate association between oocytes and granulosa cells can 
easily be damaged by freezing.  These include autocrine and paracrine hormonal 
disruptions or damage to very specialised connecting proteins and gap junctions 
between cells. 
 
Oocyte preservation with slow freezing is a useful technique in certain selected 
clinical scenarios. Where there is a risk of metastatic spread of a malignancy to the 
ovary it may be possible to retrieve single oocytes for future use.  This will allow 
microscopy evaluation before the re-implantation of the preserved tissue.  However, 
many problems exist with oocyte freezing particularly in the scenario of a patient with 
cancer diagnosis.  There is an inevitable delay before follicle aspiration because of 
ovarian hyper-stimulation that takes a few days and perhaps even a few weeks.  
This will delay the onset of chemotherapy.  Additionally only a limited number of 
oocytes can be retrieved in a single stimulation cycle. 
 
Vitrification of single oocytes has become more successful recently and when 
fertilization is performed with ICSI, pregnancy outcomes are reasonable.  There is, 
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however, still a lower pregnancy rate with vitrified oocytes when compared to fresh 
oocytes. 
 
The randomised investigation into DMSO and PROH cryopreserved ovarian tissue 
showed no significance difference in electron microscopic evaluation of the tissue.  
There was also no significant difference between both treatment groups together and 
fresh controls. That would indicate that cryopreservation using either of the slow 
freezing protocols did not cause significant damage.  A possible superior result with 
DMSO was found in post-hoc analysis but due to the low number of cases it is 
difficult to be certain of a true difference between the two groups.  One possible 
advantage of DMSO is the fact that the equilibration time was shorter.  A total 
cryopreservation time of around seven hours was one hour shorter with DMSO 
compared to PROH. 
 
Slow freezing of ovarian cortical strips is technically feasible in a South African 
fertility laboratory.  After the initial cost of the acquisition of the new equipment, the 
cost per individual patient was reasonable.  The most important cost factor in this 
study was the electron microscopy evaluations and the start-up equipment 
expenses. 
 
Ovarian cortical tissue cryopreservation is a practical and useful technique for 
patients wanting to preserve ovarian function after gonadotoxic treatment. 
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Figure 17 Micrograph of primordial follicle with large areas of lysis (×) in the oocyte 
cytoplasm.  Ultrastructures present for evaluation were stromal nuclei (SC-N) with 
nucleoli (Nu), secretory vesicles (SV), mitochondria (M) and endoplasmic reticulum 
(ER).  The granulosa layer contained granulosa cell nuclei (GC-N), lipid droplets (L) a 
thin basal lamina (BL). Minimal microvilli (MV) and perivitelline space (PVS) were 
visible. 
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Figure 18 A primordial follicle with lytic areas (x) in the stroma. Stromal cell nuclei (SC-
N), collagen bundles (COL) and lipid droplets (L) were present in the stroma.  Lipid 
droplets (L), secretory vesicles (SV), perivitelline space (PVS), microvilli (MV), 
mitochondria (M) and endoplasmic reticulum (ER) were observed in the follicle.  TEM 
artefacts are indicated (8 ).x2000-6000. 
Addendum A 2 
 
L 
COL 
SC-N 
Nu 
M 
GC-N 
× 
× 
× 
× 
× 
× × 
× 
× 
× 
ER 
SV 
COL 
L 
PVS 
MV 
M 
L 
8  
176 
 
Addendum A 3 
  
Figure 19 Higher magnification of granulosa layer of follicle.  Desmosomes (D) and 
centrosomes (Ce) are abundant.  Gap junctions (GJ) are demonstrated.  Several lipid 
droplets (L), some in a refractile body (RB) are demonstrated.  Areas of lysis (x) and 
granulosa nuclei indentations (#) are indicated.  The basal lamina (BL), mitochondria 
(M), endoplasmic reticulum (ER & RER), intermediary- and microfilaments (IF/MF) are 
demonstrated.  Stromal nuclei (SC-N), collagen bundles (COL) and extracellular 
matrix (ECM) are demonstrated.x12000. 
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Figure 20 Micrograph of primordial follicle with small areas of lysis (×) in the stroma.  
TEM artefacts are indicated (8 ).  The stromal nuclei (SC-N), collagen bundles (COL) 
and the basal lamina (BL) are visible.  The granulosa layer contained granulosa cell 
nuclei (GC-N) and lipid droplets (L).  The intracellular separations (ICS) by the 
granulosa cell membranes are clearly seen.  Abundant mitochondria (M) and 
endoplasmic reticulum (ER) are present in the oocyte as well as a centrosome (Ce) 
and a giant refractile body containing several lipid droplets (L).x1500-4500.  
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Addendum B 
Details of chemical compounds, mediums and consumables  
 
Chemical compounds 
Cryoprotectants: 
Dimethyl Sulphoxide (DMSO) Hybri-Max™ D2650. Sterile filtered. Sigma® Sigma-
Aldrich Company Ltd., Irvine, Ayrshire KA128NB, UK. 
Molecular formula: C2H6OS 
Molar mass: 78.13g/mol 
IUPAC Name: Dimethyl sulfoxide 
Other names: Methyl sulfoxide; Methyl sulfinylmethane; DMSO 
Melting point: 16-19°C (292K) 
Boiling point: 189°C (462K) 
Density: 1.1004g/cm3 
 
1,2-Propanediol Art. 7478 Ph Eur, B P, USP. Merck, Darmstadt, Germany 
Molecular formulae: C3H8O2 
IUPAC name: Propane-1,2-diol 
Other names: Propylene glycol; 1,2-Propylenglycol; 1,2-Propanediol (1,2-
propylene glycol); Propanediol-1,2 (propylèneglycol-1,2); 
Propandiol-(1,2) (1,2-propilenglicole; 1,2-propilenoglicol); 
1,2-Propanodiol (1,2-propilenglicol) 
Molar mass: 76.10g/mol 
Melting point: -59°C 
Boiling point: 188.2°C 
Density: 1.036g/cm3 
 
Sucrose >99.5% (GC). S1888. Cell culture tested. 
Manufacturer: Sigma® Sigma-Aldrich Company Ltd., St. Louis, MO 63103, 
USA. 
 
MEDIUMS 
Base solution: 
Dulbecco’s Phosphate-Buffered Saline with Calcium and Magnesium without 
Phenol Red (D-PBS + CaCl2 + MgCl2) liquid. Sterile.1178.  
Manufacturer: Gibco™Invitrogen™Auckland, N.Z. 
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Melting point: No data available. 
Boiling point: No data available. 
 
Mediums: 
Quinn’s Advantage™ Media with HEPES. Sterile. 
Manufacturer: SAGE Assisted Reproduction Products™ A Cooper Surgical 
Company. In-Vitro Fertilization, Inc., Trumbull, CT 06611, 
U.S.A. 
Quinn’s Advantage™ HSA (Human Serum Albumin). Sterile. Manufacturer:   
SAGE Assisted Reproduction Products™ A Cooper Surgical 
Company. In-Vitro Fertilization, Inc., Trumbull, CT 06611, 
U.S.A. 
Solution: 100mg/ml total protein (weight/volume) in saline solution. 
pH 7.4±0.2 
Osmolality: 280±10mOsm/kg water 
 
Consumables 
Cryovials: 
Cryo.s™PP, 2ml conical round-based internal thread with screw cap 
Manufacturer: Greiner Bio-One GmbH, 72636 Frickenhausen, Germany 
 
Petri dishes:  
Falcon®3003, 100x20mm, Becton Dickinson Labware, NJ, USA. 
Manufacturer: Cellstar®, 35x10mm Greiner Bio-One GmbH, 72636 
Fickenhausen, Germany. 
Sterilizing micro filters: 
Manufacturers: Ministart®, 0.20µm, Sartorius, Vivascience, Hannover, 
Germany 
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Addendum C 
PATIENT FORMS 
Patient Information and Consent forms 
Hierdie vorm is ook in Afrikaans beskikbaar 
 
Information Sheet for Ovarian Biopsy and Cryopreservation 
We are providing you with the following information in order for you to be able to make an 
informed decision about whether you wish to freeze your ovarian tissue. We want to be sure 
you understand this fully before you formally agree to participate. Be sure to ask any 
questions you have about the information that follows and we will do our best to explain and 
to provide any further information you require. 
 
In order to treat the illness from which you are suffering, you will require surgery, 
chemotherapy and/or radiotherapy which are likely to cause permanent damage to your 
ovaries such that they will no longer be able to produce eggs. By removing some ovarian 
tissue before you start this treatment and carefully freezing it, it will be possible to protect 
some of your eggs from the harmful effects of the chemotherapy or radiotherapy you are 
shortly to undergo. 
 
Ovarian tissue is collected at a minor operation called a laparoscopy. This is performed 
under general anaesthesia, when a telescope, about the thickness of a pencil, is placed 
through your navel and a small piece of ovarian tissue is removed through two smaller 
incisions, lower down on your abdomen.  
 
There are potential risks involved with this procedure, of which you should be aware:  
There is a very small risk of a reaction to the anaesthetic agents; a small chance of infection; 
damage to the other pelvic organs; and if you have abnormal blood clotting mechanisms, a 
chance of bleeding after the procedure.  
 
Some women undergoing abdominal surgery for their condition may be able to have ovarian 
tissue removed at the time of surgery and so avoid the need for a laparoscopy. A piece or 
pieces of ovarian tissue will be removed. In some cases it may be necessary to remove a 
whole ovary, in order to maximize your chances of saving a useful number of eggs.  
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You will not be asked to take any drugs, make any extra visits to the hospital or to have any 
additional blood tests.  
 
The use to which we can put your ovarian tissue is complicated by the fact that only very 
immature eggs in the ovary will survive the freezing process.  The frozen tissue may, at a 
later stage, be re-implanted into your body and possibly restore ovarian function. The 
benefits of normal ovarian function may be hormonal. Hormones secreted by the ovaries 
protect the body against ageing and in particular the strength of your bones. 
  
Some people have expressed concern that the re-implantation may risk reintroducing some 
untreated cancer cells back into your body. There may be other risks associated with ovarian 
re-implantation that we do not know about at present. Research is presently on-going to look 
at both these risks and ways of reducing the potential harm. 
 
At this stage you are consenting only to collect ovarian tissue for storage. If and when you 
decide you wish to use the tissue, the details of any procedure will be explained to you and 
you will be asked to sign a separate consent form. Your participation is entirely voluntary 
and, whatever your decision, it will not affect your treatment in any way. We understand that 
this is a difficult time for you and that you may wish to discuss the implications of the storage 
of your ovarian tissue. 
 
In the event of your death, the stored ovarian tissue will either be destroyed or be used for 
research purposes. You will be asked to sign a separate consent form instructing us what to 
do.  
 
If you require any further information regarding the proposed research or have any concerns 
regarding any potential side-effects, please feel free to discuss them with your doctor. 
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Information Sheet for Ovarian Tissue Re-implantation 
We are providing you with the following information in order for you to be able to make an 
informed decision about whether you wish re-implant your stored ovarian tissue. We want to 
be sure you understand this fully before you formally agree to participate. Be sure to ask any 
questions you have about the information that follows and we will do our best to explain and 
to provide any further information you require. 
 
In order to treat the illness from which you are suffering, you required surgery, chemotherapy 
and/or radiotherapy which could cause permanent damage to your ovaries. Part of your 
ovarian tissue was stored and can now be re-implanted. 
 
The re-implantation is done under local anaesthesia except when you may require general 
anaesthesia for another reason. A small cut of less than 1 centimetre is made in your 
forearm and the piece of tissue is then inserted and sutured with absorbable sutures. The 
cut is made on the inner aspect of the arm. Sometimes it may be necessary for the tissue to 
be implanted in the abdominal cavity. This will happen during a laparoscopy. Your doctor will 
inform you about the most suitable place for your implantation. 
 
Some people have expressed concern that the re-implantation may risk reintroducing some 
untreated cancer cells back into your body. There may be other risks associated with ovarian 
re-implantation that we do not know about at present. Research is presently on-going to look 
at both these risks and ways of reducing the potential harm. There is a very small risk that 
cancer cells may be re-implanted with the ovarian tissue. The tissue is carefully examined 
before re-implantation to prevent this problem. 
 
You will not be asked to take any medication after re-implantation. 
 
The benefits of re-implantation may be hormonal. Hormones secreted by the ovaries protect 
the body against ageing and in particular the strength of your bones. 
 
At this stage you are consenting to re-implantation of ovarian tissue. Your participation is 
entirely voluntary and, whatever your decision, it will not affect your treatment in any way.  
 
If you require any further information regarding the proposed research or have any concerns 
regarding any potential side-effects, please feel free to discuss them with your doctor 
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Hierdie vorm is ook in Afrikaans beskikbaar 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
 
TITLE OF THE RESEARCH PROJECT: 
 
A STUDY TO EVALUATE OVARIAN CRYOPRESERVATION TO REDUCE LONG 
TERM HORMONAL DYSFUNCTION ASSOCIATED WITH CANCER TREATMENT 
IN WOMEN 
 
REFERENCE NUMBER: N05/10/182 
 
PRINICIPAL INVESTIGATOR: Dr MH Botha  
 
ADDRESS: Dept. Obstetrics & Gynaecology, Tygerberg Hospital, TYGERBERG 
 
CONTACT NUMBERS: 
 
Tel: 021 9385696 
Cell: 0844024023 
Fax: 021 9384648 
Email: mhbotha@sun.ac.za 
 
You are being invited to take part in a research project. Please take some time to read the 
information presented here, which will explain the details of this project. Please ask the study staff 
or doctor any questions about any part of this project that you do not fully understand. It is very 
important that you are fully satisfied that you clearly understand what this research entails and how 
you could be involved. Also, your participation is entirely voluntary and you are free to decline to 
participate. If you say no, this will not affect you negatively in any way whatsoever. You are also free 
to withdraw from the study at any point, even if you did agree to take part. 
 
This study has been approved by the Committee for Human Research at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
 
What is this research study all about? 
· Please read the information sheet “Information Sheet for Ovarian Biopsy and 
Cryopreservation” that will be provided to you, carefully. 
 
Why have you been invited to participate? 
 
· Your participation in this project will result in the broadening of the knowledge of 
preservation of ovarian function after cancer treatment.  
 
Will you benefit from taking part in this research? 
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· By removing some ovarian tissue before you start this treatment and carefully freezing it, it 
may be possible to protect some of your eggs from the harmful effects of the chemotherapy 
or radiotherapy you are shortly to undergo. The frozen tissue may, at a later stage, after 
thawing be re-implanted into your body and may possibly restore ovarian function. The 
benefits of normal ovarian function may be hormonal. Hormones secreted by the ovaries 
protect the body against ageing and in particular the strength of your bones. This procedure 
may sometimes restore fertility. 
 
Are there in risks involved in your taking part in this research? 
· The possible risks are clearly described in the information sheet - Please read the 
information sheet that will be provided to you, carefully. 
 
If you do not agree to take part, what alternatives do you have? 
· Participation is voluntary, and you may refuse to participate in the project and may at any 
time withdraw your participation from the project. Refusal or withdrawal from the project will 
in no way affect your present or future treatment at the clinic. The researcher may also 
withdraw you from the project if he/she considers it to be in your best interest. 
 
Who will have access to your medical records? 
· All information collected will be treated confidentially. The results will be used for publication 
in human fertility related journals, without revealing the identity of any individual. On 
completion of the project, the final outcomes of the project will be available to you. 
 
What will happen in the unlikely event of some form of injury occurring as a direct result of 
your taking part in this research study? 
· At this stage you are consenting only to collect ovarian tissue for storage. If and when you 
decide you wish to use the tissue, the details of any procedure will be explained to you and 
you will be asked to sign a separate consent form. The freezing and storage of ovarian 
tissue will not cause any injury to you. 
Will you be paid to take part in this study and are there any costs involved? 
· No, you will not be paid to take part in the study and there will be no costs involved for you, if 
you do take part. 
Is there any thing else that you should know or do? 
· You should inform your family practitioner or usual doctor that you are taking part in a 
research study.  
· You can contact     Dr MH Botha at Tel 021 9385696       if you have any further queries or 
encounter any problems. 
· You can contact the Committee for Human Research at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
· You will receive a copy of this information and consent form for your own records. 
· You will sign a consent form to instruct us that in the event of your death, frozen ovarian 
tissue will either be destroyed or used for research purposes.  
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By Signing below, I………………………….. agree to take part in  a research study  
entitled:-  
 
A STUDY TO EVALUATE OVARIAN CRYOPRESERVATION TO REDUCE LONG TERM 
HORMONAL DYSFUNCTION ASSOCIATED WITH CANCER TREATMENT IN WOMEN 
 
I declare that: 
· I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
· I have had a chance to ask questions and all my questions have been adequately answered. 
· I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
· I may choose to leave the study at any time and will not be penalized or prejudiced in any 
way. 
· I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
 
 
 
Signed at (place)…………………………….on (date) ……………………………….. 2………… 
 
 
 
 
………………………….. ……………………                                       ……………………… 
Signature  of Participant     Date of birth                                            Signature of Witness  
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Declaration by Investigator 
 
I  (name )  …………………………………………………declare that:- 
 
· I explained the information in this document to …………………………….. 
· I encouraged him/her to ask questions and took adequate time to answer them. 
· I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
· I did/did not use a translator. (If a translator is used then the translator must sign the 
declaration below. 
 
Signed at  (place)…………………………..on (date) ………………………….. 2………. 
 
 
…………………………..                                                        ……………………… 
Signature  of Investigator                                                     Signature of Witness.  
 
 
 
 
Declaration by Translator  
  
I (name )  …………………………………………………declare that:- 
 
· I assisted the investigator (name)…………………………. to explain the information in this 
document to (name of participant)………………………….. using the language medium of 
Afrikaans/Xhosa/Other ……………..…………... 
· We encouraged him/her to ask questions and took adequate time to answer them. 
· I conveyed a factually correct version of what was related to me. 
· I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
 
 
. 
Signed at  (place)…………………………..on (date) ………………………….. 2…… 
 
…………………………..                                                        ……………………… 
Signature of Translator.                                                     Signature of Witness.  
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WRITTEN CONSENT FOR HANDLING OF OVARIAN TISSUE  
 
 
Ovarian Cryopreservation Project for Oncology Patients 
 
 
Name of Patient: .......................………    Date:……………………….. 
Address:  ………………………………… 
  ………………………………… 
  ………………………………… 
I have read the attached information on the experimental freezing programme for ovarian tissue. I 
have been given a copy to keep. I have had the opportunity to discuss the details and ask questions 
about this information. I understand that I must undergo the operation of laparoscopic ovarian 
biopsy in order that some of my ovarian tissue may be cryopreserved (frozen) and stored for my 
possible future use. I understand that this tissue may not survive the freezing and thawing process 
and that the Hospital cannot be held responsible for this. I understand that this technique is new and 
experimental and thus I understand that the technique may not work.  
 
However, I am willing to undergo the operation accepting these reservations and I understand that 
no guarantee can be given to me regarding future success.  
 
I understand that in the event of my death, or should I no longer require my ovarian tissue, it will 
be:-   a) disposed of * 
                                    b) made available for research purposes* 
                                       (* delete as appropriate) 
 
I have been given the opportunity to take part in counseling regarding the implications of the 
proposed storage of my ovarian tissue. 
 
 
 
PATIENT'S NAME (BLOCK CAPITALS)  . ..................………………………..….. 
 
PATIENT'S SIGNATURE    ……………………………………… … 
 
PATIENT'S DATE OF BIRTH                                      ..................………………………..….. 
 
 
PATIENT'S WITNESS' NAME (BLOCK CAPITALS) …………………………………………. 
 
WITNESS' SIGNATURE    …………………………………………. 
 
 
DOCTOR’S NAME (BLOCK CAPITALS)             …………………………………………. 
 
DOCTOR’S SIGNATURE    ……….………………………………… 
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Addendum D 
PATIENT DETAILS FORM 
Project no:N05/10/182 
Note: 1. To be completed for/by every patient entering this project! 
2. Attach 2 copies of signed cryopreservation consent forms to this form! 
3. Place TBH patient stickers on every form and/or page! 
Please complete in block letters, as accurate and thorough as possible. 
Personal Details 
Date: 
Surname: 
Full names: 
Date of Birth:    Place of Birth: 
ID no. (Identification book no.): 
Hospital no.: 
Local Clinic / Doctor: 
Occupation:  
Do you have any children?   Ages:   
Any previous serious illnesses?(specify):  
Any previous serious operations?(specify): 
Any prescription medication past 90days?(specify):  
Tel(h):   (w) 
Cell: 
Home Address: 
 
 
 
Postal Address: 
 
Next of kin:     Relationship: 
Tel(h):   (w) 
Cell: 
Home Address:     Postal Address: 
 
 
 
Possible personal reason(s) for entering the study:  
To have children:  To regain hormones:  Both: 
Other (specify): 
 
Completed by ______________________ at _______________________________ 
Patient Signiture ________________________ Name _______________________ 
Medical Doctor _________________________ Name ________________________ 
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PATIENT & PROCEDURE INFORMATION FORM 
Project no:N05/10/182 
Note: 1. To be completed for every patient entering the project! 
2. Attach 2 copies of signed cryopreservation consent forms to this form! 
3. Place TBH patient stickers on every form and/or page! 
Patient 
Surname: 
Full names: 
DOB: ID no: 
Hospital no: Cell: 
Diagnosis and Pre-Operation Details     
Date diagnosed: Treatment: 
Cancer type:  
Location:  
Stage: Treatment duration: 
Date: FSH  (IU/l ): LH  (IU/l ): E2  (pmol/l ): 
    
    
    
Any other illness? Specify: 
Additional medication prescribed: 
Surgical Procedure  
Date: Theatre: 
Procedure: Time procedure started: 
Specimen: Time procedure finished: 
Collection holder: Time tissue retrieved: 
Cryopreservation  
Sample no: Dissection by: 
Time tissue recieved: Cryo by: 
Time freezing started: Total strips in storage: 
Initial total strips: % Strips for storage: 
Total vials in storage: DMSO: PROH: 
Storage place: DMSO: PROH: 
Colour of vials: DMSO: PROH: 
Date cryopreservation results report sent: 
Pre-Transplantation Details – Dr MH Botha 
Date treatment completed: 
Metastasis present?:  Yes  /  No  Date: 
Date: FSH  (IU/l ): LH  (IU/l ): E2  (pmol/l ): 
    
    
    
Any other illness during/after treatment? Specify: 
If yes, other prescription medication taken: 
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PATIENT & PROCEDURE INFORMATION FORM 
Project no:N05/10/182 
Note:1. To be completed for every patient recieving transplantation! 
2. Attach 2 copies of signed transplantation consent forms to this form! 
3. Place TBH patient stickers on every form and/or page! 
Thawing Details 
Date: Vials: Strips: Start:  End: Media: Reason: Done by: 
        
        
        
        
        
        
        
Histology 
Date sent: Tissue sent: Date results recieved: Done by: 
    
    
    
    
    
    
Transplantation Details – Dr MH Botha 
Date: Strips: Location: Anaesthetic: Start: End: 
      
      
      
      
      
      
Post-Transplantation Details – Dr MH Botha 
Date: FSH  (IU/l ): LH  (IU/l ): E2  (pmol/l ): Follicles? 
     
     
     
     
     
     
     
 
Medical Scientist: ______________________Name: ________________________ 
 
Medical Doctor: ________________________Name: ________________________ 
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CRYOPRESERVATION DETAILS 
Project no:N05/10/182 
Note:1. To be completed for every patient having ovarian tissue cryopreserved.  
2. Place TBH patient stickers on every form and/or page! 
Date: Sample no: 
Patient: DOB:    Age: 
Specimen: Est. time retrieved:  : 
Total strips counted: Time taken to dissect: 
Batches: 1  /   2 % Strips for storage: 
Batch 1:  n=   Time started: _____:______ 
 Control n=   BCode 
DMSO n= PROH n= 
DMSOeq n=  BCode PROHeq n= BCode 
DMSO freeze n= PROH freeze n= 
Vial no. Vial colour: Vial no. Vial colour: 
1. n= 
 
Bcode  
Tank 
1. n= 
 
Bcode  
Tank 
2. n= Tank 2. n= Tank 
3. n= Tank 3. n= Tank 
4. n= Tank 4. n= Tank 
5. n= Tank 5. n= Tank 
Batch 2:  n=   Time started: _____:______ 
 Control n=   BCode 
DMSO n= PROH n= 
DMSOeq n=  BCode PROHeq n= BCode 
DMSO freeze n= PROH freeze n= 
Vial no. Vial colour: Vial no. Vial colour: 
1. n= 
 
Bcode  
Tank 
1. n= 
 
Bcode  
Tank 
2. n= Tank 2. n= Tank 
3. n= Tank 3. n= Tank 
4. n= Tank 4. n= Tank 
5. n= Tank 5. n= Tank 
Please mark block with üwhen tissue thawed and/or sent for histology. 
Medical Scientist: ______________________Name: ________________________ 
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RESULTS REPORT OF FREEZING OF OVARIAN TISSUE 
Project no: N0/10/182 
Note: 1. To be completed for every patient entering the project! 
2. Attach 1 copy of consent forms to this form! 
 
 
Date: _____________________ 
 
 
Dear ________________________________________ 
 
Tygerberg Hosiptal number: ____________________ 
 
Your ovarian tissue were frozen and stored.  Yes / No 
 
 
If yes, please complete: 
 
Date of freezing:  
Ovarian tissue recieved for freezing:  
% Ovarian tissue kept in storage *:  
Vial colour identification:   
Storage place:   
   
   
Referring Dr.  
* Amount of ovarian tissue left in storage available for future treatment, for example transplantation, expressed as 
% of original tissue sample. 
 
If not, please explain: _____________________________________ 
_________________________________________________________
_________________________________________________________
___________________________________________________ 
 
Signed at _______________________ on ______ of _____________20___. 
 
Medical Scientist: _____________________ Name: __________________ 
Senior Medical Scientist: _______________ Name: __________________ 
Medical Doctor: _______________________ Name: __________________ 
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Chapter 5: Cryopreservation of ovarian tissue as a strategy 
to protect hormonal function and fertility against 
gonadotoxic treatment 
 
Abstract 
With modern treatment 70% or more of children will survive their cancer diagnosis. 
Many treatments have serious, harmful late effects including an effect on future 
fertility and hormone production.  Ovarian function plays a key role in the regulation 
of sexual development during puberty, the regulation of normal menstrual function 
and peripheral effects on bone and other tissues.  Ovulation is essential for normal 
reproduction.  Chemotherapy may be very toxic to ovaries. Radiotherapy, even in 
low doses of 10 to 15 Gray will deplete the number of primordial follicles and will 
cause premature ovarian failure. 
 
This review describes the indications, technique and outcome of grafting after 
cryopreservation of ovarian cortical tissue.  
 
A detailed description of 13 cases with grafting of cryopreserved ovarian tissue is 
included. This is the largest group reported to date. Pre-menopausal patients with 
locally advanced cervical squamous carcinoma had pre-radiotherapy laparoscopic 
oophorectomy. Ovarian dissection to remove the cortex was performed and the 
cortex then divided into small strips. Ovarian tissue cryopreservation was done with 
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a slow freezing protocol. After completion of chemo-radiotherapy, thawed tissue was 
introduced back into the patients. 
 
Return to hormone production took more than 6months after re-implantation of 
tissue. Levels of circulating gonadotrophins remained high despite estrogen 
production and follicle formation.  
 
Ovarian cryopreservation is a relatively simple technique to safeguard hormonal 
function (and in certain cases fertility) in children and young women with cancer who 
are at risk of ovarian failure due to treatment. 
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Introduction 
Normal ovarian function produces endocrine and exocrine effects.  Endocrine 
ovarian function plays a key role in regulation of sexual development during puberty, 
regulation of normal menstrual function, and peripheral effects on bone, breast, 
heart, brain and other tissues.  Exocrine function in the form of ovulation is essential 
for ovum production and normal reproduction.   
 
Many young girls and women survive the diagnosis of cancer due to modern 
treatment modalities.  Many of these treatment modalities have serious, harmful, 
late-effects including ovarian failure. [1]   Ovarian toxicity due to chemotherapy is 
related to the age of treatment and younger patients have better post-treatment 
ovulation figures. It may be beneficial to protect the ovaries during chemotherapy 
cycles with combined oestrogen and progesterone therapy.  [2]  
 
Radiotherapy, even in modest doses of 10-15Gy, will deplete primordial follicles 
which will impair ovarian function. In a group of 38 patients treated with radiotherapy 
up to a total dose of 30Gy, only one retained normal ovarian function. [3]  
 
Various options for ovarian sparing have been proposed of which transposition of the 
ovaries is one option.  Surgery is performed to transpose ovaries from their normal 
position in the pelvis to a site outside the field of pelvic radiotherapy.  This technique 
has had mixed success due to scatter radiation and vascular compromise. [4] [5]  [6] 
[7]  However, transposition does not offer any protection against the potential late 
effects of chemotherapy.  Alkylating agents, used in the management of 
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haematological malignancies in young girls, are particularly toxic to ovarian function. 
[8]  
 
There are a few reports on transplantation of fresh ovarian tissue or complete 
ovaries to a location outside the field of radiotherapy. Animal studies demonstrated 
the potential for vascular anastomoses of ovaries in locations distant from the 
original.  [9] Transplantation may be effective where extended fields of radiotherapy 
may make transposition on the original vascular supply impossible.  It will, however, 
not protect against toxic systemic chemotherapy. 
 
Where transposition or transplantation of fresh tissue will be of no benefit due to 
systemic chemotherapy an option may be to remove ovarian tissue for the period of 
therapy, preserve the tissue and to replace ovarian tissue when toxic treatment is 
finished. Cryopreservation of spermatozoa has long been successfully used when 
men were treated with toxic chemotherapeutic regimes.  The first live birth from 
cryopreserved ovarian tissue, which was re-implanted after sterilising cancer 
treatment, was recently reported from Belgium.  [10]  
 
The American Society of Reproductive Medicine practice committee categorised the 
use of ovarian tissue cryopreservation with transplantation at a later stage as an 
experimental technique. [11] It should only be performed after approval by a local 
ethics committee.  They suggested that it should always be performed under 
controlled conditions and be carefully monitored. 
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Who may benefit from ovarian tissue cryopreservation? 
 
The obvious candidates for ovarian cryopreservation are young girls with 
haematological cancer who need aggressive chemotherapy regimes.  When bone 
marrow transplants are considered, children often receive whole body irradiation with 
doses adequate to cause premature ovarian failure.  There are, however, many 
other forms of cancer where treatment directly affects ovarian function.   
 
Most reported cases of frozen-thawed ovarian tissue transplantation focus on 
protection of fertility in cases of cancer in young women. However, there may be 
other reasons as well for using stored ovarian tissue for transplantation. Ovarian 
dysgenesis and twins discordant for premature ovarian failure may be treated with 
donated heterologous transplantation after matching the patient and donor. [12] [13] 
[14] Another (as yet unpublished) indication may be to extend the fertile period in 
older healthy women. 
 
Despite the experimental nature of ovarian tissue cryopreservation, ovarian tissue 
harvesting and banking has been offered to many patients in clinical practice over 
the last two decades. [15] [16] [17] Although a number of reports have been 
published on ovarian tissue re-implantation there is very little information on the 
reproductive outcomes after successful transplantation. This may be due to the small 
number of patients, the various techniques used, the volume of ovarian tissue that is 
re-implanted and the limited availability of the technology. 
 
209 
 
Many different strategies have been reported using a variety of tissues sizes.  The 
use of cortical strips has been reported for fresh and frozen samples and whole 
ovary transplantation has been attempted to the ovarian fossa.  
 
Tissue transplantation to the original site or to a transplantation location near the 
original site is referred to as orthotopic transplantation.  Transplantation to an intra-
abdominal site has been achieved with either laparoscopy or laparotomy. Several 
authors described ovarian transplantation to the ovarian stump or the peri-ovarian 
region.  [10] 
 
Transplantation to sites distant from the original is referred to as it heterotopic.  Many 
alternative heterotopic sites have been tested for re-implantation including the arm, 
rectus abdominus muscle, the anterior abdominal wall, and the supra-pubic area. 
[18] 
 
Cervical carcinoma is the most common cancer of women in South Africa  [19] and 
patients often present with advanced disease where ovary sparing surgery is not an 
option. Standard therapy for advanced cervical carcinoma involves high doses of 
pelvic radiotherapy with concomitant chemotherapy as radio-sensitiser.  The doses 
of radiotherapy needed for tumour sterilisation are invariable high enough to cause 
rapid ovarian failure. [20]   There is an abrupt drop in oestrogen levels due to an 
absence of follicogenesis. Young patients with cervical carcinoma receiving radical 
radiotherapy will undergo immediate menopause with severe menopausal symptoms 
and potential long-term sequelae including osteoporosis and premature ageing.  A 
high proportion of these patients are cured and the survivors of cervical carcinoma 
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thus present a unique challenge for the preservation of endocrine ovarian function.  
The use of hormone replacement therapy has many difficulties particularly in a 
resource-poor environment.  Compliance is generally poor where access to health 
care is difficult. If a non-invasive procedure is available to preserve endocrine 
function it will improve not only quality of life but also the general health. There are 
reports in the literature where ovarian cryopreservation was used to preserve ovarian 
function in patients with advanced squamous cervical carcinoma. [18]  [21]  
 
When cancer therapy for malignancy is not toxic to the endometrial cavity and the 
uterus, pregnancy from cryopreserved ovarian tissue is possible. 
 
Ethical issues 
 
Harvesting and storage of human tissue and in particular gonadal tissue may present 
ethical problems. The technique of ovarian tissue cryopreservation must still be 
considered as experimental, but it may reduce anxiety about future fertility at a time 
when many other difficult decisions must be made. [22] Primum non nocere can be 
translated from Latin as "First, do no harm." Non-maleficence, which is the ethical 
principle that flows from this, is a fundamental principle in medical ethics. The risk of 
the operation to obtain ovarian tissue and the potential risk to re-introduce cancer 
cells at transplantation of frozen-thawed tissue should be carefully considered. 
Cancer is by definition a local and systemic disease.  At a certain point during the 
disease process, a tumour may become metastatic and involve organs distant from 
the primary tumour.  Microscopic metastases are difficult to diagnose with routine 
imaging and even careful microscopic examination of tissue may not identify 
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individual cells or small groups of cells.  It is therefore very important to consider the 
risk for metastatic disease to the ovary very carefully before removal and storage of 
such ovarian tissue for future re-implantation.   
 
The histological examination of fresh and thawed ovarian tissue has been described 
and it should be part of routine practice to evaluate harvested tissue for the presence 
of microscopic metastases. [18] [23]   If there is any doubt about possible re-
introduction of carcinoma, it remains prudent not to store the tissue in the first 
instance. The risk for ovarian metastases from haematological malignancies in 
children is usually very low with the exception of leukaemia. [23]  
The risk for ovarian metastases from squamous cell carcinoma of the cervix is also 
very low. [24] [25] No reports have been published at present where cancer cells 
have been re-introduced through preservation of ovarian tissue. 
 
Consent 
 
Patient autonomy at the time of taking consent should be a high priority. Care should 
be taken when the procedure is offered that coercion is avoided. Family members 
may pressurise a young women to “preserve the family line”. Due to the paucity of 
good quality information about nearly all aspects of ovarian cryopreservation, it is 
nearly impossible to give well-informed, structured and evidence-based counselling 
to a potential patient before undergoing ovarian cryopreservation. [26]  It is important 
to underline the experimental nature of the procedure without giving patients and 
their parents false hope about future fertility.  
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Dudzinski (2004) states that: “Clinically and ethically, cancer treatment takes priority 
over potential restoration of fertility, as the latter has no value to the woman who has 
died of cancer”. [22]  Despite this small risk, techniques of ovarian cryopreservation 
and thawing are rapidly developing and may provide the only option for a patient to 
retain some hope of future fertility.  
 
In the counselling of minors, extra care should be taken. The Royal College of 
Obstetricians and Gynaecologists working party report on ovarian tissue storage 
suggested assessment of Gillick competence. [26] Gillick competence is a British 
legal term which refers to the ability of a child younger than 18 years of age to give 
consent for medical procedures. In clinical practise the child should be involved with 
the decision making and be fully informed about the expected benefits and potential 
problems. 
 
Thawing and use of the cryopreserved tissue should be discussed at initial taking of 
consent.  The further storage or destruction of the tissue, in case of death of the 
tissue donor, should also be discussed carefully. 
 
When information is given about the expected benefit of ovarian tissue 
cryopreservation it is important to remember another principle of medical ethics 
namely “making clinical decisions that are best for the patient” (Beneficence). The 
information about success rates and pregnancy outcomes is at present still limited 
and the procedure should be regarded as experimental. 
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Removal of ovarian tissue 
 
Removal of ovarian tissue should preferably be done with the least invasive available 
technique.  In certain cases a patient may require general anaesthetic for an 
examination as part of cancer staging. Laparoscopic oophorectomy or multiple 
ovarian biopsies may be scheduled at the same time to reduce the risks involved in 
repeated general anaesthesia.  If there is doubt whether the cancer treatment will 
cause ovarian failure, only one ovary should be removed and the other left in-situ.  
Harvesting of gonadal tissue must be done within the required guidelines as 
stipulated in the National Health Act of South Africa. 
 
Re-implantation 
 
Re-implantation of ovarian tissue may be immediate after completion of treatment if 
the aim is to restore endocrine function only. If the aim is to restore fertility, it is 
preferable to wait for a disease free period of around two years since most 
malignancies reoccur during the fist 24 months after completion of treatment. This 
will only be feasible in hormone insensitive tumours and where further systemic 
chemotherapy will not harm the re-implanted tissue. As soon as the risk of ovarian 
toxicity due to therapy has passed, tissue strips can be replaced in orthotopic or 
heterotopic positions.  Many heterotopic sites have been proposed including the 
neck, femoral triangle, forearm, breast and abdominal wall. [9]  If the ovarian tissue 
is replaced with the aim of restoring fertility, it may be best to allow a disease-free 
period of at least two years before attempts at pregnancy are made.   
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Literature review on ovarian function after re-implantation of 
previously cryopreserved ovarian tissue 
 
Author and year Number of 
cases 
Measure of function 
Oktay 2000 [27] [28] 1 Hormone production 
Radford 2001 [29] 1 Hormone production 
Callejo 2001 [30] 1 Hormone production 
Oktay 2004 [31] 1 Embryo development after ART 
Donnez 2004 [10] 1 Live birth (orthotopic transplant) 
Kim 2004 [18] 1 Hormone production 
Wolner-Hanssen 2005 [32] 1 Hormone production 
Meirow 2005 [33] [34] 1 Live birth 
Tryde Schmidt 2004 [35] 3 Oocyte retrieval 
Donnez 2006 [36] 1 Hormone production 
Oktay 2006 [37] 1 Live birth (heterotopic transplant) 
Demeestre 2006 [38] [39] 1 Pregnancy (miscarriage + live birth) 
Rosendahl 2006 [40] 1 Pregnancy (biochemical) 
Andersen 2008 [41] 6 Hormone production in 6 
4 Pregnancies after ART, 2 live births 
Silber 2008 [42] 1 pregnancy 
Dittrich 2008 and 2009  [43] [44] 1 Hormone production 
Sánchez 2008 [45] 4 Hormone production in 2 patients 
Donnez 2008  (including patients 
form earlier reports) [46] 
5 Hormone production in all 5 
Live birth in 1 (see 2006 and 2004) 
Kim 2009 (including patients form 
earlier reports) [47] 
4 Hormone production in 4 
Follicle aspiration in 2 
Sánchez-Serrano 2009 [48] 1 Live birth  twins after oocyte vitrification as well) 
 
Table 23 Summary of reported cases of outcome after transplantation 
cryopreserved ovarian tissue 
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Table 23 shows a summary of the reported cases of re-implantation of 
cryopreserved ovarian tissue.  This summary excludes all transplantations of fresh 
ovarian tissue and shows how the authors evaluated function of the transplants. 
 
The first report on transplantation of previously cryopreserved ovarian tissue was 
announced in a letter to the editor of the New England Journal of Medicine in June 
2000. [27] A 29-year old woman was reported who had a right salpingo-
oophorectomy at the age of 17 with a wedge resection of the ovary for a diagnosis of 
benign cystic teratomas.  She later had the remaining ovary removed because of 
severe menometrorrhagia.  Eighty pieces of tissue were sutured onto a cellulose 
membrane and returned to the peritoneal cavity by laparoscopy.  She had 
stimulation protocol with menopausal gonadotrophins that was started 15 weeks 
after transplantation that led to hormone production. 
 
The procedure of re-implantation was further described in a general article published 
in June 2001. [28] From this description it is unclear why high doses of human 
menopausal gonadotrophin (HMG) were necessary to stimulate the grafts.  The 
authors stated that the patient had “hypothalamic amenorrhoea”. 
 
Radford followed in April 2001 with the first case report of a patient receiving the 
implantation after cancer therapy. [29]  This 36-year old patient had a single ovary 
removed before chemotherapy and 19 months after treatment, when the hormone 
profile confirmed premature ovarian failure; two strips of cortical tissue were re-
implanted.  The authors describe that the cortex was dissected into 1x0.5cm strips 
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and that seven strips could be harvested from one ovary.  She started producing 
oestrogen about seven months after re-implantation with ultrasonic confirmation of 
the follicular development. 
 
A report from Spain included one patient where ovarian tissue was cryopreserved 
before re-implantation. [30] The patient volunteered for the transplantation and had a 
bilateral salpingo-oophorectomy together with hysterectomy done for uterine 
leiomyomata.  She was 47 years of age and had the ovarian tissue re-implanted in 
the rectus abdominus muscle.  The authors describe the process of “mincing of 1 
cubic cm of ovarian cortical tissue into 40 to 45 fragments” which were then placed 
into a muscle pocket in the rectus abdominus. This patient produced oestrogen after 
“three to four months” and had an ovarian follicle of 16mm in diameter demonstrated 
by ultrasound. 
 
The first report of fertilization of an oocyte aspirated from previously cryopreserved 
tissue was published in the Lancet in March 2004.  [31] The patient was a 30-year 
old with premature ovarian failure of her remaining ovary after high-dose 
chemotherapy for a stage IIb breast cancer.  She also had bone marrow 
transplantation but the reason for this was not explained in the paper.  All the 
available cortical strips (15 in total) were implanted into the patient’s anterior 
abdominal wall.  In total she had eight separate oocyte retrievals producing a total of 
20 oocytes of which eight were acceptable for IVF.  Two embryos resulted from this 
of which one had abnormal morphology.  The last remaining embryo was transferred 
to the patient’s uterus but failed to progress to a pregnancy. 
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The first successful live birth was described in 2004. [10]  At that stage the reporting 
team from Belgium already had 146 patients who had ovarian cryopreservation 
before the onset of chemotherapy of which only two had re-implantation.  The 
pregnancy resulted after ovarian cortical biopsies were taken in a 25-year old woman 
before she received treatment for Hodgkin’s lymphoma.  The patient also had 38 
Gray of radiotherapy but it is not clear from the report which part of the body was 
irradiated.  Biochemical menopause followed treatment for cancer.  Re-implantation 
was done during a series of three laparoscopy procedures and at the third procedure 
all remaining tissue was re-implanted.  Approximately six months after the second 
implant the patient had a rise in Beta HCG levels.  The pregnancy was achieved 
without any ovarian stimulation but the pregnancy was supported with 600mg 
progesterone vaginally daily.  A healthy girl with good Apgar score was born. 
 
A report from South Korea in 2004 showed hormone production 14 weeks after 
transplantation in a patient with cervical cancer stage Ib. [18]  It is not clear from the 
report why both ovaries were removed at the time of radical hysterectomy before the 
final decision about radiotherapy was made.  Nonetheless the patient received 
radiotherapy as well and after exclusion of ovarian metastases, 40 strips were 
transplanted into a space below the breast between the breast tissue and the 
pectoralis muscle.  A second group of tissue strips was transplanted in the anterior 
abdominal wall.  By 14 weeks the first increase in serum oestrogen was detected 
and ultrasound confirmed a follicle of 16x11mm in the abdominal transplant site. 
 
A case report from Sweden described re-implantation of cryopreserved tissue after 
stem cell transplantation and chemotherapy as treatment for red cell aplasia.  [32] 
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Here a site 8cm distal to the anti-cubital fossa in the forearm was used for 
transplantation.  Follicle formation was confirmed with ultrasound up to a maximum 
diameter of 12.6mm.  
 
A successful pregnancy was also described in a letter to the editor of the New 
England Journal in a patient who had been treated for non-Hodgkin’s lymphoma by 
first and second line chemotherapy before ovarian tissue was removed for cyro-
preservation. [33] This was followed by high-dose chemotherapy which led to 
premature ovarian failure.  After re-implantation of the ovarian tissue into the 
remaining ovary, oocyte aspiration was performed with in vitro fertilization.  A normal 
healthy girl was born after a single embryo was transferred.  The authors state that 
“we cannot rule out the possibility that the egg was derived from the native ovary, we 
consider this possibility very unlikely”.   
 
A single metaphase II oocyte was retrieved after a stimulation protocol after 
transplantation of the frozen thawed tissue in a 32-year old patient with Hodgkin’s 
lymphoma.  Fertilization did not occur after intra cytoplasmic sperm injection (ICSI) 
but follicular activity remained. [35]  
 
An interesting case report describes a live birth after “heterotopic ovarian tissue 
transplantation”. [37] This 52-year old patient was treated for Hodgkin’s lymphoma 
four years before which did not cause ovarian failure.  She developed a relapse and 
was offered heterotopic stem cell transplantation.  Before she started chemotherapy 
in preparation for the stem cell transplantation the left ovary was removed 
laparoscopically.  After completion of treatment she did not menstruate for two-and-
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a-half years and the hormone levels were in the menopausal range.  However, 
shortly after heterotopic transplantation of frozen thawed tissue (two months after the 
transplant) her hormone levels indicated ovulation.  At that time the patient already 
had a six week intra-uterine pregnancy with an absent foetal heart.  The pregnancy 
was evacuated.  She was pregnant very shortly after this pregnancy and delivered a 
healthy female child.  The authors note that the most likely explanation is recovery of 
normal ovarian function in the ovary that was left behind; however, another 
explanation may be a new production of primordial follicles through a possible re-
activation of germ cells is also a theoretical possibility. 
 
A case report from Brussels describes the transplantation of cryopreserved ovarian 
tissue in a patient after treatment for stage IV Hodgkin’s disease. [39] What is 
interesting is that this patient had combined heterotopic and orthotopic             
transplantation.  The ovarian transplant was done according to the initial description 
of Donnez. [36]  Some tissue was re-implanted in the atrophic remaining ovary and 
the rest was implanted in a peritoneal window near the ovary.  The remaining tissue 
was implanted in the abdominal wall just below the trocar port incision.  The ovarian 
site produced the largest follicles and this lead the authors to suggest that “the local 
environment and/or the vascularisation in the ovary could favour the restoration of 
ovarian function from transplanted cortical ovarian tissue”.  This patient had a 
spontaneous pregnancy which unfortunately was followed by a miscarriage. 
 
A further report on the patient initially described by Demeestre describes a second 
orthotopic and heterotopic transplantation about one year after the first 
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transplantation. [38]  This second transplantation was followed by the spontaneous 
pregnancy during the fifth menstrual cycle.  A healthy girl was delivered. 
 
A case report from Denmark described re-implantation of frozen thawed tissue in a 
patient after treatment for stage IIb Hodgkin’s disease. [40] Tissue was re-implanted 
in three sites namely the atrophic ovary, the right pelvic side wall and in the anterior 
abdominal wall.  A metaphase II oocyte was aspirated at the third attempt from the 
ovary and ICSI resulted in an embryo.  A serum ß-HCG confirmed a chemical 
pregnancy, however, this pregnancy failed to progress.  Another oocyte was 
aspirated from the abdominal wall and was successfully fertilized with ICSI.  Transfer 
of the embryo did not result in a pregnancy.  The authors of this case report are 
sceptical about the origin of the oocytes that resulted in the live birth reported by 
Donnez and Meirow.  “However in both cases the origin of the fertilized oocytes can 
be questioned.  Although unlikely, it cannot be ruled out that the fertilized oocytes 
originated from the remaining ovarian tissue rather that in the thawed ovarian 
transplants”. 
 
A combined report from three centres in Denmark reports on six women after re-
implantation of frozen thawed ovarian tissue. [41] Out of the six cases all had 
orthotopic transplantation of between 20 and 100% of the stored tissue.  Of the six 
two women delivered one healthy child each and a third had an early miscarriage at 
seven weeks gestation.  The fourth patient had a biochemical pregnancy.  Two 
patients did not become pregnant.  All the patients had assisted reproduction and the 
two live births followed after transfer of embryos. 
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A paper by Silber describes a series of monozygotic twins treated with ovarian tissue 
transplantation from one sister to the other when the first has become menopausal. 
[42]  This was done to treat premature ovarian failure and a total of eight such pairs 
of twins where transplantation had taken place were described.  In one pair of twins 
fresh tissue was originally transplanted with normal ovarian function for 36 months 
after the transplant.  The patient then experienced menopausal symptoms and 
stored frozen-thawed tissue was then transplanted.  This tissue originated from the 
patient’s sister.  She conceived five months later but there is no detail about the 
outcome of the pregnancy in the paper.  
 
In 2009 an interesting histological evaluation of transplanted tissue was published 
from Germany. [44]   A patient treated for anal carcinoma had pre-treatment ovarian 
tissue cryopreservation. [43]  Re-implantation was performed two-and-a-half years 
after remission into peritoneal pockets near the ovary.  At approximately four months 
oestrogen levels started to rise but the grafts stopped functioning at around 11 
months.  A second laparoscopy was performed to re-implant more tissue but at the 
same time some of the old tissue strips were removed and examined histologically.  
It was found that despite the drop in hormone production primordial follicles were still 
present in some of the tissue. 
 
Of the 200 women who received ovarian cryopreservation in the Vallencia 
programme for fertility preservation only four had re-implantation of tissue. [45] 
Although this follow-up is very short two out of the four had hormonal evidence of 
ovarian function. 
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A recent publication by Donnez outlines three further cases not previously reported 
in the literature.  The indications for cryopreservation were advanced Hodgkin’s 
lymphoma, advanced non-Hodgkin’s lymphoma and Wegener’s                
granulomatosis.  [46] Two patients had a laparotomy and one had a laparoscopy for 
orthotopic transplantation.  In all three patients GnRh antagonist was started in 
combination with oestrogen and progesterone for a period of 8 weeks before 
transplantation.  This was done in order to reduce circulating FSH and LH 
concentrations.  High FSH and LH concentrations may induce significant activation 
of follicles soon after ovarian tissue being transplanted. [49] The authors do not 
mention the details of two other cases of transplantation that did not result in 
hormone production. 
 
A case report describes the twin pregnancy of a patient previously treated for breast 
cancer. [48] She had a laparoscopic right ovarian cortex extraction after which she 
completed 6 cycles of chemotherapy and 25 fractions of radiotherapy.  
Approximately two years after completion of treatment, ovarian tissue was 
transplanted onto the remaining left medulla.  After initial poor response to ovarian 
stimulation a total of 14 oocytes were retrieved during three cycles.  Nine of the 
fourteen oocytes were vitrified and all 14, including the 9 vitrified oocytes, were 
fertilized by ICSI.  Eventually only two embryos, both resulting from the vitrified 
oocytes, were transplanted. It led to the birth of two boys delivered by caesarean 
section at approximately 33 weeks gestation.  This is the first report of cryopreserved 
tissue that was stimulated and the aspirated oocytes re-frozen through a process of 
vitrification that led to a successful pregnancy. 
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A systematic review of the transplantation of ovarian tissue was published at the end 
of 2008. [50] Included in the review were 25 reports about ovarian transplantation 
with the primary aim to describe the return to ovarian function, including the 
maintenance of ovarian function  in the short-  and long-term after transplantation. 
Fresh and previously cryopreserved tissue was included in the study. Details about 
46 patients could be included and the median age of the patients were 36 (range 15 
to 49). Out of the total of 46 patients, 3 had one or more fresh, whole ovary 
transplanted with or without anastomoses of the small blood vessels. [51] [52] [12] 
Two of these cases had transplantation with own ovaries to the upper limb outside 
the field of pelvic radiation for Hodgkin’s lymphoma, and another case for cervical 
cancer.  Ovarian function was confirmed after transplantation. 
 
Ovarian transplantation was reported in 23 patients who were confirmed to be in 
ovarian failure before transplantation; FSH levels >30 IU/l. [50]  Confirmation of 
return to ovarian function was by using follicular growth and return to menstruation in 
19 cases and by detection of follicles in the remaining four cases (these four cases 
all had hysterectomy previously).  The median time to return of ovarian function was 
120 days with range from 60 to 244. The median follow up after returning to ovarian 
function was only 210 days and during this period, 4 out of the 23 women again 
developed ovarian failure, with reduced oestrogen production. All those individuals 
with ovarian failure were older, with a median age of 37.5 years compared to 33 
years for those who did not have recurrent ovarian failure.  All four women who had 
the recurrent ovarian failure had transplants of small cortical strips. 
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In an effort to describe the pregnancy rate after ovarian tissue transplant the authors 
of the review looked at 25 women with intact uteri and found a total of 11 
pregnancies in nine women. Two of these pregnancies were subsequently excluded 
from the final analysis because the transplanted tissue was in the anterior abdominal 
wall outside the peritoneal cavity in the presence of another ovary in a normal 
anatomical position. Six pregnancies in five women were achieved spontaneously, 
and the remaining three pregnancies were achieved through IVF. 
 
In the discussion of the results from this review article, the authors states that 
“ovarian tissue transplantation, using cryopreserved tissue is not yet equivalent to 
that of a fresh grafts”. The authors also conclude that “transplantation of ovarian 
tissue can re-establish ovarian function after premature ovarian failure.  However, 
evidence is not sufficient to evaluate the long-term efficacy and longevity of ovarian 
grafts.” [50] 
 
From this review it is clear that various factors will influence the success of re-
establishment of ovarian function, longevity of the grafts and the hormone levels 
achieved. Older women, using previously frozen tissue and transplanting only a 
portion of the tissue may all negatively influence the eventual outcome. 
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Clinical study: Ovarian tissue transplantation after 
cryopreservation  
Aim 
 
This descriptive study is a combined experimental (cryopreservation of ovarian 
tissue) and clinical (transplantation of frozen-thawed ovarian tissue) study. Ovarian 
tissue was obtained for cryopreservation from pre-menopausal patients with 
advanced cervical cancer. The standard therapy for these patients was radical 
chemo-radiation. In the experimental part of the study tissue samples were 
randomised into two groups and preserved according to different cryopreservation 
protocols. This part of the study is described in more detail in Chapter 4.  
 
The clinical part of the study evaluated preservation of endocrine function after 
transplantation of frozen-thawed ovarian tissue.  After radiotherapy, frozen-thawed 
ovarian tissue was transplanted back into patients to evaluate preservation of 
endocrine function.  
 
Ethics approval 
This study was approved by the local institutional review board of the Faculty of 
Health Sciences, Stellenbosch University. Project number: N05/10/182 
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Materials and methods 
Patients 
· A sample of convenience was taken from a group of patients who 
received their consultations, surgery and therapy for advanced 
squamous cervical carcinoma at the unit for gynaecological oncology, 
Tygerberg Hospital.  
· Patients  with advanced squamous cervical carcinoma planned for 
curative chemo-radiotherapy  
· The patients were entered into the study on basis of voluntary 
informed consent  
· Patients younger than 45 years of age with normal FSH and E2 levels 
· HIV non-infected 
Procedures 
· Laparoscopic oophorectomy during examination under anaesthesia for 
cancer staging 
· Preparation of cortical strips under sterile conditions.  
· Histological evaluation of tissue strips for evaluation of metastatic 
disease 
· Cryopreservation of ovarian tissue 
· Thawing 
· Histology of thawed ovarian tissue for evaluation of follicle survival. 
· Re-implantation  
· Follow-up of hormonal function. 
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Detailed methodology 
 
Tissue was removed with laparoscopic oophorectomy in all cases. The patient was 
put in the supine position and catheterised preoperatively.  An examination under 
anaesthesia was performed as part of the tumour staging.  A sub-umbilical incision 
was made through the skin and a Verres needle was passed.  The peritoneal cavity 
was inflated with 2 ½ litres of CO2, after which a 10 mm trocar was inserted.  Two 
additional 5 mm ports were inserted; one near Palmer’s point and the other 
approximately 5 cm away infero-laterally. A third, 5 mm trocar was placed in the right 
iliac fossa.  This configuration of ports gave the ideal approach to both ovaries.  The 
individual ovaries were elevated out of the pelvis with a grasper and the vascular 
pedicle was cauterised carefully and then cut. After complete removal of the first 
ovary it was placed in the vesico-uterine pouch.   
 
The second ovary was then elevated in a similar fashion and removed after careful 
cauterisation of the vascular pedicle.  The second ovary was then also placed in the 
vesico-uterine pouch.  Up to this point the 10mm primary trocar at the infra-umbilical 
site have been the port for a 10mm 30º laparoscope which was now removed and a 
5mm 30º laparoscope was placed through the Palmer’s point 5mm trocar.  An 
endobag was passed through the 10mm port and the two dissected ovaries were 
placed within the endobag and subsequently removed from the abdomen.  In case of 
larger sized ovaries it was necessary to increase the size of the incision in the 
sheath to accommodate the size of the ovaries.  After removal of the ovaries it was 
kept in the sterile endobag and transported to the laboratory where the dissection 
was performed in a laminar flow cabinet in a completely sterile fashion to prevent 
contamination.  
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Figure 21 Dissection of tissue in laminar flow cabinet 
 
 
 
Figure 22 Dissection of ovarian cortex from underlying stroma 
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The dissection of the ovarian strips was performed by first bisecting the ovary and 
removing most of the cortex. See Figure 22. The cortex was divided into 2mmx5mm 
strips. See Figure 23. 
 
  
 
 
 
 
Figure 23 Ovarian strips after dissection 
 
The remaining tissue of the ovary which was mostly the stroma of the ovary was sent 
for normal light microscopy.  Tissue strips were then divided into separate containers 
and prepared for cryopreservation.  See Figure 24. 
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Figure 24 Cortical strips in cryovials 
 
Re-implantation (grafting) 
When the tissue was needed for re-implantation it was thawed to room temperature.  
 
 
Figure 25 Tissue strips inserted under skin of upper arm 
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In the current study the contents of two cryo vials were used for every single 
transplant.  This represented between 10 and 20 strips per transplant.  At present 
there is no clear indication in the literature about the optimal amount of tissue that is 
necessary for oestrogen production and/or follicle formation.  The volume of tissue 
used in our study was also partly determined by the re-implantation site in the arm 
because the volume of tissue would have been too much if all the tissue was re-
implanted at the same time. 
 
The anterior aspect of the upper arm was used for re-implantation. See Figure 25. 
The implantation was scheduled to coincide with the insertion of brachytherapy 
(under general anaesthesia). Otherwise the re-implantation was done under local 
anaesthesia after the completion of systemic treatment that may harm the 
transplanted tissue. A small incision of less than a centimetre was made and the 
tissue strips placed in a subcutaneous tunnel. The skin was closed with an 
absorbable suture. See Figure 25. 
 
Figure 26 Blood taken at transplantation for hormone profile 
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Results 
 
In the current study all the participants had advanced cervical cancer, which 
necessitated whole pelvic irradiation with subsequent total ovarian failure.  All the 
patients also required systemic chemotherapy as part of treatment, and therefore the 
only option was to do cryopreservation of tissue until after completion of the 
treatment.  Both ovaries were removed in all but one of the described cases and all 
the patients in this series had confirmed ovarian function before removal of ovarian 
tissue and had confirmed ovarian failure at the time of the re-implantation. All the 
patients had no evidence of metastatic tumour on light microscopy in ovarian tissue 
of the remaining stromal tissue. 
 
The local laboratory defined oestrogen levels below 37pmol/l as non-detectable.  In 
the hormone graphs all the values reported as <37 pmol/l was changed to 5 pmol/l to 
make the graphs easier to read. 
 
All patients who had tissue transplantation between June 2006 and June 2008 are 
included in the report. A total of 17 patients were available for transplantation during 
this period. 3 patients declined transplantation after counselling and one patient that 
received transplantation had no follow-up at all. She was from a small village outside 
Oudtshoorn and could not be traced. The other 13 patients are described in more 
detail below. 
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Figure 27 Scar of implantation site one month after the procedure 
 
Individual patient details 
Patient 1 
 
Patient number 1 was a 33-year old G5 P3 with one previous miscarriage and one 
previous termination of pregnancy that presented with a bulky stage IIb cervical 
cancer.  For this she was offered whole pelvic irradiation with concomitant 
chemosensitization and brachytherapy to the cervix.  She had a laparoscopic 
oophorectomy without complications and both ovaries were removed.  In total 102 
strips were available after dissection of the cortical tissue.  Ninety of the strips were 
available for cryopreservation after the necessary samples were prepared for 
histology and electron microscopy studies. 
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Figure 28 Visible swelling in upper arm due to follicle formation 
 
Before oophorectomy the oestrogen level was 370 pmol/l, FSH 4.2 IU/l and the LH 
4.0 IU/l.  At insertion of the brachytherapy under general anaesthesia after 
chemotherapy was completed, 11 strips were re-inserted in the right upper arm 
about 2cm above the cubital fossa.  The strips were randomly selected from the 
DMSO group.   
 
This patient was HIV negative at inclusion to the study and at the start of 
radiotherapy.  When pelvic progression was confirmed at around 11 months after 
completion of radiotherapy, a follow-up HIV test was positive.  The patient was 
started on highly active retroviral therapy with a good initial virological response.   
 
The first sign of oestrogen production was noted eight months after transplantation 
with a peak level at month 11 of 126 pmol/l. See Figure 28 and Table 24. 
Unfortunately the patient died 25 months after re-implantation due to renal failure 
caused by ureteric obstruction secondary to progressive pelvic disease.   
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Table 24 Summary of hormone profile patient 1 
Patient 2 
 
Patient number 2 was a 36-year old G4 P3 M1 who presented with a locally 
advanced stage IIIb cervical cancer for which she was offered whole pelvic 
irradiation and concomitant chemosensitization and cervical brachytherapy.  She had 
a pre-treatment laparoscopic oophorectomy and both ovaries were removed.  
Surgery was uncomplicated.   
 
A total of 116 strips were available after dissection of the ovarian cortex.  One 
hundred and eight of these strips were cryopreserved after tissue for histology and 
electron microscopy was removed. 
 
-2 0 1 2 4 8 11 12 13 14 17 19
E2 (pmol/l) 370.0 93.0 5.0 5.0 5.0 59.0 126.0 5.0 5.0 5.0 5.0 5.0
FSH (IU/l) 4.2 38.7 38.6 37.6 38.5 7.8 27.4 9.5 1.2 0.0 24.7 32.9
LH (IU/l) 4.0 26.0 30.1 17.9 27.7 30.5 1.7 0.3 54.6 2.9 42.8
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Re-implantation was done at insertion of brachytherapy after chemotherapy has 
been completed.  A total of 12 strips were re-inserted in the right upper arm.  These 
strips were from the PROH group.  
 
Preoperative measurements were E2 198.8 pmol/l, FSH 6.2 IU/l and LH 8.2 IU/l.  
Despite relatively high and rising levels of gonadotrophins she had evidence of 
follicle formation at month 10 with an oestrogen level of 300 pmol/l.  There was 
another rise in E2 at month 12. See Table 25. The high FSH and LH levels could 
possible be due to the patient’s age and also due to the small number of strips re-
inserted (only 12). 
 
 
 
Table 25 Summary of hormone profile patient 2 
 
  
-2 0 3 9 10 11 12 14 16
E2 (pmol/l) 5.5 5.0 5.0 5.0 300.0 5.0 39.0 5.0 5.0
FSH (IU/l) 6.2 54.0 67.7 75.9 69.6 81.4 71.7 89.8 92.3
LH (IU/l) 0.0 47.8 30.8 37.6 47.8 51.1 43.3 46.1 52.2
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Patient 3 
 
Patient number 3 was a 27-year old G2 P2 that presented with stage IIb squamous 
carcinoma of the cervix with parametrial invasion on the left.  For this she had neo-
adjuvant chemotherapy and a radical hysterectomy.  Histology confirmed a poorly 
differentiated tumour with a positive surgical margin.  She continued to have 
complete whole pelvic irradiation as well.  She had a laparoscopic oophorectomy 
before the start of the radiotherapy and both ovaries were removed without any 
difficulty.  
 
A total of 129 strips have been removed of which 122 were cryopreserved after 
histology and electron microscopy were performed. 
 
Re-implantation was performed at commencement of brachytherapy in the left upper 
arm.  A total of 14 strips were re-implanted. Pre-operative oestrogen level was less 
than 37pmol/l but FSH was 5.8 IU/l and the LH 3.1 IU/l.  She had evidence of 
oestrogen production at month eight with a sudden decrease in the FSH and LH 
levels from month five after the re-implantation after an initial rise to 87 (FSH) and 84 
(LH) respectively.  However, from month eight the FSH and LH started to rise again 
and continued to rise until her death due to locally advanced tumour month 18 after 
the re-implantation. See Table 26. 
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Table 26 Summary of hormone profile patient 3 
Patient 4 
 
Patient number 4 was a 38-year old G4 P4 who presented with stage IIIb cervical 
cancer.  For this she had radical radiotherapy with chemosensitization.   
 
This patient had bilateral oophorectomy but only 54 strips were available after 
dissection due to small volume ovaries.  Only 36 strips were available for 
cryopreservation after some of the strips were deemed inadequate because of a 
large corpus luteum distorting the anatomy. 
 
Pre-operative E2 was 346 pmol/l, FSH was 3.2 IU/l and LH was 2.8 IU/l.  Re-
implantation was performed at the end of radiotherapy with insertion of the 
brachytherapy and 10 strips were inserted in the upper arm.  These strips were from 
the PROH group. 
-2 0 1 2 3 5 6 8 11 14
E2 ((pmol/l) 5.0 5.0 5.0 5.0 5.0 5.0 5.0 190.0 50.0 5.0
FSH (IU/l) 5.8 33.9 54.7 59.6 87.0 28.9 1.1 62.4 58.9 72.0
LH (IU/l) 3.1 21.6 42.0 73.7 84.8 5.0 0.1 18.3 55.4 77.0
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 Despite very high levels of FSH and LH she started producing oestrogen from 
month 11.  The levels peaked at month 12 around 165 pmol/l.  The FSH and LH 
stayed over 150 IU/l after removal of the ovaries. See Table 27. This is perhaps due 
to the patient’s age and the low number of strips re-implanted. 
 
Table 27 Summary of hormone profile patient 4 
Patient 5 
 
Patient number 5 was a 41-year old gravida 6 para 6 that presented with stage IIIb 
squamous carcinoma of the cervix.  Pre-treatment E2 was 94 pmol/l and the FSH 
was 4.4 IU/l and the LH 7.8 IU/l.  She had a laparoscopic oophorectomy of both 
ovaries without any complications. 
 
This patient had a total of 75 strips after dissection of which 68 were available for 
cryopreservation.  A 50-minute delay in one batch of the tissue was due to a 
-1 0 1 4 6 11 12 14 19
E2 (pmol/l) 346.0 5.0 5.0 34.0 5.0 51.0 165.0 62 89.0
FSH (IU/l) 3.2 200.0 150.0 150.0 150.0 284.0 172.6 182.7 173.4
LH (IU/l) 2.8 173.4 207.4 156.2 250.0 148.0 190.0 189.0 142.7
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software problem after a USB mouse was inserted into the computer. This caused in 
the software programme to stop responding. 
 
Re-insertion was done and at insertion of the brachytherapy and a total of 12 strips 
preserved in PROH was done on the left arm.  These strips were not from the batch 
with the delay in the cryotherapy protocol. 
 
 She had high levels of FSH of around 100 which steadily declined over the following 
months.  The first production of oestrogen was detected at month 8 and continued 
past month 25.  See Table 28. 
 
 
Table 28 Summary of hormone profile patient 5 
 
  
-1 0 2 4 7 8 11 13 17 25
E2 (pmol/l) 94.0 5.0 19.0 5.0 5.0 168.0 97.0 219.0 5.0 109.6
FSH (IU/l) 4.4 67.0 97.5 104.6 99.0 73.9 66.1 66.1 73.0 57.5
LH (IU/l) 7.8 71.1 67.7 101.0 109.0 88.0 81.7 84.0 68.5 44.2
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Patient 6 
 
Patient number 6 was a 40-year old G2 P2 that presented with a stage IIIb 
squamous carcinoma of the cervix.  She was offered radical radiotherapy with 
chemosensitization and had a pre-treatment oestrogen level of 49 pmol/l, FSH of 3.6 
IU/l and a LH of 0.1 IU/l.  
 
A total of 100 strips were available for cryopreservation.  Re-implantation was done 
in the right upper arm under general anaesthesia with insertion of the brachytherapy.  
A total of 15 strips preserved in PROH were re-inserted. 
 
 At month four there was already a peak in oestrogen with level of 132 pmol/l.  The 
FSH and LH also decreased to levels below 50.  She continues to produce 
oestrogen for at least the first 21 months after re-implantation. See Table 29. 
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Table 29 Summary of hormone profile patient 6 
 
Patient 7 
 
Patient number 7 was a 37-year old G3 P3 who presented to us with a squamous 
cell carcinoma of the cervix stage IIIb.  She had a laparoscopic oophorectomy 
without any difficulties and her pre-operative oestrogen level was < 37 pmol/l, FSH 
was 5.2 IU/l and the LH 3.3 IU/l.   
 
A total of 72 strips were available after dissection of which 68 were available for 
cryopreservation.  She had an implant under local anaesthesia 6 weeks after 
completion of radiotherapy and chemotherapy.  A total of 13 strips cryopreserved in 
DMSO were re-inserted.   
-2 0 1 4 8 10 13 18 21
E2 (pmol/l) 49.0 45.0 5.0 132.0 5.0 96.0 109.0 83.1 63
FSH (IU/l) 3.6 54.5 44.2 50.3 21.2 34.6 46.7 41.9 50
LH (IU/l) 0.1 49.3 62.6 48.4 15.6 45.0 52.0 34.3 46.7
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At month 16 after the first transplantation she complained of menopausal symptoms 
and requested an additional transplantation.   
 
She had a high oestrogen level at month three after the implantation of 116 pmol/l 
which is difficult to explain, however, from month 6 onwards she had sustained levels 
of oestrogen above 100 pmol/l which declined around month 16.  This despite 
continuously elevated levels of FSH over 100 IU/l and LH over 70 IU/l. See Table 30. 
The second transplantation was a little bit higher up in the left upper arm and 14 
DMSO preserved strips were re-inserted. 
 
 
 
Table 30 Summary of hormone profile patient 5 
 
-3 0 3 4 6 10 13 16 17 19
E2( pmol/l) 5.0 78.0 116.0 5 106 202.0 194.0 93.0 36.5 88.0
FSH (IU/l) 5.2 92.4 121.3 143.3 109 118.0 123.3 146.5 117.3 119.2
LH (IU/l) 3.3 76.5 72.0 70.1 77 85.0 82.2 77.2 83.0 57.7
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Patient 8 
Patient number 8 was a 38-year old woman. She had a pre-operative oestrogen of 
255 pmol/l, the LH was 1 IU/l and the FSH was not recorded.  The patient had 110 
strips available after laparoscopic oophorectomy and dissection of tissue.  A total of 
106 were available for cryopreservation.   
 
The re-implantation was done under general anaesthesia at the time of insertion of 
the brachytherapy 10 strips cryopreserved in DMSO were inserted in the right upper 
arm. 
 
This patient showed very low oestrogen response with levels just over 50 at month 9 
with high FSH levels throughout. See Table 31. It is unsure whether she produced 
any follicles.  Ten strips were re-implanted. 
 
 
Table 31 Summary of hormone profile patient 8 
-2 0 2 3 6 9 11 13 16
E2 pmol/l 255.0 140 5 5 5 56 44.1 34.0 5.0
FSH IU/l 91.1 65.4 83.4 78.6 115 109.3 104.2 100.7
LH IU/l 1.0 95.2 58.4 78.6 75 96.7 87.0 88.0
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Patient 9 
 
Patient number 9 was a 30-year old G1 that presented with a stage IIb squamous 
carcinoma of the cervix.  For this she had neo-adjuvant chemotherapy, radical 
hysterectomy and post-operative whole pelvic irradiation due to poor prognostic 
factors.  Pre-treatment E2 was 293 pmol/l, FSH was 7.1 IU/l and LH 5.4 IU/l.  A 
laparoscopic oophorectomy was performed and a single ovary was removed before 
the start of the neo-adjuvant chemotherapy. She had a laparoscopic oophorectomy 
for only one ovary because the primary treatment was neo-adjuvant chemotherapy 
and possible surgery that could result in possible normal ovarian function in the 
remaining ovary.   
 
Only one ovary was removed and 42 strips were available for cryopreservation.   
 
However, after completion of full dose chemotherapy a radical hysterectomy was 
performed and due to poor prognostic indicators on the histology including a positive 
surgical margin, she was offered whole pelvic irradiation as well.  After treatment 
with radiotherapy she was in premature ovarian failure.   
 
Re-implantation was done under local anaesthesia 8 months after the original 
cryopreservation.  Twenty-one DMSO preserved strips were available for re-
implantation but during the re-implantation procedure one tissue strip became 
unsterile and was not useable.  The strips were implanted into the left arm.  At the 
time of re-implantation the other ovary was in premature ovarian failure with an FSH 
level of 109.5 IU/l and an LH level of 103.3 IU/l and an E2 level of only 58 pmol/l.  
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This dropped to less than detectable at month four.  However, from month five the 
oestrogen levels started rising and at month six a follicle was present with an 
oestrogen level of 183 pmol/l.  She continued to produce oestrogen and the FSH 
levels came down to 52.3 IU/l and the LH levels came down from over 100 IU/l to 
62.2 IU/l. See Table 32. 
 
 
 
 
Table 32 Summary of hormone profile patient 9 
 
Patient 10 
 
Patient number 10 was a 38-year old G3 P3 that presented with stage IIIb cervical 
cancer.  She was on treatment for underlying hypertension and diabetes on oral 
-8 0 1 2 3 4 5 6 7 9 10
E2 (pmol/l) 293 58 45 5 45 5 67 183 47.7 164 68
FSH (IU/l) 7.1 109.5 118.1 124.2 141.8 125.4 111.5 122.8 70.3 52.3 55.7
LH (IU/l) 5.4 103.3 122.3 108.2 120.2 98.3 111.6 113.4 47.4 62.2 78
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medication.  For the cancer she was offered radical radiotherapy with concomitant 
chemosensitization.  Pre-treatment her E2 was 138.0 pmol/l and the FSH was 5.4 
IU/l and the LH 1.4 IU/l.  Two ovaries were removed with laparoscopic oophorectomy 
without any complications.   
 
A total of 82 strips were available for cryopreservation in the second batch of tissue 
there were slight delays at minus 19.5 degrees Celsius and again at minus 24 
degrees Celsius due to a computer problem. 
 
Re-implantation was performed under general anaesthesia in the left upper arm 
during insertion of the brachytherapy.  Twelve DMSO strips from three vials in the 
first batch were re-inserted.  These strips were not from the delayed batch. 
 
Twelve strips were re-implanted.  The re-implantation was performed after 
completion of treatment.  The oestrogen level stayed low and the FSH and LH levels 
continued to rise until it reached a plateau around month seven.  She never 
produced any follicles for at least 21 months after re-implantation.    The oestrogen 
levels continue to stay low without any evidence of follicle formation and she 
declined another implant. See Table 33. 
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Table 33 Summary of hormone profile patient 10 
 
Patient 11 
 
Patient number 11 was a 27-year old G2 who presented with a stage IIb cervical 
cancer.  She was offered radical radiotherapy with chemosensitization. Pre-operative 
E2 level was < 37 pmol/l and her FSH was 5.4 IU/l and LH 6.2 IU/l.  She had a 
laparoscopic oophorectomy before the commencement of treatment.   
 
This patient had 144 strips available for cryopreservation.  Re-implantation was done 
with 14 strips preserved in DMSO in the left upper arm. 
 
At month six after transplantation she started producing a follicle with oestrogen 
levels of 114 pmol/l.  The FSH and LH stayed high despite the oestrogen production. 
-2 0 3 8 11 14 15 18 21
E2 (pmol/l) 138 38 5 5 5 5 5 5 5
FSH (IU/l) 5.4 52.2 93.7 63.4 109.1 123 111.2 97.7 89.7
LH (IU/l) 1.4 80.5 102.5 66.9 91.7 91.9 72.8 104 96
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She had a peak of oestrogen at month six after re-implantation and continued to 
produce oestrogen to least month 15; this despite high levels of gonadotrophins in 
the region between 60 and 80 IU/l. See Table 34. 
 
 
 
Table 34 Summary of hormone profile patient 11 
 
Patient 12 
 
Patient number 12 was a 33-year old who presented with stage IIIb cervical 
carcinoma for which she was offered radiotherapy with chemosensitization.  Pre-
treatment she had a laparoscopic oophorectomy with removal of both ovaries. 
Unfortunately the patient had anaphylactic reaction to the anaesthetic and was 
admitted postoperatively into the Intensive Care Unit. She recovered fully.   
  
-2 0 1 2 5 6 9 13 15
E2 (pmol/l) 5.0 5.0 5.0 5 5 114 107 68 89
FSH (IU/l) 5.4 57.5 76.0 50.8 83.5 52.9 60.3 58.8
LH (IU/l) 6.2 65.5 78.1 57.5 78.6 66.8 60.8 72.9 80
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This patient had a total of 68 strips available for cryopreservation.  She had very 
small ovaries.  Re-insertion was done at the same time as the brachytherapy under 
general anaesthesia. 
 
Re-insertion of 14 strips cryopreserved in DMSO was performed.  At insertion of the 
brachytherapy she had an oestrogen level at month three of 59 pmol/l and a peak of 
over 100 pmol/l at month eight.  She continued to produced oestrogen at month 14 
but was then lost to follow-up. See Table 35. 
 
 
 
Table 35 Summary of hormone profile patient 12 
  
-2 0 3 8 10 14
E2 pmol/l 72 5 59 105.8 83.9 195.6
FSH IU/l 3.7 71.9 106.7 54.4 63.8 55.2
LH IU/l 1.1 45.1 42.9 39.4 47 40.3
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Patient 13 
 
Patient number 13 was a 25-year old G3 P3 that presented with stage IIIb cervical 
carcinoma.  She had a bilateral oophorectomy pre-treatment and she was offered 
radical radiotherapy and chemosensitization.  
 
This patient had 64 strips available for cryopreservation.  Twelve DMSO 
cryopreserved strips were re-implanted six weeks after completion of radical 
radiotherapy under local anaesthesia. 
 
Unfortunately no blood sample for hormone profile was taken on the day of re-
implantation. 
 
 She had a relatively short follow-up period but started producing oestrogen at month 
eight and continued to have elevated oestrogen levels until at least month thirteen.  
She had a steady increase in the gonadotrophins levels after month eight. See Table 
36. 
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Table 36 Summary of hormone profile patient 13 
 
Discussion 
 
This is the largest cohort of patients reported from one centre with implantation 
results after cryopreservation of cryopreserved ovarian tissue. It confirms that 
ovarian tissue slow freezing is a useful tool to protect follicles against irreversible 
damage caused by cancer therapy. Patients were very positive about the possibility 
of safeguarding their future hormone production. 
 
Laparoscopic oophorectomy was in general without any complications.  One of the 
patients had only one ovary removed due to abnormal adhesions of the right ovary to 
the pelvic side. This patient is not included in the detailed description, because she 
declined transplantation of cryopreserved tissue. The oophorectomy procedure 
-3 2 5 8 9 11 13
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FSH IU/l 6.1 127.5 3.3 19.5 35.4 40 60
LH IU/l 9.9 75.3 27.9 39.2 33.7 40
0
50
100
150
200
250
Ho
rm
on
e 
le
ve
ls
/ M
on
th
s s
in
ce
 tr
an
sp
la
nt
at
io
n Patient 13
253 
 
became easier with time as experience improved.  In the beginning the positioning of 
the trocars made it difficult to orientate the endobag but after a few cases, the 
procedure took less than 45 minutes in total.  All the specimens were removed 
through the primary 10 mm sub umbilical port but it was sometimes necessary to 
increase the size of the incision slightly. 
 
 
Re-implanted ovarian cortex may require 4-5 months before follicogenesis resume. 
[10] [21] This may be due to the fact that only primordial follicles survive the freezing 
process and that more developed (larger) germ cells undergo wastage due to 
intracellular ice formation and disruption of the microtubules.  The earliest indication 
of oestrogen production occurred in two patients during month three. The laboratory 
defined oestrogen levels below 37 pmol/l as non-detectable.  Of the 13 patients 
reported here, only patient, number 10 did not have any evidence of oestrogen 
production. See Table 37. The routine imaging of the ovarian tissue was not 
performed at every follow-up visit.  However, patient number 1, 3, 5, 7, 9 and 13 all 
had visible distension of the transplanted tissue, suggesting follicle formation. 
 
The term menopause is defined as the permanent cessation of menstruation after 
the loss of ovarian activity.  In clinical practice, the diagnosis of menopause is 
usually based on a history of amenorrhoea and  can be confirmed with a hormone 
profile.  In the peri-menopause, the menstrual cycle will increase in length, and the 
level of FSH usually increases significantly. [53]  Inhibin levels are usually lowered 
but oestrogen and LH may still be at normal levels.  With normal ageing the follicular 
reserve starts to decline at around 35 years of and Inhibin may be a better marker of 
ovarian reserve than follicle stimulating hormone. [54]  
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Patient Age Number 
strips 
Cryoprotec
tant 
E2 Production 
 ( >37pmol/l) 
Length of 
follow-up 
1 35 11 DMSO Months 8 and 11 19 
2 37 12 PROH Months 10 and ?12 16 
3 28 14 DMSO Months 8 and 11 14 
4 38 10 PROH Months 11,12,14,19 19 
5 42 12 PROH Months 8,11,13,25 25 
6 40 15 PROH Months 4,10,13,18,21 21 
7 37 13 DMSO 6,10,13,16 19 
  14 DMSO 19  
8 28 10 DMSO 9 and ?11 16 
9 30 20 DMSO ?3,5,6,7,9,10 10 
10 39 12 DMSO No oestrogen production 21 
11 27 14 DMSO 6,9,13,15 15 
12 33 14 DMSO 3,8,10,14 14 
13 25 12 DMSO 8,9,11,13 13 
 
Table 37 Summary of individual patient details 
 
Anti-Mullerian Hormone can serve as a marker for the evaluation of the ovarian 
reserve. AMH is expressed in human follicles immediately after recruitment right up 
to the selection stage (4-6mm diameter). Levels in serum of AMH in normal cycling 
women decline with age and become undetectable in menopausal women.  [55] 
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It is very difficult to pinpoint an exact level of FSH and LH, which corresponds with 
clinical menopause.  A level of 30 international units per litre is often quoted as a 
marker of biochemical menopause.    Some authors report an early return of FSH to 
pre-menopausal levels after re-implantation of cryopreserved ovarian tissue.  Others 
report of post re-implantation hormone levels that FSH and LH levels remained 
elevated. [46] [30] In the case series reported here nearly all the levels of 
gonadotrophins were above the 30 international units per litre despite oestrogen 
production. The amount of tissue grafted may play an important role, because in all 
cases reported here only a small fraction of the dissected ovarian cortex was 
implanted. The reduced number of follicles in the transplanted tissue may not 
produce high enough levels of Inhibin to control gonadotrophin production.  The 
effect of reduced Anti Mullerian Hormone produced by the transplanted tissue is also 
possibly responsible for persistent high gonadotrophin levels. 
 
High levels of circulating gonadotrophins may recruit a high number of follicles soon 
after implantation. This may increase the number of follicles that is destined to 
become artretic. It may be beneficial to control the gonadotrophin secretion by 
administering gonadotrophin releasing hormone antagonists before tissue re 
implantation. [46] In animals a high number of mitoses in granulosa cells were noted 
shortly after transplantation and the number of primordial (resting) follicles decreased 
rapidly due to recruitment of large numbers of follicles. [56]  
 
After careful electron microscopic study of five early cases a possible improved 
outcome was found in the DMSO group.  After the results became available and 
despite the fact that differences were not statistically significant, a decision was 
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made to only use DMSO cryopreserved tissue for transplantation.  However, all four 
cases that had transplanted tissue from the PROH protocol produced oestrogen.  
This indicates that despite ultrastructural damage the effect was not lethal, and that 
tissue survival was adequate for clinical hormone production. 
 
Other groups reported functional grafts up to 21 and 25 months after re-implantation. 
[21]  The follow-up in the current series of patients reported here is relatively short 
but at least three patients were still producing detectable levels of oestrogen more 
than 19 months after implantation. 
 
Conclusion 
This clinical study confirms that ovarian tissue cryopreservation with two different 
cryprotectant protocols was successful in restoring low level oestrogen production in 
the majority of patients.  The aim of this prospective clinical study was not to restore 
fertility because all the patients described here received whole pelvic irradiation 
which made normal pregnancy impossible. However, by demonstrating the 
successful hormone production of tissue implanted in a heterotopic position, a proof 
of principle was demonstrated for use in many different clinical situations. 
 
There was no time delay for the initiation of chemotherapy or radiotherapy.  That 
makes the storage of ovarian cortex a very practical option compared to oocyte 
retrieval and preservation of embryos or oocytes.  It is inevitable that the stimulation 
cycle to obtain multiple follicles for aspiration will delay the onset of treatment.  This 
makes oocyte cryopreservation problematic in many clinical scenarios.  The number 
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of primordial follicles in ovarian tissue cryopreservation is substantial and may offer a 
better chance of subsequent fertility when compared to oocyte or embryo freezing. 
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Chapter 6: Integrated approach to fertility sparing in 
cancer treatment for young women 
Abstract 
An integrated approach for fertility preservation is necessary and clinicians should be 
aware of their respective roles in the management of young women with cancer.   
 
The incidence and treatment of cancer in young women and how its negative effects 
may be prevented or mitigated is discussed.  Aspects of chemotherapy, radiotherapy 
and surgery are evaluated where it may affect future reproductive health. The role of 
oocyte and ovarian tissue cryopreservation is discussed. Guidelines are provided for 
clinicians.  
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Introduction 
 
“First do no harm” is the translation of primum non nocere; a precept of Hippocrates 
(around 460- 377 B.C.).  Non-maleficence, which is the ethical principle that flows 
from this, is fundamental to medical ethics.  Beneficence refers to actions that 
promote the wellbeing of others. In the management of serious disease like cancer 
there is often a conflict between these two moral imperatives. The obligation not to 
harm others is usually more stringent than the obligation to help others. In an effort 
to cure cancer (an act of beneficence) the treatment itself may at the same time also 
cause significant harm. Many treatments have serious, harmful late effects including 
an effect on future fertility and hormone production.  Every young patient deserves to 
get safe and oncologically effective treatment but with the least long term negative 
effects as possible.  A multi-disciplinary team approach involving the oncologist, 
surgeon and counsellor should include a reproductive health specialist if fertility may 
be compromised by cancer therapy. Clinicians should consider the long-term side-
effects of treatment before mapping out a treatment plan and use fertility sparing 
techniques where appropriate. 
 
William Harvey was a physician to King Charles I in England.  He was a keen hunter 
and often accompanied the king on his weekly hunting trips but still had enough time 
to publish a great work called De Generatione Animalium (on the generation of 
animals) in 1651.  On the front page there was a drawing of Zeus sitting on his 
throne holding an egg with the shell open to reveal the emergence of various 
animals, birds and insects including fallow deer that he enjoyed hunting.  On the egg 
the inscription was “Ex ovo omnia” (everything comes from the egg).  Harvey 
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speculated that all life forms started in an egg but he found it difficult to substantiate 
this belief from his experience as a hunter.  He believed that the seed of the male 
would coagulate the menstrual blood in order to form an egg which would produce 
the foetus.  He could not demonstrate this in fallow or red deer because of their very 
short breeding season and no menstruation.  At that point he could see no use for 
“female testicles”.  Despite these difficulties he continued to elaborate in his thesis 
on the theory that the egg was the source of all living things.  It was only a few years 
later that Neils Stensen of Denmark described that fact that “female testicles” of 
mammals contained eggs and should rather be called ovaries.  According to some 
historians he was undoubtedly the unsung hero of the ovary “we should be referring 
to ovarian follicles as Svensen’s follicles not Graafian follicles”. [1]  
 
Cancer in young people 
 
The incidence of childhood cancer (generally calculated under and up to the age of 
15) is 110 to 130 per million children per annum. [2] It is estimated that the 
cumulative risk of a child being diagnosed with cancer is slightly higher in boys at 
1:444 compared to girls which is one is 1:594. [3]  In South Africa accurate figures 
for childhood cancer are not available. The reported incidence is around 70-80 per 
million, however it is estimated that one in 600 children will suffer from cancer before 
they turn 16. Many of these cancers are diagnosed late or may not be diagnosed at 
all. [4] 
 
With modern treatment methods the majority of children will survive cancer. The 
most prevalent tumours before the age of 15 include acute lymphoblastic leukaemia / 
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non Hodgkin’s lymphoma, Hodgkin’s lymphoma, brain tumours and Wilms’ tumour. 
[5] The prognosis for patients diagnosed before the age of 15 improved dramatically 
over the last three decades and more than 80% of cases survive longer than 5 
years. More than 70% will be long-term survivors.  Information from cancer statistics 
during the 1970 to 1980’s indicate that in the United States, the cure rate of all 
childhood cancers combined was between 70-90%. [6]  The estimated 5 year 
survival of children of both sexes improved from 50.4% in 1973 to 79.2% in 1990. [7]  
 
Older children and young adults have historically not been studied to the same 
extent as young children with regards to cancer incidence. The age range for 
adolescence for the purpose of oncology studies has been set at 15-19 years. [8] 
“Young Adult Oncology” refers to a larger group of young people between the ages 
of 15-29 years. [9]  This group of young people is at a very important developmental 
phase particularly for establishment of normal hormonal and sexual function.  The 
most important tumours in the United States are summarised in Table 38. Figures 
from the National cancer registry of South Africa indicate that the most common 
cancer of reproductive women aged 15-29 in South Africa is cervical cancer followed 
by breast cancer and Kaposi’s sarcoma. [10]  
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Age 15-19 20-24 25-29 
Lymphoma % 26 (1) 22 (1) 16 (2) 
Leukaemia % 12 (2) 7 4 
Central nervous system % 10 (3) 7 5 
Endocrine system % 9 12 11 
Skin % 8 14 (2) 18 (1) 
Male genital % 8 13 (3) 11 
Female genital % 8 8 12 (3) 
 
Table 38 The relative frequencies (rank) of cancers in adolescents and young 
adults in the United States aged 15-29. [11] 
 
Anti-cancer therapy may increase the rate of follicular loss and therefore premature 
ovarian failure, with subsequent premature menopause which is one of the common 
toxic side effects of cancer treatment. [12] Chemotherapy causes amenorrhoea in 
40-68% of cases depending on various factors.  [13] Chemotherapy may damage 
primordial follicles directly with demise of follicular cells.  Human and animal studies 
also showed that chemotherapy damage ovarian pre-granulosa cells, with increased 
apoptosis during oocyte and follicle loss. [14] [15] Ovarian stromal cell damage plays 
a key role due to their importance in hormonal function of follicles and perhaps also 
in the repair process after chemotherapy treatment. [16] Vascular complications 
associated with anti-neoplastic agents have been reported. One recognised 
mechanism for such toxicity include drug-induced endovascular damage. [17] 
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Aspects to consider before chemotherapy 
 
One of the most important clinical factors that may influence the risk for permanent 
ovarian damage is the age at treatment. The risk for ovarian failure increases with 
age. [18] [19] [20] [21] This fact should be kept in mind when advice is given to 
women who need chemotherapy after the menarche. 
 
Certain anti-neoplastic agents cause more ovarian damage. The risk associated with 
the use of some agents are summarised in Table 39.  In certain circumstances muti-
drug regimes may be tailored to decrease the risk for ovarian failure. In a study on 
primordial follicle counts after chemotherapy it was found that “patients treated with 
alkylating regimens had significantly lower primordial follicle counts when compared 
with those who received non- alkylating agents and with those who did not receive 
any chemotherapy.” [22] 
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High Risk 
 
Moderate Risk Low or No Risk 
Cyclophosfamide Cisplatin Methotrexate 
Busulfan Adriamycin 5- Fluorouracil 
Melphalan Paclitaxel (limited evidence) Actinomycin D 
Procarbazine  Bleomycin 
Nitrogen Mustard  Vincristine 
Chlorambucil   
Vinblastine   
Cytarabine   
 
Table 39 Risk for gonadotoxicity associated with different chemotherapy agents. 
Adapted from [16] and [23] 
 
Smaller primordial follicles may survive the insult of chemotherapy better and 
suppression of follicle development during treatment may protect the ovary. 
Suppression of follicle development by gonadotrophin-releasing hormone agonists 
(or antagonists) (GnRHa) or combined oral contraceptives have been reported in the 
literature. Two recent review articles on the topic of ovulation suppression with 
GnRHa to protect against chemotherapy induced ovarian toxicity and amenorrhoea 
summarises the lack of a definite answer. [24] [25]  The first was of the opinion that 
the currently available information is not enough to reach a definite conclusion and 
the second also concluded their review by stating that there is not enough convincing 
statistical evidence concerning the reduction of premature ovarian failure (POF) to 
treat young women with GnRH agonists. Conflicting reports of the protection makes 
271 
 
further studies essential. The best evidence so far for the potential benefit of oral 
contraceptives during chemotherapy is from a large retrospective report from 
Germany. [26] However, oral contraceptives have never been adequately tested in a 
randomised controlled trial. [27] 
 
Aspects to consider before radiotherapy 
 
The estimated LD50 (median lethal dose) of an oocyte is is less than 4 Gray. [12]  
Shielding of ovaries may protect against radiation induced failure. [28] [29]  The 
uterus may be damaged by radiotherapy. Reduced uterine volume and decreased 
elasticity of the myometrium can be found in girls who received pelvic-, abdominal- 
or total body irradiation before puberty. [30] [31] Cranial irradiation may cause hypo-
pituitarism in doses over 30 Gray. [32] [33]  Effective shielding during treatment 
reduce the dose to healthy tissue. 
 
Ovarian trans-position outside the field of radiotherapy may reduce the dose to the 
ovary. [34] Lateral trans-position of the ovaries to the para-colic gutters can reduce 
the radiotherapy dose by up to 95%.[35] 
 
Aspects to consider before surgery 
 
Treatment for cervical pre-cancer can cause long-term reproductive sequelae. One 
has to caution against blanket treatment of all patients purely for abnormal cytology 
results.  We know that between five and 40% of all patients with abnormal cytology 
might not have histological abnormality on LLETZ cone biopsy. [36] It is therefore 
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necessary to do a thorough colposcopic evaluation and to treat only those patients 
with a recognizable abnormality.  If there is doubt about the severity of the 
abnormality, a biopsy should confirm a CIN II lesion or higher to justify treatment by 
destruction or resection of the transformation zone.  Over-treatment may jeopardize 
a patient’s future reproductive performance. Cervical conisation might lead to 
infertility by causing cervical stenosis or a decrease in the production of cervical 
mucus. [37]  Cervical stenosis seems to occur more often after cold knife cone 
biopsy than laser conisation or LLETZ. A larger cone is associated with a greater 
occurrence of cervical stenosis. [38] [39] Other risks associated with previous 
cervical surgery include spontaneous miscarriages [40], premature labour before 37 
weeks [41] and an increase in the number of caesarean sections done for cervical 
dystocia. [40] [42] [43] 
 
Small early stage cervical cancers may be suitable for uterus-sparing surgery.  [44] 
Dargent and others developed radical trachelectomy for the treatment of early 
cervical tumours.[45] [46] Even though subsequent pregnancies are sometimes 
complicated by miscarriage, premature preterm rupture of membranes, early delivery 
and premature infants it offers a solution for patients with early tumours who would 
like to retain the chance for pregnancy. [47] 
 
There are a number of young women who develop endometrial cancer. They usually 
present with excess oestrogen associated with obesity, infertility and nulliparity. 
There are many case reports of early stage, low-grade endometrial cancers that 
have been treated using uterus conserving therapies. [48] [49] [50] [51] A small 
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number of early-stage endometrial cancers were treated with partial hysteroscopic 
resection followed by GnRHa for three months. [52]  
 
Selected patients with Borderline Ovarian Tumours (BOTs) or early stage invasive 
epithelial cancer (FIGO stage Ia) with well differentiated tumours may be managed 
with fertility sparing surgery. [53] [54] [55] [56] [57] [58] In these patients accurate 
surgical staging is of the utmost importance.  Only if, after careful surgical staging, 
the patient remains a FIGO stage Ia can conservative management and omission of 
adjuvant therapy be safely advised. 
 
Cryopreservation of oocytes or ovarian tissue as an option for 
fertility sparing 
 
In certain clinical situations the ovaries of a young woman will be exposed to high 
doses of toxic cancer therapy. If surgical transposition will be of no benefit due to 
systemic chemotherapy an option may be to remove ovarian tissue for the period of 
therapy. Preservation of ovarian tissue before cancer treatment and later 
transplantation of the tissue (when toxic treatment is finished) may restore hormonal 
function and sometimes even fertility.  
 
The self-evident candidates for ovarian tissue or oocyte cryopreservation are young 
women and girls with haematological cancer who need aggressive chemotherapy 
regimes.  Children often receive whole body irradiation with doses adequate to 
cause premature ovarian failure in cases where bone marrow transplants are 
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prepared.  There are, however, many other forms of cancer where treatment directly 
affects ovarian function.   
 
Oocyte cryopreservation 
 
The survival and ultimate normal functioning of an oocyte after the process of 
cryopreservation has been more difficult to achieve when compared to sperms and 
embryos. Success is compromised by the complexity of the intra- and sub-cellular 
organelles which are far more complex than in smaller cells like sperm and pre-
implantation embryos.  Early work done on frozen murine oocytes showed spindle 
abnormalities and other damage due to cryopreservation and exposure to 
cryoprotectants. [59] [60] Metaphase II oocytes are structurally quite complex with 
the fragile meiotic spindle being one of the most vulnerable structures.   
 
There are indications that, with improving technical ability, slow-freezing of oocytes is 
becoming more efficient with increases in survival rates of individual oocytes, better 
fertilization rates and ultimately an improvement in pregnancy rates. [61]  Recently 
vitrification (ultra rapid cooling technique) of human oocytes has been described and 
the success rate after vitrification seems to be improving.  [62]  
 
The ovarian stimulation period before oocyte retrieval remains the most problematic 
aspect of oocyte cryopreservation because of the delay in the start of treatment for 
patients with underlying malignancy. In order to reduce the time necessary ovarian 
stimulation may be started in the luteal phase. [63]  A very similar time from start to 
retrieval was achieved in patients starting stimulation in the follicular phase and the 
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luteal phase of the menstrual cycle.  Another concern about possible increased 
incidence of chromosomal abnormalities in cryopreserved oocytes seems to be 
ungrounded.  There is no evidence that chromosomal abnormalities are more 
frequent when fertilization does occur, even if it is at a lower rate than with fresh 
oocytes,  [64]  [65] 
 
The number of oocytes retrieved in a cycle is usually low.  In a report on 18 young 
women with a mean age of 19 years (range 14-26), an average of 15 oocytes were 
retrieved per cycle. [66]  The success of stimulation protocols is lower in older 
women and, if we consider that only a fraction of the thawed oocytes will fertilise, it 
may be better to preserve ovarian tissue where a larger pool of oocytes will survive. 
The advantage of oocyte freezing is a potentially lower risk of reseeding of cancer 
cells because a much smaller volume of tissue is transplanted. 
 
Ovarian tissue cryopreservation 
 
Ovarian tissue samples are relatively large and morphologically complex.  
Cryopreservation methodology is difficult to optimise and standardise.  Ovarian 
tissue cryopreservation is still in its experimental stages and is not a routine option 
offered to cancer patients.  Despite the experimental nature of ovarian tissue 
cryopreservation, ovarian tissue harvesting and banking has been offered to many 
patients in clinical practice over the last two decades. [67] [68] [69] The histological 
examination of fresh and thawed ovarian tissue for metastatic tumour should be part 
of routine practice to evaluate tissue for the presence of microscopic metastases. 
[70]  [71] 
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Re-implantation of ovarian tissue may be immediate after completion of treatment if 
the aim is to restore endocrine function only. If the aim is to restore fertility, it is 
preferable to wait for a disease free period of around two years since most 
malignancies recurs during the first 24 months after completion of treatment.  Tissue 
transplantation to the original site or to a transplantation location near the original 
site is referred to as orthotopic transplantation.  Transplantation to an intra-
abdominal site has been achieved with either laparoscopy or laparotomy. Several 
authors described ovarian transplantation to the ovarian stump or the peri-ovarian 
region.  [72]  Transplantation to sites distant from the original is referred to as 
heterotopic.  Many alternative heterotopic sites have been tested for re-implantation 
including the arm, rectus abdominus muscle, the anterior abdominal wall, and the 
supra-pubic area. [70] 
 
Many small case series have been published about hormonal and reproductive 
outcome after re-implantation of frozen-thawed ovarian tissue.  In a study from South 
Africa we described hormonal function in 12 out of 13 patients who had heterotopic 
transplantation of frozen-thawed ovarian tissue. After laparoscopic oophorectomy 
ovarian cortical tissue strips were made by first bisecting the ovary and removing 
most of the cortex.  The cortex was then divided into 2x5 mm strips. The strips were 
preserved using a controlled slow freezing method. After cancer treatment rapid 
thawing of the tissue and heterotopic transplantation was performed to the upper 
arm.  The study is a proof of principle and shows the way forward for further study. 
Many questions still remain including: 
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· What is the optimal freezing and thawing protocol for tissue strips 
· How much tissue should be transplanted at one time 
· How long will tissue continue to function? 
· Should we suppress gonadotrophins before implantation as suggested by 
others? [73] 
· Can we use other markers of ovarian reserve like Anti-Mullerian Hormone and 
Inhibin to predict graft longevity and function? 
 
Conclusion 
 
The diagnosis of cancer usually comes as a tremendous shock to any person.  It is 
even more unexpected in children and young people and there is a lot of anxiety and 
fear around the time of diagnosis and planning of treatment.  Clinicians involved in 
the care of these young people cannot escape the pressure of the situation and often 
focus solely on the survival and cure of the patient without the necessary concern 
about the long-term effects of the proposed treatment plan.  There may be 
completely safe and effective treatment options that will minimise late harmful 
effects, including hormonal dysfunction and infertility.  To improve the chances of 
taking a good decision about treatment it is important to involve a multidisciplinary 
team, including a fertility expert.  At the time of diagnosis the focus will invariably be 
on cure of the disease but a calm, informed discussion about future fertility can go a 
long way to inform the patient and the family members about the risks involved in a 
particular treatment plan and possible solutions. 
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All medical personnel involved in the care of young people with cancer should be 
educated about the available fertility sparing options. 
 
Medical oncologists need to take into consideration the risk for gonadotoxicity with 
each chemotherapy agent or combination of agents that will be used.  Effective 
regimes with lower risk are often available. Combined oral contraceptives and 
gonadotrophin suppression may offer some protection of follicular reserve but at 
present there is not enough evidence to support this strategy entirely.  
Gonadotrophins may be beneficial for other reasons in certain hormone sensitive 
tumours including oestrogen dependent breast cancers. If the risk for premature 
ovarian failure is high, e.g. an older patient receiving ovarian-toxic treatment, 
cryopreservation of ovarian tissue constitutes a viable option for future re-
implantation. 
 
Radiation oncologists should be aware of the risk of ovarian and uterine damage due 
to radiotherapy, whether it is because of direct exposure or scattered radiation. 
Shielding is often a fairly simple way of protecting ovarian and uterine function 
although it can be time-consuming.  Pre-exposure surgical transposition may be of 
help in selected cases.  However, there may still be a risk for some damage due to 
scatter radiation and vascular compromise.  If the risk for ovarian failure is high, 
cryopreservation of ovarian tissue or oocytes should be considered.  At present, 
there is no convincing evidence that suppression of ovarian function with 
contraceptives or gonadotrophins make any difference whatsoever in the risk for 
future ovarian failure after radiotherapy exposure. 
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Surgeons should think and plan carefully before any surgical intervention taking into 
consideration the longer term risks associated with the planned surgery.  Even small 
procedures performed for pre-cancer lesions may have profound effects on future 
pregnancies.  In early invasive disease a conservative operation with retention of 
future fertility is often available. 
 
Infertility specialists must be well-informed about the different options for fertility 
preservation.  They should be able to give suitable advice, not only to the patient and 
family, but also to the other care givers in the team. Cryopreservation of embryos 
and semen samples has long been an integral part of assisted reproductive 
techniques.  It is now important to also develop the laboratory protocols for 
cryopreservation of oocytes and ovarian tissue. 
 
In the South African environment we have now demonstrated that the laboratory 
facilities are able to offer cryopreservation of ovarian tissue as an effective service to 
patients.  By investigating two different cryopreservation protocols and showing no 
significant difference in the ultra structure of the tissue it is clear that there may be 
more than one effective protocol for successful storage. 
 
Developing the necessary laboratory capacity by training of laboratory technicians in 
the new techniques are of the utmost importance.  A well controlled clinical 
environment with very high safety and ethical standards is essential as the only way 
to protect the cryopreserved tissue, and ultimately the patient.  Histological 
evaluation of tissue for possible metastatic disease prior to preservation must always 
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be part of the process.  Centres of excellence need to be established with expertise 
in this rather low-frequency service.  
 
In a South African setting cryopreservation of ovarian tissue can be done effectively. 
The re-implantation of previously cryopreserved tissue has been performed 
successfully in an adequately large group of patients to demonstrate the principle.  
Although this technique is still experimental, we can now argue that cryopreservation 
of ovarian tissue should become part of good clinical practice in suitable patients. 
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